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Background: Cognitive–behavioural therapy (CBT) for childhood anxiety disorders is associated with
modest outcomes in the context of parental anxiety disorder.
Objectives: This study evaluated whether or not the outcome of CBT for children with anxiety disorders in
the context of maternal anxiety disorders is improved by the addition of (i) treatment of maternal anxiety
disorders, or (ii) treatment focused on maternal responses. The incremental cost-effectiveness of the
additional treatments was also evaluated.
Design: Participants were randomised to receive (i) child cognitive–behavioural therapy (CCBT); (ii) CCBT
with CBT to target maternal anxiety disorders [CCBT+maternal cognitive–behavioural therapy (MCBT)];
or (iii) CCBT with an intervention to target mother–child interactions (MCIs) (CCBT+MCI).
Setting: A NHS university clinic in Berkshire, UK.
Participants: Two hundred and eleven children with a primary anxiety disorder, whose mothers also had
an anxiety disorder.
Interventions: All families received eight sessions of individual CCBT. Mothers in the CCBT+MCBT arm
also received eight sessions of CBT targeting their own anxiety disorders. Mothers in the MCI arm received
10 sessions targeting maternal parenting cognitions and behaviours. Non-specific interventions were
delivered to balance groups for therapist contact.
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Main outcome measures: Primary clinical outcomes were the child’s primary anxiety disorder status and
degree of improvement at the end of treatment. Follow-up assessments were conducted at 6 and 12 months.
Outcomes in the economic analyses were identified and measured using estimated quality-adjusted life-years
(QALYs). QALYS were combined with treatment, health and social care costs and presented within an
incremental cost–utility analysis framework with associated uncertainty.
Results: MCBT was associated with significant short-term improvement in maternal anxiety; however, after
children had received CCBT, group differences were no longer apparent. CCBT+MCI was associated with
a reduction in maternal overinvolvement and more confident expectations of the child. However, neither
CCBT+MCBT nor CCBT+MCI conferred a significant post-treatment benefit over CCBT in terms of child
anxiety disorder diagnoses [adjusted risk ratio (RR) 1.18, 95% confidence interval (CI) 0.87 to 1.62,
p= 0.29; adjusted RR CCBT+MCI vs. control: adjusted RR 1.22, 95% CI 0.90 to 1.67, p= 0.20,
respectively] or global improvement ratings (adjusted RR 1.25, 95% CI 1.00 to 1.59, p= 0.05; adjusted
RR 1.20, 95% CI 0.95 to 1.53, p= 0.13). CCBT+MCI outperformed CCBT on some secondary outcome
measures. Furthermore, primary economic analyses suggested that, at commonly accepted thresholds of
cost-effectiveness, the probability that CCBT+MCI will be cost-effective in comparison with CCBT
(plus non-specific interventions) is about 75%.
Conclusions: Good outcomes were achieved for children and their mothers across treatment conditions.
There was no evidence of a benefit to child outcome of supplementing CCBT with either intervention
focusing on maternal anxiety disorder or maternal cognitions and behaviours. However, supplementing
CCBT with treatment that targeted maternal cognitions and behaviours represented a cost-effective use of
resources, although the high percentage of missing data on some economic variables is a shortcoming.
Future work should consider whether or not effects of the adjunct interventions are enhanced in particular
contexts. The economic findings highlight the utility of considering the use of a broad range of services
when evaluating interventions with this client group.
Trial registration: Current Controlled Trials ISRCTN19762288.
Funding: This trial was funded by the Medical Research Council (MRC) and Berkshire Healthcare Foundation
Trust and managed by the National Institute for Health Research (NIHR) on behalf of the MRC–NIHR
partnership (09/800/17) and will be published in full in Health Technology Assessment; Vol. 19, No. 38.
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Plain English summary
Anxiety disorders are characterised by a level of fear and avoidance that interferes in day-to-day life.They are among the most common emotional difficulties experienced by children and present a risk for
ongoing emotional difficulties in later life. A talking therapy called cognitive–behavioural therapy (CBT)
is effective for the treatment of childhood anxiety disorders; however, if parents also have an anxiety
disorder children often do not benefit as much as they should. We set out to establish whether or not
supplementing CBT for the child (child cognitive–behavioural therapy; CCBT) with (i) CBT focused on
maternal anxiety disorders, or (ii) an intervention focused on maternal parenting responses, would lead to
better child treatment outcomes than CCBT alone.
A total of 211 children were randomly allocated to (i) CCBT and CBT for the maternal anxiety disorder
(CCBT+maternal CBT); (ii) CCBT and an intervention focused on how the mother interacted with her child
[CCBT+mother–child interaction (MCI)]; or (iii) CCBT alone.
In terms of children’s anxiety disorder diagnoses, severity and symptoms, there was only limited evidence
that supplementing individual CBT for children with anxiety disorders with either intervention significantly
improved treatment outcomes. However, when the cost and relative benefits of treatment to the child
were taken into account, the intervention focused on the MCI was good value for money compared with
CCBT alone.
These findings suggest that, in the context of maternal anxiety disorders, adding treatment focused on
how mothers respond to their child, but not treatment focused on maternal anxiety disorders, may be a
cost-effective approach to treatment.
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Scientific summary
Background
Anxiety disorders are among the most common psychological disorders in childhood and are associated with
adverse outcomes throughout the life course. Psychological treatments [specifically cognitive–behavioural
therapy, (CBT)] have established effectiveness; however, one group who have not been found to benefit as
much as others are children with anxiety disorders who have a parent who also has an anxiety disorder.
There has been limited consideration of how to improve treatment outcomes for children with anxiety
disorders in the context of parental anxiety disorder. Two trials have delivered CBT for the parental
disorder alongside CBT for the child; however, in both these cases the parental CBT was brief and did not
significantly improve parental anxiety. It remains unclear whether or not successful treatment of parental
anxiety would lead to benefits in child anxiety outcomes following CBT.
An alternative explanation for the relatively poor outcomes for children with anxiety disorders in the
context of parental anxiety is that particular parenting responses (that are more common among highly
anxious parents) may reinforce child anxiety disorder and, thus, militate against good treatment outcomes.
Particular parental responses that have been implicated in the maintenance of child anxiety disorders
include an overprotective parenting style, expressed anxiety when the child faces a challenge, and negative
expectations about the child’s competence and coping.
The aim of the trial was to establish the relative clinical effectiveness and cost-effectiveness of treatments
of (i) maternal anxiety, and (ii) key parenting responses, for children with anxiety disorders who have a
primary-caregiving mother with a current anxiety disorder.
Objectives
This randomised controlled trial (RCT) for child anxiety disorder occurring in the context of maternal anxiety
disorder, set out to address the following principal questions:
1. Is the impact of child cognitive–behavioural therapy (CCBT) enhanced by first providing CBT to the
mother for her own anxiety disorder?
2. Is the impact of CCBT enhanced by the addition of therapeutic measures designed to target maternal
parenting responses?
In addition the following secondary questions were addressed:
i. Is sustained improvement in child anxiety significantly associated with a reduction in maternal anxiety?
ii. Is sustained improvement in child anxiety significantly associated with improvements in maternal
modelling, encouragement, overcontrolling/overprotective behaviour and associated cognitions?
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Methods
We carried out a RCT in which we compared CCBT with (i) CBT focused on the maternal anxiety disorder
in addition to CCBT, and (ii) an intervention focused on promoting positive maternal responses to the
child in addition to CCBT. The randomisation ratio was 1 : 1. The randomisation was carried out with a
remote facsimile system and was minimised for child age, gender, primary anxiety disorder diagnosis, and
baseline severity of the child and the mother’s primary anxiety disorder.
Participants were recruited from referrals to NHS Child and Adolescent Mental Health Services
across Berkshire.
The inclusion criteria for children were age (7–12 years) and primary diagnosis of a current anxiety disorder
according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (American
Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington, DC:
American Psychiatric Association; 2000). The inclusion criteria for mothers were that the mother was the
primary carer and had a current DSM-IV anxiety disorder. Exclusion criteria for children were significant and
intellectual impairment, a current prescription of psychotropic medication that had not been at a stable
dose for at least 1 month and without agreement to maintain a stable dose for the duration of the study,
and previous receipt of six or more sessions of CBT. Exclusion criteria for mothers were significant
intellectual impairment, a severe comorbid disorder (that would interfere with the mothers ability to
participate in treatment sessions), or a current prescription of psychotropic medication that had not been
at a stable dose for at least 1 month and without agreement to maintain a stable dose for the duration of
the study.
The primary outcomes were the number of children who were free of their primary anxiety disorder
diagnosis, and the number who were classified as ‘much’ or ‘very much’ improved on the Clinical Global
Impression – Improvement scale immediately after the treatment phase. Further follow-ups were conducted
6 and 12 months after the end of treatment. Secondary outcomes were the severity of the child’s primary
diagnosis, the number of children who were free of all their anxiety diagnoses, child- and mother-reported
child anxiety symptoms, impact and comorbid symptoms, and teacher-reported anxiety and adjustment
at school.
Outcomes for the economic analyses were identified and measured using quality-adjusted life-years (QALYs),
estimated on the basis of child reports on the European Quality of Life-5 Dimensions at all assessments from
baseline to the 12-month follow-up. Costs associated with each treatment arm were based on patient-level
resource use data, collected as an integral part of the trial data collection process on the basis of mother and
therapist report.
All children received individual CBT over eight weekly sessions. Mothers randomised to the maternal
cognitive–behavioural therapy (MCBT) treatment arm received eight weekly individual CBT sessions focused
on their own difficulties with anxiety. Mothers in the other two arms received a non-specific intervention
[non-directive counselling (NDC)] to balance for therapist contact. Mothers in the CCBT+mother–child
interaction (MCI) arm received 10 therapeutic sessions (over 8 weeks; eight with the mother alone and two
with the mother and child) which were designed to target potentially anxiogenic maternal parenting
behaviours. Those in the other two treatment arms received a non-specific intervention to balance for
therapist contact (family health; FH). All therapists followed written manuals, received regular supervision and
audio-recorded treatment sessions so that adherence to treatment protocols could be evaluated.
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Results
A total of 676 potential participants were assessed for eligibility. Of these, 435 participants did not meet
eligibility criteria (in the majority of cases because the mother did not have a concurrent anxiety disorder)
and 30 eligible families did not give consent to participate. A total of 211 children were randomised,
with 84% assessed at the post-treatment assessment, and 72% and 65% at 6- and 12-month follow-up
assessments, respectively.
At baseline 69 participants were randomised to the MCBT+CCBT arm, 71 participants to MCI+CCBT
and 71 participants to CCBT+ non-specific interventions. The three randomised groups were comparable
at baseline. Analysis of audio-recordings of treatment sessions showed that there were no significant
differences in adherence to the CCBT treatment protocol across the three treatment arms. The content of
the targeted and non-specific interventions were significantly different in the case of both MCBT and NDC,
and MCI and FH, in both cases indicating that the content of the treatments differed as intended. There
was also evidence that both the MCBT and MCI interventions were associated with some change in the
variables that they were targeting. Immediately after the MCBT intervention, mothers in the CCBT+MCBT
arm were 1.63 times more likely to have recovered from their primary diagnosis and 2.51 times more likely
to have recovered from all their anxiety diagnoses compared with mothers in the CCBT arm. However,
there were no significant differences on maternal self-report questionnaire scores. Furthermore, by the
later assessment points maternal recovery rates improved for all treatment arms and differences between
arms were no longer significant. In comparison to those in the CCBT arm, mothers who received
CCBT+MCI showed a greater change in observed overprotection and expectations relating to how scared
and in control their child would be compared with the CCBT arm. Significant differences were not found
on any other measures of parenting response.
The primary analysis indicated that, for the number of children free of their primary diagnosis, although the
CCBT+MCBT and CCBT+MCI arms were associated with better outcomes, these were not significantly
different from the CCBT arm [CCBT+MCBT risk ratio (RR) 1.21, 95% confidence interval (CI) 0.86 to 1.71,
p= 0.280; CCBT+MCI vs. CCBT RR 1.24, 95% CI 0.88 to 1.74, p= 0.219]. This was also the case for
the number ‘much’ or ‘very much’ improved (CCBT+MCBT RR 1.24, 95% CI 0.99 to 1.57, p= 0.065;
CCBT+MCI RR 1.18, 95% CI 0.93 to 1.50, p= 0.179). At the 6- and 12-month follow-up assessments
CCBT+MCI (but not CCBT+MCBT) continued to be associated with relatively high recovery rates, but
neither of the groups differed significantly from CCBT. Significantly more children (92%) in the CCBT+MCI
arm, compared with the CCBT arm (73%), showed a reduction in severity of their primary diagnosis 6 months
post treatment [χ2(1)= 6.19; p= 0.013]. A similar pattern was found at the 12-month follow-up; however,
this was not statistically significant. No significant differences were found on child, mother or teacher
between treatment arms at any assessment point.
Analysis of the secondary research questions yielded inconsistent results, both across reporters and
assessment time points. There was not a consistent pattern of association between change in maternal
anxiety or parenting responses and change in child outcomes, so clear conclusions about mechanisms of
change cannot be drawn at this stage.
The economic evaluations suggested that from a health service perspective only, the mean health cost of
the CCBT+MCBT arm was on average £233.55 (95% CI –£6.81 to £473.92) higher than the CCBT arm,
whereas mean child QALY gain was 0.033 (95% CI –0.101 to 0.035) lower. Similarly, incremental
health-care costs in the CCBT+MCI arm were on average £233.16 (95% CI –£6.81 to £473.92) higher than
the CCBT arm, with the child QALY gain 0.028 (95% CI –0.030 to 0.086) higher. The cost-effectiveness
acceptability curve (CEAC) for the CCBT+MCBT arm suggested that, given the distribution of the
incremental cost-effectiveness ratios, CCBT+MCBT is highly unlikely to be cost-effective at current
willingness-to-pay thresholds for an extra QALY (£20,000–30,000) with a probability lower than 0.1. The
CEAC for the CCBT+MCI arm, however, revealed that the probability that CCBT+MCI is cost-effective in
comparison with CCBT alone is around 75%. These results should, however, be interpreted in light of an
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important limitation of the data, namely the high percentage of missing values in some of the follow-up
resource use and outcome variables. This shortcoming was dealt with using appropriate data imputation
techniques; however, imputation cannot account for potentially non-random reasons for missing data.
Conclusions
Implications for health care
l The novel intervention that focused on modifying maternal parenting responses was associated with
some benefit to children and mothers with anxiety disorders, and is likely to be cost-effective.
Incorporating effective measures to address maternal cognitions and behaviours when interacting with
her child may improve health outcomes for children with anxiety disorders in the context of maternal
anxiety disorder.
l We can be confident that supplementing individual CCBT with CBT to target the maternal anxiety
disorder is unlikely to confer substantial health benefits and is unlikely to be cost-effective. Given
the intensity of this intervention and its general lack of effectiveness we think it is unlikely that
supplementing CCBT with this intervention will improve child outcomes.
Future research implications
l Given that CCBT alone was sufficient for the majority of patients, it is possible that any benefits
from the MCI and MCBT interventions may be enhanced in particular contexts; for example, in the
context of particular maternal or child anxiety disorders or high levels of severity. Future research that
directly addresses these possibilities is warranted.
l The relatively low level of association between change in maternal anxiety and responses and child
anxiety, may suggest that other factors may account for the modest treatment outcomes typically
found among children with anxiety disorders who have mothers with anxiety disorders (such as genetic
or broader social/environmental factors). Future research is warranted to address these issues.
l The economic evaluation provides insight as to the broad range of services accessed by this client
group, hence it is recommended that future economic evaluations in this area incorporate data
collection on this full range of services in order to capture the full impact of new interventions for this
client group.
Trial registration
This trial is registered as ISRCTN19762288.
Funding
This trial was funded by the Medical Research Council (MRC) and Berkshire Healthcare Foundation Trust
and managed by the National Institute for Health Research (NIHR) on behalf of the MRC–NIHR partnership
(09/800/17) and will be published in full in Health Technology Assessment; Vol. 19, No. 38.
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Chapter 1 Introduction
Scientific background
Anxiety disorders are among the most common psychological disorders in childhood, affecting 2.6–5.2% of
children under the age of 12 years.1,2 These disorders adversely affect children’s functioning in personal, social
and academic domains,3,4 raise the risk for disorders in adolescence and adulthood,5 and carry a substantial
health and social cost.6 Following advances in the development of successful cognitive–behavioural therapies
(CBTs) for adult anxiety disorders,7 CBT for child anxiety disorders has now been developed. Although there is
still some uncertainty over the optimal form of such an intervention, recent systematic reviews of outcome
research indicate that the general CBT approach produces significant therapeutic benefit in this patient group,
with, on average, 59% of anxious children no longer meeting criteria for their primary anxiety disorder
following CBT.8 However, it is clear from these reviews, and from the individual treatment trials, that the
outcome is highly variable, with a significant proportion (40.6%) of patients retaining their anxiety diagnoses
following treatment.8
Parental anxiety disorders are associated with poor treatment outcomes
One way of further improving children’s responses to treatment is to identify predictors of poor outcome
which are amenable to therapeutic change. One of these is parental emotional distress, in particular
parental anxiety disorder, which has been found to be associated with up to a 50% reduction in child
recovery following treatment.6,9–13 This is of great significance given that the rate of anxiety disorder among
the parents of anxious children is raised.14,15 Indeed, in a consecutive series of children referred for
treatment of an anxiety disorder in our clinic, two-thirds of the mothers were found to have a current
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)16 anxiety disorder (with no
elevated rate of current disorder among the fathers), almost three times the base rate.17
Two studies to date have examined whether or not targeting parental anxiety might benefit child treatment
outcome. Cobham and colleagues9 found that supplementing child cognitive–behavioural therapy (CCBT)
with parent anxiety management was associated with significantly improved diagnostic outcomes for children
with anxiety disorders whose parents had elevated trait anxiety; however, this group did not maintain a
specific benefit from the parent anxiety management treatment at a 3-year follow-up.18 More recently,
Hudson and colleagues19 used a similar design but classified groups according to parental anxiety disorder
status. In this study, CCBT+ parent anxiety management did not confer a significant benefit over CCBT post
teatment or at a 6-month follow-up assessment. Notably, both studies administered brief treatments for
parental anxiety which did not have an overall impact on parental anxiety symptoms or disorder. The question
therefore remains open as to whether or not successful treatment of parental anxiety might benefit
child outcome.
Other mechanisms associated with poor outcomes
An alternative possibility is that it might not be parental anxiety, per se, that is prognostically significant for
child response to treatment but, rather, the parenting practices associated with high levels of parental
anxiety that themselves reinforce or maintain the child disorder. Specific parenting responses have been
implicated in the maintenance of child anxiety, in particular an overcontrolling and overprotective parental
style, expressed anxiety when the child is faced with challenge, 20,21 and associated parental cognitions
and expectations about child competence.22 These behaviours are known to obtain significantly more in
anxious than in non-anxious parents of children with anxiety disorder,23,24 as are associated cognitions
characterised by elevated expectations that the child will be frightened and feel out of control in the face
of a challenge.23 Recent studies have suggested that targeting parental anxiety may be pertinent only
insofar as it changes behaviours that are likely to interfere with the child’s treatment.25 These studies
suggest, therefore, that targeting parenting cognitions and behaviours, rather than parental anxiety,
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1
may be of most benefit in bringing about improvement in anxious children’s response to treatment in the
context of parental anxiety disorders.
Implications for optimal treatment outcomes
Cognitive–behavioural therapy treatments of child anxiety disorder commonly require the day-to-day
prosecution of treatment regimes to be managed by the parent (e.g. parents are typically required to model
positive responses to fear provoking stimuli and to prompt and reinforce their child’s positive responses), so it
is likely that the parent’s own anxiety and the associated disturbances in parenting responses may militate
against optimal treatment delivery. Although the CBT treatments developed to date for the treatment of child
anxiety do acknowledge the importance of both parental anxiety and parenting,26–29 there has been no
systematic evaluation of an intervention in which both parental anxiety and parenting responses are
specifically addressed. There is, therefore, a need for the development and evaluation of a CBT treatment for
child anxiety disorder in which parental anxiety and associated patterns of parental responses to the child are
systematically targeted.
Rationale for the research
The outcome from CBT for children with anxiety disorders is highly variable. Major factors contributing to this
are likely to be the presence of parental anxiety and associated disturbances in how parents respond to their
children when they are faced with challenges. Where parental anxiety has been addressed in treatment
research,26–29 for several methodological reasons, it has been difficult to assess its contribution to child
outcome. Two studies have systematically targeted parental anxiety in the treatment of child anxiety
disorders. In one,9 child anxiety outcome was better where therapeutic measures to address parental anxiety
symptoms were included, and in the other19 children’s outcomes were not improved. In both cases, as the
treatment did not significantly alter levels of parental anxiety, it remains unclear what aspect of the treatment
effected the clinical improvement in the children. Similarly, where therapeutic measures to address parenting
responses have been included,30 it has not been possible to determine the specific role of such measures in
the complex treatment package employed. A controlled trial in which both factors – treatment of parental
anxiety and measures to alter parenting responses – are systematically varied, would produce data of both
clinical utility and scientific importance. The study was determined on this basis, and there was no patient or
public input at this stage.
Although paternal behaviours are likely to contribute to the maintenance of child anxiety disorder, this
study focused on mothers for the following reasons: (i) it has been suggested that the parental responses
that may promote anxiety among children differ for mothers and fathers;31 (ii) anxiety disorders are more
common among women than men32 and, also, more common among mothers of children with anxiety
disorders than fathers;17 (iii) mothers are most commonly the primary caregiving parent in the study region
and are more likely to attend treatment sessions for their child (e.g. in a recent study in the same region,
98% of parents nominated as primary caregivers in order to attend treatment were mothers33).
Aims
The aim of the trial was to establish the relative clinical effectiveness and cost-effectiveness of treatments
of (i) maternal anxiety and (ii) key maternal parenting responses for children with anxiety disorders who
have a mother with current anxiety disorder.
INTRODUCTION
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Research questions
In a randomised controlled trial (RCT) for child anxiety occurring in the context of maternal anxiety, the
principal questions are:
1. Is the impact of CCBT enhanced by first providing CBT to the mother for her own anxiety?
2. Is the impact of CCBT enhanced by the addition of therapeutic measures designed to address
potentially anxiogenic maternal parenting responses?
Secondary questions are:
1. Is sustained improvement in child anxiety significantly associated with a reduction in maternal anxiety?
2. Is sustained improvement in child anxiety significantly associated with improvements in maternal
modelling, encouragement, overcontrolling/overprotective behaviour and associated cognitions?
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Chapter 2 Trial design and methods
Study design
The trial was set up to evaluate the benefit of supplementing individual CCBT with either treatment of
maternal anxiety disorder or treatment that targeted maternal responses when interacting with her child,
for children with anxiety disorders whose mothers also had a current anxiety disorder. A three-arm trial
was conducted in which children received individual CCBT in all three arms, supplemented by either
CBT for the maternal anxiety disorder [CCBT+maternal cognitive–behavioural therapy (MCBT)] or a
mother–child interaction (MCI) focused intervention. Non-specific interventions were also delivered in all
treatment arms in order to balance therapist contact. The main trial was supplemented with an economic
evaluation to consider the cost-effectiveness of the CCBT and MCI interventions.
Ethical approval and research governance
Ethical approval for the study was given by Berkshire Research Ethics Committee (07/H0505/156) and the
University of Reading Research Ethics Committee (07/48). The trial was registered with the International
Standard Randomised Controlled Trial Register under the reference number 19762288.
Participants
Participants were 211 children, aged 7–12 years [mean age 10.22 years, standard deviation (SD) 1.58],
with a current anxiety disorder, together with their mothers. As noted above, the study focused on
mothers as (i) intergenerational associations for anxiety disorders are most commonly found between
mothers and their children;17 (ii) mothers are most commonly the primary caregivers in the study region;
and (iii) paternal behaviours may have different associations with childhood anxiety.34 Participants were all
referred to Berkshire Child Anxiety Clinic, run jointly by Berkshire Healthcare NHS Foundation Trust and the
University of Reading, by a health or educational professional. Participants were recruited between June
2008 and May 2011, with the last follow-up assessment in February 2013.
Inclusion criteria
Child
i. Age 7–12 years.
ii. Primary diagnosis of DSM-IV generalised anxiety disorder (GAD), social phobia, separation anxiety
disorder (SAD), panic disorder (PD)/agoraphobia or specific phobia (if comorbid with another
anxiety disorder).
Mother
i. Primary carer.
ii. Current maternal DSM-IV anxiety disorder.
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Exclusion criteria
Participants were not eligible if any of the following criteria are met.
Child
i. Significant physical (where it would impede treatment delivery) or intellectual impairment (including
autistic spectrum disorders) (determined by registration with local learning disability services).
ii. Current prescription of psychotropic medication that had not been at a stable dose for at least 1 month
and without agreement to maintain that dose throughout the study.
iii. Previously received six or more sessions of systematically administered CBT for an anxiety disorder.
Mother
i. Significant intellectual impairment (determined by registration with local learning disability services).
ii. Severe comorbid disorder (e.g. severe major depressive disorder, psychosis, substance/alcohol
dependence that would interfere with the mothers ability to participate in treatment).
iii. Prescription of psychotropic medication that had not been at a stable dose for at least 1 month and
without agreement to maintain that dose throughout the study.
If participating mothers were having any ongoing treatment, this did not preclude them from participating
in the trial, but ideally, any psychotherapeutic treatment should have finished prior to initiating this trial.
Six children were recruited to the trial (two in each treatment arm) who were assigned a primary diagnosis
of anxiety disorder not otherwise specified. Following consultation with the trial management team it was
decided to include these children as the anxiety disorder not otherwise specified diagnosis reflected a slight
variation from meeting diagnostic criteria for GAD. One child was recruited to the trial (CCBT+MCI arm)
on the basis of having a primary diagnosis of selective mutism; and in this case the trial management
group agreed to inclusion as the selective mutism was comorbid with, and was considered to be a
manifestation of, social anxiety disorder. Four children were outside the specified age range at the point
of randomisation. One child was 6 years old but was due to turn the age of 7 years before initiating
treatment (CCBT+MCI arm); three turned 13 years of age between the initial assessment
and randomisation.
Recruitment procedure
The recruitment schedule is shown in Figure 1.
Informed consent
Participants were given a complete description of the study orally and in writing prior to written informed
consent being obtained from participating mothers and assent from participating children. As shown in
Figure 2, 676 children were referred and assessed for eligibility. A total of 435 families did not meet the
inclusion criteria (24 children and 311 mothers because they did not meet criteria for a current anxiety
disorder). Assent/consent was not given by 30 families.
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Does child have current anxiety disorder?
Yes
Does mother have current 
anxiety disorder? 
No
Refer back to CAMHS with
detailed assessment report
Yes
Invite to take part in trial
Does the family agree?
No
Treatment as usual (e.g. group CBT) 
Yes
Trial protocol
1.
2.
3.
Suspected anxiety disorder in child
Child aged 7–12 years
Absence of significant physical or intellectual
impairment (including ASD) in child
Assessment by trial assessors
FIGURE 1 Flow chart outlining recruitment schedule. ASD, autistic spectrum disorder; CAMHS, Child and Adolescent
Mental Health Services.
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Randomisation, concealment and blinding
Participants were randomised to one of three treatment conditions: (i) CCBT; (ii) CCBT plus CBT for
maternal anxiety disorder (CCBT+MCBT); or (iii) CCBT plus treatment focused on the MCI (CCBT+MCI).
Each of the three conditions included non-specific therapeutic interventions to balance the treatment arms
for therapist contact with both children and mothers. These were non-directive counselling (NDC; for
mothers not receiving MCBT, i.e. groups i and iii) and a family health (FH) intervention (for those not
receiving MCI, i.e. groups i and ii), see Table 1.
Randomisation was performed externally at the Centre for Statistics in Medicine (University of Oxford, UK)
on receipt of anonymised participant information by fax. Patients were randomised with a 1 : 1 : 1 ratio and
minimisation was used to ensure balanced allocation across the treatment groups for child age, gender
and type of child anxiety disorder, and baseline severity of the child’s and mother’s primary anxiety
disorder. The trial manager was informed of randomisation and allocated participants to therapists for
treatment. All assessors and coders remained blind to treatment group for the duration of the study.
Treatment group allocation
The order of treatment delivery is shown in Table 1. MCBT/NDC was delivered first, then the CCBT and
MCI/FH interventions were delivered in parallel. Each phase of treatment (MCBT/NDC, CCBT, MCI/FH) was
delivered by a different therapist.
Child cognitive–behavioural therapy
All children, in all treatment arms, received eight 1-hour weekly sessions of individual CBT delivered by 1 of 10
qualified clinical psychologists or cognitive–behaviour therapists (graduate therapists who held postgraduate
certificates/diplomas in CBT), following a manual adapted from the widely used ‘Cool Kids’ programme35
to be used on an individual rather than group basis. Core components of the treatment include
psychoeducation, identification and modification of anxious thoughts, and graded exposure to feared
situations/stimuli. The adaptations involved reducing the number of sessions to eight (from nine) as the
content could be covered more quickly on an individual basis, and altering exercises and practices so that they
worked well on an individual basis using strategies from the ‘Coping Cat’ programme.36 Sessions took place in
TABLE 1 Overview of design
Condition CCBT CCBT+MCBT CCBT+MCI
Assessment 1: pre treatment Diagnostic assessment (mother and child)+ laboratory observation of MCI
Treatment 1 NDC (8) MCBT (8) NDC (2)
Assessment 1B: mid-treatment
(number of sessions)
Diagnostic assessment (mother and child)
Treatment 2 (number of sessions) CCBT (8)+ FH (mother: 2;
child+mother: 2)
CCBT (8)+ FH (mother: 2;
child+mother: 2)
CCBT (8)+MCI (mother: 8;
child+mother: 2)
Assessment 2: post treatment Diagnostic assessment (mother and child)+ laboratory observation of MCI
Assessment 3: 6 months
post treatment
Diagnostic assessment (child)
Assessment 4: 12 months
post treatment
Diagnostic assessment (child)
Total therapy sessions Mother: 10
Child: 8
Child+mother: 2
Mother: 10
Child: 8
Child+mother: 2
Mother: 10
Child: 8
Child+mother: 2
TRIAL DESIGN AND METHODS
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the participants’ local Child and Adolescent Mental Health Services (CAMHS), at the University of Reading
Child Anxiety Clinic or within the child’s home. The focus of treatment was on helping children to identify and
challenge negative thinking styles, gradually increase exposure to feared stimuli and develop problem-solving
skills. Mothers were included briefly in giving and receiving feedback at the beginning and end of each session
(for approximately 5 minutes). To ensure therapist adherence to the CCBT treatment manual was equivalent
across condition, 75 treatment sessions (25 from each condition) were rated for adherence to the manual
(in terms of therapist stance, coverage of general and specific content) by blind raters (minimum Bachelor
of Science psychology) trained to acceptable levels of reliability [therapist stance: intraclass correlation
(ICC)= 0.76–76; general content: ICC= 0.73–0.82; specific content: ICC= 0.81–0.89]. Treatment adherence
for CCBT did not differ across the three conditions [therapist stance: F(2,72)= 1.83, p= 0.17; general content:
F(2,72)= 0.80, p= 0.92; specific content: F(2,72)= 0.23, p= 0.80].
Maternal cognitive–behavioural therapy
Maternal cognitive–behavioural therapy consisted of eight 1-hour weekly sessions delivered by one of
seven clinical psychologists or cognitive–behaviour therapists (all supervised by a highly experienced
clinical psychologist who was a British Association of Behavioural & Cognitive Psychotherapies-accredited
cognitive–behaviour therapist) following a manualised transdiagnostic treatment for adult anxiety
disorders.37 A transdiagnostic approach was applied on the basis that mothers presented with various
anxiety disorders; the effectiveness of a transdiagnostic approach to anxiety disorders has been established
in similar contexts.38 This treatment used cognitive–behavioural methods to reverse the putative
maintaining mechanisms identified through individual formulation. Treatment was delivered in the
participants’ local CAMHS, at the University of Reading Child Anxiety Clinic or within the family’s home.
Groups that did not receive MCBT received a non-specific intervention (NDC), in which mothers received a
supportive individual intervention that was not focused specifically on reducing symptoms of anxiety but
involved supportive non-directive listening for clients to facilitate self-reflection and to clarify and focus on
feelings within an accepting, non-judgemental, empathic environment, following the manual of Borkovec and
Costello.39 NDC was provided by one of five qualified counsellors (all accredited by the British Association for
Counselling & Psychotherapy), supervised by a highly experienced counsellor/psychotherapist with senior
British Association for Counselling & Psychotherapy accreditation.39 To ensure fidelity of the two treatments,
the content of therapist utterances from 100 treatment sessions (50 MCBT, 50 NDC) was allocated by
independent raters (psychology graduates), trained to a high level of reliability, to categories considered as
allowed or not allowed within each treatment condition (reliability of proportion of allowable utterances,
MCBT ICC= 0.73; NDC, ICC= 0.73). The proportion of MCBT allowable utterances was significantly higher in
MCBT than in NDC [t(98)= 6.25; p< 0.001] and the proportion of NDC allowable utterances was significantly
higher in NDC than in MCBT [t(98)= 4.40; p< 0.001], indicating that the content of the two treatments
differed as intended. As shown in Table 1, MCBT and NDC were delivered first, before the delivery of CCBT.
Mother–child interaction treatment
The MCI intervention consisted of 10 sessions delivered over 8 weeks by one of seven qualified clinical
psychologists or cognitive–behaviour therapists (supervised by an experienced clinical psychologist): eight
sessions were with the mother alone and two were with the mother and child together. This was a novel
intervention designed to target potentially anxiogenic maternal parenting behaviours. Specifically, it aimed to
enhance maternal autonomy promoting cognitions (such as confidence in her child’s ability to face challenge)
and behaviours and reduce potentially anxiogenic behaviours. This was achieved through a combination
of specific strategies from existing family interventions for childhood anxiety,30,35 with the addition of
video-feedback techniques developed and piloted by the trial investigators.40,41 Sessions took place in the
participants’ local CAMHS, at the University of Reading Child Anxiety Clinic or within the family’s home. The
two mother and child sessions were conducted within the laboratory at the University of Reading, as these
involved the mother and child completing structured tasks which were video-recorded for feedback purposes.
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To balance therapist contact, those groups that did not receive the MCI intervention received sessions that
focused on the promotion of a healthy lifestyle (see Table 1). A manual was developed for this intervention
that principally focused on following a healthy diet and participating in regular exercise using a number
of worksheets, games and activities based on existing interventions applied within school settings (FH).42–54
The FH intervention was delivered by 1 of 10 therapists [qualified clinical psychologists, cognitive–behaviour
therapists and one psychology graduate (Bachelor of Science) with extensive experience of delivering
behavioural interventions, under supervision of an experienced clinical psychologist (LW)].
Mother–child interaction/FH were delivered in parallel with CCBT for all participants. To ensure treatment
fidelity, raters who were blind to treatment condition rated audio-recordings of 40 therapy sessions on the
degree to which session content focused on the MCI or FH. Inter-rater reliability was excellent (ICC= 0.98).
MCI sessions were rated significantly higher than FH sessions on the degree to which sessions focused on
MCI (Mann–Whitney U-test= 6.01; p< 0.0001), and FH sessions were rated significantly higher on the
degree to which session focused on FH (Mann–Whitney U-test= 5.90; p< 0.0001) indicating that the
content of the two treatments differed as intended.
Data collection and management
Trial data were entered into an International Business Machine Corporation Statistical Package for the
Social Sciences database (IBM SPSS, version 17; IBM Corporation, Armonk, NY, USA) and monitoring and
tracking information was entered onto a Microsoft Access 2003 database (Microsoft Corporation,
Redmond, WA, USA). A range of data validation checks were carried out in Access, SPSS and Stata
Software Release 12 (StataCorp LP, College Station, TX, USA) to minimise erroneous or missing data.
Assessments of maternal anxiety disorder and parenting were made before and immediately following the
interventions. Assessments of child anxiety disorder status and severity were conducted before and
following treatment, as well as at 6 and 12 months after treatment. All assessors were blind to treatment
group allocation throughout the trial.
Baseline assessment
Baseline assessment for the trial comprised diagnostic interviews conducted with children and their
mothers to ascertain whether or not both the child and his/her mother met diagnostic criteria for a current
anxiety disorder. All of the follow-up measures were also administered at baseline. All baseline
assessments were conducted between May 2008 and May 2011.
Follow-up
As shown in Table 1, follow-up data collection was scheduled to take place ‘mid-treatment’ [i.e. after the
initial maternal intervention, MCBT/NDC (assessment 1B)], then ‘post treatment’ [i.e. after the CCBT
and MCI/FH intervention (assessment 2)], and 6 and 12 months from the post-treatment assessment.
Diagnostic assessments were conducted to establish whether or not interventions had successfully altered
maternal anxiety at the ‘mid-treatment’ (1B) and ‘post-treatment’ (2) assessments. To establish whether
or not the interventions had successfully altered maternal responses, observational and parent-reported
measures were administered at the ‘post-treatment’ assessment. Child diagnostic and symptom outcomes
were assessed at all time points.
All follow-up data were collected between September 2008 and February 2013. A flow chart showing all
recruitment and retention is given in Figure 2.
TRIAL DESIGN AND METHODS
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Measures
Primary outcomes
The primary outcomes were (i) the status of the child’s primary anxiety disorder and (ii) the extent of child
improvement at the post-treatment assessment. This second primary outcome was added to the primary
outcomes identified in the original protocol following its inclusion as the primary outcome in a recent major
multicentre trial for the treatment of anxiety disorders,55 with approval from the Trial Steering Committee (TSC).
Structured diagnostic interviews with children and parents
Children were assigned diagnoses on the basis of the Anxiety Disorder Interview Schedule for DSM-IV
for children, child and parent versions (Anxiety Disorders Interview Schedule – child and parent report;
ADIS-C/P).56 For the ADIS-C/P, as is standard, overall diagnoses and clinical severity ratings (CSRs)
were assigned if the child met diagnostic criteria on the basis of either the child or parent report, and the
higher CSR of the two was taken. Following convention, only those with a CSR of ≥ 4 (moderate
psychopathology) on a scale from 0 (complete absence of psychopathology) to 8 (severe psychopathology)
were considered to meet diagnostic criteria. The assessors, all psychology graduates, were trained to
administer and score the ADIS-C/P through verbal instruction, listening to assessment audio-recordings,
role-play and participating in diagnostic consensus discussions. Each of the assessor’s first 20 interviews
were discussed with a consensus team, led by a consultant clinical psychologist (LW). The assessor and the
consensus team independently allocated diagnoses and CSRs. Once assessors achieved reliability of at least
0.85, they discussed one in six interviews with the consensus team (to prevent rater drift). Reliability for
presence or absence of child diagnosis on the ADIS-C/P was κ= 0.98 (child report) and κ= 0.98 (mother
report), and CSR ICC= 0.99 (child report) and CSR ICC= 0.99 (mother report).
Clinical Global Impression – Improvement scale57
Overall improvement in child anxiety was assessed using the Clinical Global Impression – Improvement
(CGI-I) scale, a 7-point scale from 1= very much improved to 7= very much worse; scores of 1 and 2 are
accepted to represent treatment success. Inter-rater reliability was established using the same procedures
as for the ADIS-C/P. Overall mean inter-rater reliability for the assessment team was high (ICC= 0.96).
Secondary outcomes
Maternal anxiety and maternal interactive responses were assessed to establish whether or not MCI and
MCBT effectively changed these factors. Secondary outcomes included (i) the severity of the child’s primary
anxiety diagnosis; (ii) if the child was or was not free of all of their anxiety diagnoses (as assessed by the
ADIS-C/P above); (iii) child- and mother-reported child anxiety symptoms and impact and comorbid
difficulties; and (iv) teacher-reported symptoms of anxiety and adjustment to school at the post-treatment
assessment. Finally, outcomes included all of the primary and secondary measures at the 6- and 12-month
follow-up assessments.
Maternal anxiety disorder
The presence or absence of a current maternal anxiety disorder was assigned on the basis of the ADIS-IV,58
a structured diagnostic assessment designed to assess the presence and severity of DSM-IV anxiety, mood
and somatoform disorders. CSRs for each disorder present are made and range from 0 (not at all severe)
to 8 (extremely severe/distressing). A rating of 4 is considered to be the cut-off for a clinically significant
disorder. Procedures for training assessors and ensuring inter-rater reliability followed those of the ADIS-C/P.
Reliability for presence or absence of maternal diagnosis on the ADIS-IV was κ= 0.97; and for the
CSR ICC= 0.99.
Maternal symptoms of anxiety and depression
The Depression Anxiety Stress Scale (DASS-21)59 was administered to all participating mothers to assess
self-reported symptoms. The DASS-21 has demonstrated good internal consistency and concurrent validity.60
Maternal symptoms of worry were assessed using the Penn State Worry Questionnaire (PSWQ),61 a 16-item
self-report inventory designed to assess the pathological worry characteristic of GAD. Maternal symptoms of
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social anxiety were also measured using the Social Interaction Anxiety Scale (SIAS) and the Social Phobia
Scale (SPS).62 The SIAS is a 20-item self-report inventory designed to assess anxiety experienced while
interacting with others. The SPS is a 20-item self-report inventory designed to assess fear of scrutiny when
performing a task or being observed by others. Internal reliability for the scales was good across assessment
time points (DASS-21 anxiety α= 0.80–0.87; DASS-21 depression α= 0.90–0.92; PSWQ α= 0.92–0.93;
SIAS α= 0.92–0.93; SPS α= 0.91–0.94).
Maternal parenting and parental expectations
Maternal behaviours in interaction with the child was assessed by laboratory observation under conditions
of mild social, performance and physical threat.23 The social threat task involved the child preparing and
delivering a speech to a research assistant with a hand-held video camera with their mother’s support. The
performance task involved the child attempting difficult tangram puzzles following the procedure of
Hudson and Rapee.63 The physical threat task required children to investigate the content of four chambers
within a mysterious ‘black box’. To account for prior experience, the assessment was modified at the
post-treatment assessment point; for social stress the child was required to present to a panel rather than
a single research assistant, the tangram puzzles were more difficult and the black box was accompanied by
sound effects (e.g. rustling/scratching).
Observers who were blind to treatment condition coded parental behaviours on scales developed by Murray
and colleagues64 and adapted by Creswell and colleagues23 to be suitable for children aged 7–12 years and
for the specific tasks. Ratings were given for each minute of the interaction on 5-point scales (1= none,
5= pervasive/strong). As interactions varied somewhat in duration, mean scores for each task were summed
to give total scores across the full range of tasks. For the current study the following behaviours were
considered: maternal expressed anxiety; control (overprotection and intrusiveness); positivity (warmth and
encouragement); promotion of avoidance; and the general quality of the relationship. See Table 2 for a
description of each type of parenting behaviour. For each coder, in each task, a second coder independently
scored a random sample of 25 videotapes. ICCs showed good agreement across all indices (range 0.60–1.00;
mean 72). The constructs of encouragement and warmth overlap and these scales correlated highly
(p= 0.56–0.58) so were combined to form as single measure of ‘positive behaviours’.
Mothers also completed the parental overprotection measure (OP)65 to assess parenting behaviours that
restrict a child’s exposure to perceived threat or harm (e.g. ‘when playing in the park I keep my child
within a close distance of me’). This parent-reported measure has been found to correlate significantly
with observations of parent behaviours,65,66 and has been found to be reliable and valid for children aged
7–12 years.66 Internal consistency was good across the assessment time points (α= 0.87–0.89).
TABLE 2 Observed parenting behaviours
Negative behaviour
Expressed anxiety Modelling of anxiety: anxiety in facial expression (e.g. fearful expression, biting lip), body
movements (e.g. rigid posture, wringing hands), and speech (e.g. rapid, nervous, or inhibited)
Overprotection Initiates emotional and/or practical support that is not required (stroking/kissing/offering
unnecessary help while child manages independently)
Intrusiveness Interferes, verbally or physically, cutting across child behaviour, attempts to take over and
impose own agenda
Promotion of avoidance Actively encourages/supports child avoidance of task (e.g. saying ‘you don’t have to do it’)
Positive behaviour
Encouragement
(autonomy–promotion)
Provides positive motivation to child to engage in the task, showing enthusiasm regarding
both task and child capacity/efforts
Warmth Affectionate, expresses positive regard for child, both verbally and physically
Quality of relationship Sense of relatedness and mutual engagement between mother and child (e.g. talking,
listening, laughing and joking with each other)
TRIAL DESIGN AND METHODS
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Maternal expectations were assessed before initiating the challenge tasks. Immediately after receiving the
instructions for each task, mothers were taken to a separate room where they were asked to provide
ratings regarding their child’s response.23 In the current study we were interested in their responses
regarding (a) how their child would feel about doing the task (0 not scared at all, 10 extremely scared);
(b) how they would feel while their child was doing the task (0 not anxious at all, 10 extremely anxious);
(c) how much their child could do about how the task went (0 nothing at all, 10 a lot); and (d) how much
they could do about their child’s feelings and behaviours during the task (0 nothing at all, 10 a lot).
Ratings were combined across the three tasks to represent their expectations across a range of
challenge contexts.
Symptoms of child anxiety
The Spence Child Anxiety Scale (SCAS)29,67 assessed child- and parent-reported child anxiety symptoms.
The child version [Spence Child Anxiety Scale – child report (SCAS-c)] requires children to rate how often
they experience each of 38 anxiety symptoms, presented alongside six positive filler items. The SCAS-c
and Spence Child Anxiety Scale – parent report (SCAS-p) have demonstrated high internal reliability and
concurrent validity with other well-known anxiety measures.29,67
Impact of child anxiety
The Child Anxiety Impact Scale (CAIS) was used to measure the extent to which anxiety interferes in a
child’s life.68 The Child Anxiety Impact Scale – child report (CAIS-c) and Child Anxiety Impact Scale – parent
report (CAIS-p) covers three psychosocial domains (school, social activities and family functioning) and
consists of 34 items, each rated on a 4-point scale to indicate how much anxiety has caused problems
(not at all, just a little, pretty much, very much). The CAIS-c and CAIS-p have demonstrated good reliability
and validity.68,69
Symptoms of child comorbid difficulties
The Short Mood and Feelings Questionnaire (SMFQ)70 assessed child- and parent-reported symptoms of
child low mood. The Short Mood and Feelings Questionnaire – child report (SMFQ-c) and Short Mood and
Feelings Questionnaire – parent report (SMFQ-p) are brief, 13-item measures which require children or
parents to report how often in the past 2 weeks they have experienced a number of symptoms. The
SMFQ-c has demonstrated high internal reliability and concurrent validity with other well-known measures
of symptoms of depression.70 The conduct problems scale from the Strengths and Difficulties Questionnaire
(SDQ)71 was used to assess child- and parent-reported behavioural disturbance. The Strengths and
Difficulties Questionnaire – child report (SDQ-c) and Strengths and Difficulties Questionnaire – parent
report (SDQ-p) are known to have good psychometric properties and scores correlate highly with other
well-known scales.71
Internal reliability for all these scales was good across assessment time points (SCAS-c α= 0.92–0.94;
SCAS-p α= 0.88–0.93; CAIS-p α= 0.69–0.91; SMFQ-c α= 0.89–0.94; SMFQ-p α= 0.90–0.93), with the
exception of the SDQ conduct scales where internal reliability was marginal (SDQ-p α= 0.54–0.68; SDQ-c
α= 0.55–0.69), although this may reflect the relatively low number of items, and the CAIS-c at the
initial assessment (α= 0.52), although for this scale internal reliability was higher at subsequent
assessments (α= 0.88–0.96).
Teacher-reported child symptoms and adjustment
Teacher reports were collected in an attempt to provide an objective assessment of child adjustment in the
school domain before and after treatment. To assess teacher perceptions of child anxiety symptoms they
completed an adapted version of the SCAS (Spence Child Anxiety Scale – teacher report; SCAS-t). This
comprised the 30 items that it was felt that teachers would be in a position to comment on (i.e. removing
items about, for example, sleep, heights, animal fears). Teachers also completed the conduct scale of the
parent/teacher report form of the SDQ (Strengths and Difficulties Questionnaire – teacher report; SDQ-t)71
which comprised five items. Finally, teachers completed a new measure of the child’s adjustment to school
(Child Adjustment to School – teacher report; CAS-t), which focused on avoidance or worry about common
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school-based activities, such as showing things to the class, participating in group activities, speaking to the
teacher. This comprised eight items that were rated on a 3-point scale from 0 (not true) to 2 (certainly true),
see Appendix 4. Internal reliability for all these scales was acceptable across assessment time points (SCAS-t
α= 0.91–0.96; SDQ-t α= 0.64–0.78; CAS-t α= 0.89–0.92).
Sample size
The study was powered to provide 90% power at the 5% (two-sided) significance level to detect a 30%
difference in the proportion of children who recovered from their primary anxiety disorder post treatment
in the CCBT+MCI or CCBT+MCBT conditions compared with the CCBT condition, with an estimated
remission rate for the CCBT group of 40%.9 Although the effects of the non-specific treatment on child
outcomes were not clear, using the 40% remission rate from Cobham and colleagues9 was considered
reasonable to account for the effect of CCBT plus any non-specific intervention, given the substantially
briefer form of CCBT delivered in the current trial.
A difference of 30% in the proportion of anxiety-free children following completion of the treatment was
considered to be the minimum that would be clinically worthwhile taking into account the increased
resources required and change to service delivery that would be required if either of these interventions
were found to be effective and implemented in practice. The required sample size of 56 children per group
was increased to allow for an estimated 20% loss to follow-up. The sample size was estimated as if two
independent trials were conducted, with no adjustment for multiple testing, as recommended by Machin
and colleagues.72
Statistical analysis
A comprehensive statistical analysis plan was prepared before embarking on the analysis. All primary and
secondary analyses, apart from the per-protocol (PP) sensitivity analyses, were conducted on the
intention-to-treat (ITT) population. The primary end points (recovery from primary diagnosis and overall
improvement in anxiety (CGI-I ratings) at post treatment and other binary end points were analysed using
a modified Poisson regression approach with robust error variance adjusting for the minimisation factors
[child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other)], baseline severity
of the child’s and the mother’s primary anxiety disorder (ADIS-IV CSR). The modified Poisson regression
approach described by Zou73 is an alternative to logistic regression which allows for estimation of risks
ratios (RRs) rather than odds ratios. Sensitivity analyses of the primary end points included (i) no adjustment
for minimisation criteria; (ii) PP population (this included those participants who had received at least half
of the treatment sessions and had data for the post-treatment assessments, with the exception of one
mother in the MCBT condition who also received the MCI intervention in error, rather than the FH control;
data from this family was also removed for the PP analyses); and (iii) multiple imputation analysis. Missing
data for the primary end points were multiply imputed by chained equations methods.74 All results from
sensitivity analyses were very similar to the primary results. Interim analyses were conducted by the trial
statistician when 156 participants had been recruited following a request from the funders. The interim results
were kept confidential from the trial manager, all assessors, therapists and their supervisors.
Questionnaire scores, maternal behaviours and maternal cognitions were modelled using linear regression
models with the change from baseline as the dependent variable, adjusted for baseline score and
minimisation factors. There were outliers present in some of the regression models; however, these were
reviewed and were not considered to be due to incorrect completion of the questionnaires. Furthermore,
their removal did not change the conclusions from the regression.
All analyses were conducted using Stata software.
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Chapter 3 Trial results
Patient flow and numbers analysed
Patient flow is shown in Figure 2. The number of available participants for each treatment arm were
as follows:
l post treatment: CCBT n= 56 (79%), CCBT+MCBT n= 60 (87%), CCBT+MCI n= 62 (87%)
l 6 months post treatment: CCBT n= 49 (69%), CCBT+MCBT n= 53 (77%), CCBT+MCI n= 51 (72%)
l 12 months post treatment: CCBT n= 43 (61%), CCBT+MCBT n= 50 (70%), CCBT+MCI n= 46 (65%).
Baseline data
Baseline characteristics were well balanced across treatment groups (Table 3).
TABLE 3 Baseline characteristics by treatment allocation
Baseline characteristic Category CCBT, n (%) CCBT+MCBT, n (%) CCBT+MCI, n (%)
Child ethnicity White British 67 (94.4) 58 (84.1) 55 (77.5)
White Irish 1 (1.4) 1 (1.4)
Any other white background 5 (7.2) 7 (9.9)
White and black Caribbean 1 (1.4)
White and black African 1 (1.4)
White and Asian 2 (2.9)
Any other mixed background 1 (1.4)
Indian 1 (1.4)
Pakistani 2 (2.9) 1 (1.4)
Any other Asian background 1 (1.4) 2 (2.8)
Caribbean 1 (1.4)
Any other ethnic group 1 (1.4)
Did not wish to state ethnicity 1 (1.4)
Not recorded 1 (1.4) 1 (1.4)
Child gender Male 34 (47.9) 35 (50.7) 32 (45.1)
Female 37 (52.1) 34 (49.3) 39 (54.9)
Martial status Single, never married 2 (2.8) 5 (7.2) 5 (7.0)
Married (first time) 28 (39.4) 41 (59.4) 38 (53.5)
Remarried 8 (11.3) 3 (4.3) 5 (7.0)
Divorce/separated 21 (29.6) 11 (15.9) 12 (16.9)
Living with partner 11 (15.5) 9 (13.0) 8 (11.3)
Not recorded 1 (1.4) 3 (4.2)
continued
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TABLE 3 Baseline characteristics by treatment allocation (continued )
Baseline characteristic Category CCBT, n (%) CCBT+MCBT, n (%) CCBT+MCI, n (%)
Employment mother Unemployed 21 (29.6) 23 (33.3) 18 (25.4)
Part time 33 (46.5) 33 (47.8) 37 (52.1)
Full time 14 (19.7) 8 (11.6) 13 (18.3)
Not recorded 3 (4.2) 5 (7.2) 3 (4.2)
Employment father Unemployed 1 (1.4) 6 (8.7) 5 (7.0)
Part time 1 (1.4) 1 (1.4)
Full time 50 (70.4) 50 (72.5) 53 (74.6)
NA 5 (7.0) 1 (1.4) 1 (1.4)
Not recorded 15 (21.1) 11 (15.9) 11 (15.5)
Overall SES Higher professional 29 (40.8) 39 (56.5) 38 (53.5)
Other employed 29 (40.8) 16 (23.2) 26 (36.6)
Unemployed 2 (2.8) 1 (1.4)
Not recorded 11 (15.5) 14 (20.3) 6 (8.5)
Mother education School completion 21 (31.3) 11 (17.7) 22 (33.9)
Further education 34 (50.8) 32 (51.6) 27 (41.5)
Higher education 7 (10.5) 12 (19.4) 12 (18.5)
Postgraduate qualification 5 (7.5) 7 (11.3) 4 (6.2)
Father education School completion 17 (34.7) 12 (22.6) 23 (39.7)
Further education 17 (34.7) 20 (37.7) 20 (34.5)
Higher education 9 (18.4) 15 (28.3) 11 (19.0)
Postgraduate qualification 6 (12.2) 6 (11.3) 4 (6.9)
Child ADIS-C/P
primary diagnosis
SAD 19 (26.8) 16 (23.2) 21 (29.6)
Social phobia 16 (22.5) 18 (26.1) 14 (19.7)
GAD 22 (31.0) 20 (29.0) 24 (33.8)
Other 14 (19.7) 15 (21.7) 12 (16.9)
Specific phobia 8 (11.3) 11 (15.8) 5 (7.0)
PD without agoraphobia 1 (1.4)
PD with agoraphobia 1 (1.4)
Agoraphobia without PD 3 (4.2) 2 (2.9) 3 (4.2)
Selective mutism 1 (1.4)
Anxiety disorder not
otherwise specified
2 (2.8) 2 (2.9) 2 (2.8)
Child ADIS-C/P primary
diagnosis CSR
Moderate 4 6 (8.5) 5 (7.2) 5 (7.0)
Moderate 5 21 (29.6) 19 (27.5) 19 (26.8)
Severe 6 36 (50.7) 37 (53.6) 40 (56.3)
Severe 7 8 (11.3) 8 (11.6) 7 (9.9)
Child mood disorder
(major depressive
disorder/dysthymia)
No diagnosis 62 (87.3) 62 (89.9) 67 (94.4)
Diagnosis 9 (12.7) 7 (10.1) 4 (5.6)
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Manipulation checks: effects of the interventions on maternal
anxiety and responses
Manipulation checks were conducted to evaluate whether or not the MCBT and MCI interventions
successfully altered maternal anxiety and maternal responses, respectively.
Change in maternal anxiety
Recovery from maternal primary diagnosis at assessment 1B
As shown in Table 4, from the CCBT group eight mothers had missing data for their primary ADIS-IV
diagnosis at the mid-treatment assessment (assessment 1B, i.e. after the MCBT intervention), for the
CCBT+MCBT group this was four mothers and for CCBT+MCI this was one mother.
TABLE 3 Baseline characteristics by treatment allocation (continued )
Baseline characteristic Category CCBT, n (%) CCBT+MCBT, n (%) CCBT+MCI, n (%)
Child age (years) 6 1 (1.4)
7 4 (5.6) 5 (7.2) 7 (9.9)
8 12 (16.9) 7 (10.1) 13 (18.3)
9 9 (12.7) 12 (17.4) 12 (16.9)
10 17 (23.9) 17 (24.6) 13 (18.3)
11 18 (25.4) 16 (23.2) 13 (18.3)
12 10 (14.1) 11 (15.9) 11 (15.5)
13 1 (1.4) 2 (2.8)
Mother’s ADIS-IV
primary disorder
Specific phobia 12 (16.9) 17 (24.6) 9 (12.7)
GAD 37 (52.1) 35 (50.7) 40 (56.3)
Social phobia 9 (12.7) 14 (20.3) 11 (15.5)
PD 1 (1.4) 1 (1.4)
Agoraphobia 2 (2.8) 1 (1.4) 2 (2.8)
OCD 1 (1.4)
PTSD 1 (1.4)
Major depressive disorder 5 (7.0)
Hypochondriasis 2 (2.8)
Anxiety disorder not
otherwise specified
1 (1.4) 2 (2.9) 8 (11.3)
Mother ADIS-IV CSR of
primary disorder
Moderate 4 20 (28.2) 18 (26.1) 18 (25.4)
Moderate 5 22 (31.0) 25 (36.2) 21 (29.6)
Severe 6 22 (31.0) 22 (31.9) 24 (33.8)
Severe 7 6 (8.5) 4 (5.8) 8 (11.3)
Very severe 8 1 (1.4)
Mother mood disorder
(major depressive
disorder/dysthymia)
No diagnosis 57 (80.3) 58 (84.1) 56 (78.9)
Diagnosis 14 (19.7) 11 (15.9) 15 (21.1)
NA, not applicable; OCD, obsessive–compulsive disorder; PTSD, post-traumatic stress disorder; SES, socioeconomic status.
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As shown in Table 5, at assessment 1B, 23 mothers (37%) in the control group had recovered from their
primary diagnosis. In the CCBT+MCBT group 38 mothers (59%) had recovered and in the CCBT+MCI
group 30 mothers (43%) had recovered.
Mothers in the CCBT+MCBT group were 1.63 times more likely to recover from their ADIS-IV primary
diagnosis by assessment 1B than those in the CCBT group [adjusted RR 1.63, 95% confidence interval (CI)
1.13 to 2.36; p= 0.009]. The adjusted RR for CCBT+MCI versus CCBT is 1.22 (95% CI 0.83 to 1.81;
p= 0.314) (Table 6).
Recovery from all anxiety diagnoses at assessment 1B
As shown in Table 7, the CCBT group had the largest per cent of missing data for mothers at assessment
1B with 13%, the CCBT+MCBT group had 6% and the CCBT+MCI group had 1%.
As shown in Table 8, in the CCBT group 10 mothers (16%) had recovered from all anxiety diagnoses by
assessment 1B. However, in the CCBT+MCBT group there were 25 recovered mothers (39%) and in the
CCBT+MCI group there were 22 recovered mothers (31%).
TABLE 5 Presence of pre-treatment ADIS-IV primary diagnosis at assessment 1B
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 23 (36.5) 40 (63.5) 63
CCBT+MCBT 38 (58.5) 27 (41.5) 65
CCBT+MCI 30 (42.9) 40 (57.1) 70
Total 91 107 198
TABLE 4 Presence of pre-treatment ADIS-IV primary diagnosis at assessment 1B (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 8 (11.3) 23 (32.4) 40 (56.3) 71
CCBT+MCBT 4 (5.8) 38 (55.1) 27 (39.1) 69
CCBT+MCI 1 (1.4) 30 (42.3) 40 (56.3) 71
Total 13 91 107 211
TABLE 6 Analysis of mothers’ recovery from pre-treatment ADIS-IV primary diagnosis at assessment 1B
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.63 1.13 to 2.36 0.009
CCBT+MCI 1.22 0.83 to 1.81 0.314
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Mothers receiving CCBT+MCBT or CCBT+MCI were more than twice as likely to have recovered from all
anxiety diagnoses by assessment 1B than mothers in the control group CCBT+MCBT (RR 2.51, 95% CI
1.43 to 4.40; p= 0.001) and CCBT+MCI (RR 2.15, 95% CI 1.21 to 3.81; p= 0.009) (Table 9).
Change in maternal self-reported symptoms at assessment 1B
Table 10 shows the results of analyses looking at the change from baseline to assessment 1B scores of
questionnaires completed by mothers about themselves. There were no significant differences between
treatment groups. Summary scores are shown in Appendix 5, Table 123.
Recovery from maternal primary diagnosis at assessment 2 (end of
all treatment)
As shown in Table 11, missing data was similar at the end of treatment (assessment 2) for mothers in the
CCBT and CCBT+MCBT groups (24% and 20%, respectively). In the CCBT+MCI group it was 13%.
TABLE 7 Presence of any ADIS-IV anxiety diagnosis in mothers at assessment 1B (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 9 (12.7) 10 (14.1) 52 (73.2) 71
CCBT+MCBT 4 (5.8) 25 (36.2) 40 (58.0) 69
CCBT+MCI 1 (1.4) 22 (31.0) 48 (67.6) 71
Total 14 57 140 211
TABLE 8 Presence of any ADIS-IV anxiety diagnosis in mothers at assessment 1B
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 10 (16.1) 52 (83.9) 62
CCBT+MCBT 25 (38.5) 40 (61.5) 65
CCBT+MCI 22 (31.4) 48 (68.6) 70
Total 57 140 197
TABLE 9 Analysis of recovery from any ADIS-IV anxiety diagnosis in mothers at assessment 1B
Parameter RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 2.51 1.43 to 4.40 0.001
CCBT+MCI 2.15 1.21 to 3.81 0.009
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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TABLE 10 Adjusted analysis of change in mothers’ self-report questionnaires at assessment 1B
Questionnaire Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
PSWQ total score CCBT 40 –2.91 (–5.91 to 0.10) Ref.
CCBT+MCBT 42 –4.96 (–7.90 to –2.01) –2.05 (–6.31 to 2.21) 0.342
CCBT+MCI 44 –3.72 (–6.59 to –0.84) –0.81 (–5.03 to 3.40) 0.704
SIAS total score CCBT 41 –0.86 (–3.37 to 1.66) Ref.
CCBT+MCBT 44 –1.24 (–3.67 to 1.18) –0.39 (–3.92 to 3.15) 0.829
CCBT+MCI 47 –0.49 (–2.84 to 1.86) 0.37 (–3.12 to 3.85) 0.835
SPS total score CCBT 41 –0.77 (–3.19 to 1.64) Ref.
CCBT+MCBT 45 –0.21 (–2.52 to 2.10) 0.56 (–2.81 to 3.94) 0.742
CCBT+MCI 46 0.07 (–2.22 to 2.36) 0.84 (–2.53 to 4.22) 0.622
DASS-21 depression
subscale
CCBT 38 –1.54 (–3.28 to 0.21) Ref.
CCBT+MCBT 43 –2.11 (–3.74 to –0.49) –0.58 (–3.00 to 1.85) 0.638
CCBT+MCI 45 –1.70 (–3.30 to –0.11) –0.17 (–2.57 to 2.23) 0.890
DASS-21 anxiety
subscale
CCBT 38 –0.38 (–2.36 to 1.60) Ref.
CCBT+MCBT 44 –1.95 (–3.79 to –0.11) –1.57 (–4.32 to 1.18) 0.259
CCBT+MCI 45 –1.99 (–3.81 to –0.18) –1.61 (–4.34 to 1.10) 0.243
DASS-21 stress
subscale
CCBT 41 –0.90 (–2.88 to 1.08) Ref.
CCBT+MCBT 45 –1.76 (–3.65 to 0.13) –0.86 (–3.63 to 1.91) 0.539
CCBT+MCI 45 –1.28 (–3.18 to 0.61) –0.38 (–3.16 to 2.40) 0.786
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
TABLE 11 Presence of pre-treatment ADIS-IV primary diagnosis at assessment 2 (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 17 (23.9) 28 (39.4) 26 (36.6) 71
CCBT+MCBT 14 (20.3) 36 (52.2) 19 (27.5) 69
CCBT+MCI 9 (12.7) 41 (57.8) 21 (29.6) 71
Total 40 105 66 211
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As shown in Table 12, there were 36 mothers (66%) in the MCBT group and 41 mothers (66%) in the
CCBT+MCI group who recovered from their primary diagnosis by assessment 2 compared with
28 mothers (52%) from the CCBT group.
The results from log-linear regression of the mothers’ recovery from their primary ADIS-IV diagnosis by
assessment 2, adjusted for minimisation factors, are shown in Table 13. There were no significant
differences between CCBT+MCBT and CCBT or between CCBT+MCI and CCBT. The adjusted RR for the
effect of CCBT+MCBT on recovery from maternal primary diagnosis was 1.23 (95% CI 0.90 to 1.68;
p= 0.201). Similarly, the adjusted RR for the effect of CCBT+MCI on recovery was 1.27 (95% CI 0.93 to
1.74; p= 0.126).
Recovery from all anxiety diagnoses at assessment 2
Missing data was similar at assessment 2 for mothers in the CCBT and CCBT+MCBT groups (24% and
20%, respectively). In the CCBT+MCI group it was 13% (Table 14).
TABLE 12 Presence of pre-treatment ADIS-IV primary diagnosis at assessment 2
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 28 (51.9) 26 (48.1) 54
CCBT+MCBT 36 (65.5) 19 (34.5) 55
CCBT+MCI 41 (66.1) 21 (33.9) 62
Total 105 66 171
TABLE 13 Analysis of mothers’ recovery from pre-treatment ADIS-IV primary diagnosis at assessment 2
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.23 0.90 to 1.68 0.201
CCBT+MCI 1.27 0.93 to 1.74 0.126
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
TABLE 14 Presence of any ADIS-IV anxiety diagnosis in mothers at assessment 2 (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 17 (23.9) 19 (26.8) 35 (49.3) 71
CCBT+MCBT 14 (20.3) 26 (37.7) 29 (42.0) 69
CCBT+MCI 9 (12.7) 29 (40.9) 33 (46.5) 71
Total 40 74 97 211
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As can be seen in Table 15, 29 mothers (47%) in the CCBT+MCI group had recovered from all ADIS-IV
anxiety diagnoses at assessment 2 and 26 (47%) from the CCBT+MCBT group. Nineteen mothers (35%)
had fully recovered from the CCBT group.
Table 16 shows the results from log-binomial regression of the mothers’ recovery from all ADIS-IV anxiety
diagnoses adjusted for minimisation factors. There were no significant improvements for the CCBT+MCBT
group (RR 1.32, 95% CI 0.85 to 2.04; p= 0.210) or the CCBT+MCI group (RR 1.35, 95% CI 0.87 to
2.10; p= 0.179).
Change in maternal self-reported symptoms at assessment 2
The regression results from the change in mothers’ self-report questionnaires can be seen in Table 17.
There were no significant differences between the CCBT+MCBT and CCBT groups or between the
CCBT+MCI and CCBT groups.
TABLE 15 Presence of any ADIS-IV anxiety diagnosis in mothers at assessment 2
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 19 (35.2) 35 (64.8) 54
CCBT+MCBT 26 (47.3) 29 (52.7) 55
CCBT+MCI 29 (46.8) 33 (53.2) 62
Total 74 97 171
TABLE 16 Analysis of recovery from any ADIS-IV anxiety diagnosis in mothers at assessment 2
Parameter RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.30 0.84 to 2.01 0.244
CCBT+MCI 1.35 0.87 to 2.10 0.180
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Change in parenting responses
Parenting behaviours
Change in maternal parenting behaviours was analysed using linear regression. Analysis in Table 18 shows
the adjusted mean change from baseline to assessment 2, for each of the seven areas in each treatment
group. The mean score over three tasks is used for each parenting behaviour. The adjusted mean
difference compares the CCBT+MCBT group with CCBT and also the CCBT+MCI group with CCBT.
A summary of scores is given in Appendix 5, Table 122.
The only significant difference was for CCBT+MCI versus CCBT in the ‘overprotection’ scores (p= 0.026).
The difference between the CCBT+MCI and CCBT arms also approached significance for maternal
self-report overprotection (p= 0.057).
Parenting cognitions
Maternal expectations were assessed before the behavioural tasks. These ratings were recorded at baseline
and at assessment 2. The following analysis, shown in Table 19, looks at the change scores from
baseline to assessment 2, analysed using adjusted linear regression.
TABLE 17 Adjusted analysis of change in mothers’ self-report questionnaires at assessment 2
Questionnaire Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
PSWQ total score CCBT 35 –7.14 (–10.67 to –3.60) Ref.
CCBT+MCBT 41 –6.71 (–10.00 to –3.42) 0.43 (–4.47 to 5.32) 0.863
CCBT+MCI 35 –6.43 (–10.01 to –2.86) 0.70 (–4.40 to 5.81) 0.785
SIAS total score CCBT 34 –3.52 (–6.77 to –0.27) Ref.
CCBT+MCBT 40 –4.80 (–7.82 to –1.79) –1.28 (–5.79 to 3.22) 0.574
CCBT+MCI 36 –4.75 (–7.93 to –1.58) –1.23 (–5.84 to 3.37) 0.597
SPS total score CCBT 35 –3.91 (–6.15 to –1.67) Ref.
CCBT+MCBT 41 –4.03 (–6.12 to –1.94) –0.12 (–3.24 to 2.99) 0.937
CCBT+MCI 36 –2.20 (–4.65 to –2.16) 1.71 (–1.49 to 4.91) 0.291
DASS-21 depression
subscale
CCBT 32 –2.83 (–5.11 to –0.55) Ref.
CCBT+MCBT 36 –3.89 (–6.05 to –1.73) –1.06 (–4.24 to 2.13) 0.511
CCBT+MCI 33 –2.59 (–4.87 to –0.31) 0.24 (–3.05 to 3.54) 0.884
DASS-21 anxiety
subscale
CCBT 32 –0.62 (–2.80 to 1.57) Ref.
CCBT+MCBT 36 –2.75 (–4.85 to –0.65) –2.13 (–5.21 to 0.94) 0.171
CCBT+MCI 33 –2.40 (–4.61 to –0.19) –1.79 (–4.95 to 1.38) 0.266
DASS-21 stress
subscale
CCBT 34 –3.60 (–5.82 to –1.39) Ref.
CCBT+MCBT 41 –2.45 (–4.48 to –0.42) 1.15 (–1.88. 4.19) 0.453
CCBT+MCI 35 –2.77 (–4.98 to –0.56) 0.83 (–2.36 to 4.02) 0.606
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
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TABLE 18 Adjusted analyses of behavioural change scores at assessment 2 (ITT analysis)
Questionnaire Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
Positive
behaviour (–)
CCBT 42 0.042 (–0.058 to 0.141) Ref.
CCBT+MCBT 45 –0.009 (–0.104 to 0.086) –0.050 (–0.190 to 0.090) 0.478
CCBT+MCI 49 0.067 (–0.024 to 0.158) 0.026 (–0.112 to 0.163) 0.714
Over-protection (+) CCBT 42 –0.016 (–0.036 to 0.005) Ref.
CCBT+MCBT 45 –0.035 (–0.055 to –0.016) –0.020 (–0.048 to 0.009) 0.174
CCBT+MCI 49 –0.048 (–0.066 to –0.029) –0.032 (–0.060 to –0.004) 0.026
Promotion of
avoidance (+)
CCBT 42 –0.019 (–0.045 to 0.007) Ref.
CCBT+MCBT 45 –0.024 (–0.049 to 0.001) –0.004 (–0.041 to 0.033) 0.813
CCBT+MCI 49 –0.042 (–0.066 to –0.019) –0.023 (–0.059 to 0.013) 0.207
Intrusiveness (+) CCBT 42 –0.058 (–0.163 to 0.046) Ref.
CCBT+MCBT 45 0.015 (–0.085 to 0.116) 0.074 (–0.074 to 0.221) 0.324
CCBT+MCI 49 –0.108 (–0.205 to –0.012) –0.050 (–0.195 to 0.195) 0.499
Anxiety (+) CCBT 42 –0.005 (–0.106 to 0.097) Ref.
CCBT+MCBT 45 0.034 (–0.063 to 0.132) 0.039 (–0.103 to 0.182) 0.589
CCBT+MCI 49 –0.013 (–0.107 to 0.080) –0.009 (–0.149 to 0.131) 0.901
Quality of
relationship (–)
CCBT 42 0.023 (–0.074 to 0.121) Ref.
CCBT+MCBT 45 0.050 (–0.044 to 0.142) 0.026 (–0.111 to 0.163) 0.712
CCBT+MCI 49 0.003 (–0.086 to 0.092) –0.020 (–0.155 to 0.114) 0.763
POI total score (+ ) CCBT 34 –5.83 (–9.07 to –2.59) Ref.
CCBT+MCBT 38 –6.41 (–9.51 to –3.31) –0.58 (–5.06 to 3.89) 0.7974
CCBT+MCI 34 –10.32 (–13.60 to –7.04) –4.49 (–9.12 to 0.14) 0.0573
–, shows that a low score indicates dysfunction and hence an increase indicates an improvement; +, shows that a high
score indicates dysfunction and hence a decrease indicates an improvement; POI, Parent Over-Involvement Questionnaire;
ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
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For the pre-task ‘scared’ rating and pre-task ‘child in control’ rating there were significant differences
between CCBT+MCI and CCBT (p= 0.029 and p= 0.046, respectively). A summary of mean scores is
provided in Appendix 5, Table 125.
Primary outcomes
Missing data
Nine (13%) participants allocated to CCBT+MCBT and nine (13%) participants allocated to CCBT+MCI
were not able to be measured for the primary end points. These rates of missing data were slightly lower
than for participants allocated to CCBT (21%). Baseline characteristics of participants with or without
missing primary outcomes are given in Tables 20–22.
TABLE 19 Adjusted analyses of cognition change scores at assessment 2 (ITT analysis)
Questionnaire Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
Pre-task ‘child
scared’ (+)
CCBT 40 –0.69 (–1.12 to –0.26) Ref.
CCBT+MCBT 45 –1.22 (–1.62 to –0.82) –0.53 (–1.12 to 0.07) 0.083
CCBT+MCI 46 –1.36 (–1.76 to –0.96) –0.67 (–1.26 to –0.07) 0.029
Pre-task ‘mother
anxious’ (+)
CCBT 40 –0.87 (–1.32 to –0.42) Ref.
CCBT+MCBT 45 –1.43 (–1.85 to –1.01) –0.56 (–1.18 to 0.07) 0.079
CCBT+MCI 46 –1.43 (–1.85 to –1.02) –0.56 (–1.18 to 0.06) 0.077
Pre-task ‘child in
control’ (–)
CCBT 40 0.25 (–0.12 to 0.63) Ref.
CCBT+MCBT 45 0.75 (0.40 to 1.10) 0.50 (–0.03 to 1.02) 0.063
CCBT+MCI 46 0.78 (0.44 to 1.13) 0.53 (0.01 to 1.05) 0.046
Pre-task ‘mother in
control’ (+/–)
CCBT 40 –0.28 (–0.80 to 0.23) Ref.
CCBT+MCBT 45 –0.07 (–0.55 to 0.41) 0.21 (–0.51 to 0.93) 0.564
CCBT+MCI 46 –0.08 (–0.55 to 0.39) 0.20 (–0.50 to 0.91) 0.569
–, shows that a low score indicates dysfunction and hence an increase indicates an improvement; +, shows that a high
score indicates dysfunction and hence a decrease indicates an improvement; +/–, shows that it is unclear whether a high
score or a low score indicates dysfunction; ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
TABLE 20 Presence of pre-treatment ADIS-C/P primary diagnosis at assessment 2: child
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 15 (21.1) 27 (38.0) 29 (40.9) 71
CCBT+MCBT 9 (13.0) 35 (50.7) 25 (36.2) 69
CCBT+MCI 9 (12.7) 37 (52.1) 25 (35.2) 71
Total 33 99 79 211
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TABLE 21 Clinical Global Impression: child – Improvement at assessment 2
Treatment allocation Missing, n (%)
Much/very much
improved, n (%)
Not much/very much
improved, n (%) Total, n (%)
CCBT 15 (21.1) 36 (50.7) 20 (28.2) 71
CCBT+MCBT 9 (13.0) 48 (69.6) 12 (17.4) 69
CCBT+MCI 9 (12.7) 47 (66.2) 15 (21.1) 71
Total 33 131 47 211
TABLE 22 Baseline characteristics by whether or not missing ADIS-C/P assessment at assessment 2
Baseline characteristic Category
Assessment 2
Completed, n (%) Missing, n (%)
Gender Male 84 (83.2) 17 (16.8)
Female 94 (85.5) 16 (14.5)
Marital status Single, never married 7 (58.3) 5 (41.7)
Married (first time) 90 (84.1) 17 (15.9)
Remarried 13 (81.3) 3 (18.8)
Divorce/separated 39 (88.6) 5 (11.4)
Living with partner 25 (89.3) 3 (10.7)
Not recorded 4 (100.0)
Employment mother Unemployed 48 (77.4) 14 (22.6)
Part time 89 (86.4) 14 (13.6)
Full time 30 (85.7) 5 (14.3)
Not recorded 11 (100.0)
Employment father Unemployed 10 (83.3) 2 (16.7)
Part time 2 (100.0)
Full time 128 (83.7) 25 (16.3)
NA 4 (57.1) 3 (42.9)
Not recorded 34 (91.9) 3 (8.1)
Overall SES Higher professional 93 (87.7) 13 (12.3)
Other employed 57 (80.3) 14 (19.7)
Unemployed 3 (100.0)
Not recorded 25 (80.6) 6 (19.4)
ADIS-C/P primary diagnosis (initial assessment) SAD 45 (80.4) 11 (19.6)
Social phobia 42 (87.5) 6 (12.5)
GAD 51 (77.3) 15 (22.7)
Other 40 (97.6) 1 (2.4)
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TABLE 22 Baseline characteristics by whether or not missing ADIS-C/P assessment at assessment 2 (continued )
Baseline characteristic Category
Assessment 2
Completed, n (%) Missing, n (%)
ADIS-C/P primary diagnosis CSR (initial assessment) Moderate 4 12 (75.0) 4 (25.0)
Moderate 5 50 (84.7) 9 (15.3)
Severe 6 97 (85.8) 16 (14.2)
Severe 7 19 (82.6) 4 (17.4)
ADIS-C/P primary diagnosis CSR at assessment 1B No diagnosis 3 (100.0)
Mild 3 6 (100.0)
Moderate 4 25 (92.6) 2 (7.4)
Moderate 5 52 (85.2) 9 (14.8)
Severe 6 86 (91.5) 8 (8.5)
Severe 7 5 (71.4) 2 (28.6)
Very severe 8 1 (100.0)
Not recorded 12 (100.0)
Child age (years) 6 1 (100.0)
7 11 (68.8) 5 (31.3)
8 27 (84.4) 5 (15.6)
9 28 (84.8) 5 (15.2)
10 41 (87.2) 6 (12.8)
11 43 (91.5) 4 (8.5)
12 25 (78.1) 7 (21.9)
13 3 (100.0)
NA, not applicable; SES, socioeconomic status.
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Unadjusted analyses: primary end points
As shown in Table 23 and Figure 3, 48% of the children in the CCBT arm were free of their primary
diagnosis status at assessment 2 compared with 58% of children in the CCBT+MCBT and 60% of
children in the CCBT+MCI arms.
The unadjusted RR for the effect of CCBT+MCBT versus CCBT on recovery from primary ADIS-C/P diagnosis
by assessment 2 was 1.21 (95% CI 0.86 to 1.71; p= 0.280). This was very similar to the unadjusted estimate
of the effect of CCBT+MCI versus CCBT, RR 1.24 (95% CI 0.88 to 1.74; p= 0.219).
The unadjusted RR for the effect of CCBT+MCBT versus CCBT on CGI-I by assessment 2 was 1.24
(95% CI 0.99 to 1.57; p= 0.065) and for the effect of CCBT+MCI versus CCBT the RR was 1.18
(95% CI 0.93 to 1.50; p= 0.179). Frequencies are displayed in Table 24 and Figure 4.
TABLE 23 Presence of pre-treatment ADIS-C/P primary diagnosis at assessment 2: child
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 27 (48.2) 29 (51.8) 56
CCBT+MCBT 35 (58.3) 25 (41.7) 60
CCBT+MCI 37 (59.7) 25 (40.3) 62
Total 99 79 178
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FIGURE 3 Presence of pre-treatment ADIS-C/P child primary diagnosis.
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Multiple imputation analyses
Multiple imputations were used to account for missing data for the two primary end points. Twenty
imputed data sets were developed using the Stata ‘ice’ function for multiple imputation with chained
equations. Imputation models were developed using variables for treatment allocation, minimisation
factors [child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline
severity (ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother
self-report) of the mother’s primary anxiety disorder] as well as assessment of ADIS-C/P CSR at assessment
1B, assessment of ADIS-C/P primary diagnosis at assessment 1B, CGI-I at assessment 1B and baseline
mother’s depression (DASS-21 – depression), child depression symptoms (SMFQ-c), child behavioural
problems (SDQ-conduct) and presence of child social phobia.
Results from multiple imputation analyses, which were the primary analyses, along with adjusted RRs are
presented in Table 25. Adjusted analyses for log-binomial regression models did not converge (as is often
the case), therefore the modified Poisson regression framework with robust error variance was used as
specified in the analysis plan, which gives almost identical CIs.
Confidence intervals for all estimates remained similar regardless of the method of analysis.
0.28
0.64
0.80
0.77
0.22
0.80
0.77 0.78
0.21
0.76
0.88
0.80
Pr
o
p
o
rt
io
n
 m
u
ch
/v
er
y 
m
u
ch
 im
p
ro
ve
d
CCBT CCBT + MCBT CCBT + MCI
8 weeks
16 weeks
6 months
12 months
0.0
0.2
0.4
0.6
0.8
FIGURE 4 Child CGI-I.
TABLE 24 Clinical Global Impression: child – Improvement at assessment 2
Treatment allocation
Much/very much improved,
n (%)
Not much/very much improved,
n (%) Total, n (%)
CCBT 36 (64.3) 20 (35.7) 56
CCBT+MCBT 48 (80.0) 12 (20.0) 60
CCBT+MCI 47 (75.8) 15 (24.2) 62
Total 131 47 178
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TABLE 25 Results for primary end points (unadjusted, adjusted and multiple imputation analyses)
Assessment 2 RRa 95% CI p-value
ADIS-C/P primary diagnostic status: child
Unadjusted
CCBT Ref.
CCBT+MCBT 1.21 0.86 to 1.71 0.280
CCBT+MCI 1.24 0.88 to 1.74 0.219
Adjusteda
CCBT Ref.
CCBT+MCBT 1.22 0.88 to 1.67 0.228
CCBT+MCI 1.21 0.88 to 1.65 0.243
Multiple imputationa
CCBT Ref.
CCBT+MCBT 1.18 0.827 to 1.62 0.285
CCBT+MCI 1.22 0.90 to 1.67 0.203
CGI-I: child
Unadjusted
CCBT Ref.
CCBT+MCBT 1.24 0.99 to 1.57 0.065
CCBT+MCI 1.18 0.93 to 1.50 0.179
Adjusteda
CCBT Ref.
CCBT+MCBT 1.25 0.99 to 1.57 0.058
CCBT+MCI 1.18 0.93 to 1.50 0.173
Multiple imputationa
CCBT Ref.
CCBT+MCBT 1.26 1.00 to 1.59 0.054
CCBT+MCI 1.20 0.95 to 1.53 0.133
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
Per-protocol analysis of primary outcomes at assessment 2
The PP population is a subset of the ITT population and excludes from the analysis participants who were
ineligible or had significant non-compliance.
The CCBT arm PP population contained 58 children, the CCBT+MCBT arm contained 60 children and the
CCBT+MCI arm contained 64 children. This is a total of 182 children in the PP population, whereas
the ITT population contains 211 children.
Table 26 shows for each treatment group the proportion of children who had recovered from their primary
diagnosis by assessment 2; in both the CCBT+MCBT and CCBT+MCI arms this was 59% and in the
CCBT arm it was 49%.
As shown in Table 27, the adjusted RR for the effect of CCBT+MCBT versus CCBT on recovery from
primary ADIS-IV diagnosis by assessment 2 was 1.17 (95% CI 0.85 to 1.62; p= 0.328). This was very
similar to the adjusted estimate of the effect of CCBT+MCI versus CCBT, RR 1.19 (95% CI 0.86 to
1.64; p= 0.288).
The proportion of patients where the CGI-I rating improved by assessment 2 is shown in Table 28; in the
CCBT arm this was 64%, in the CCBT+MCBT arm it was 80% and in the CCBT+MCI arm it was 75%.
As shown in Table 29, the adjusted RR for the effect of CCBT+MCBT versus CCBT on improvement in
CGI-I by assessment 2 was 1.26 (95% CI 0.99 to 1.59); p= 0.056. The adjusted estimate of the effect of
CCBT+MCI versus CCBT was RR 1.18 (95% CI 0.93 to 1.52; p= 0.170).
TABLE 26 Presence of pre-treatment ADIS-C/P primary anxiety diagnosis at assessment 2: child
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 27 (49.09) 28 (50.91) 55
CCBT+MCBT 33 (58.93) 23 (41.07) 56
CCBT+MCI 36 (59.02) 25 (40.98) 61
Total 96 76 172
TABLE 27 Analysis of pre-treatment ADIS-C/P primary anxiety diagnosis at assessment 2: child
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.17 0.85 to 1.62 0.328
CCBT+MCI 1.19 0.86 to 1.64 0.288
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Secondary outcomes
Severity of child’s primary Anxiety Disorder Interview Schedule diagnosis at
assessment 2
By assessment 2, 59% of the CCBT arm, 73% of the CCBT+MCBT arm and 73% of the CCBT+MCI arm
children had seen an improvement of at least 2 points (Figure 5 and Tables 30 and 31).
There were no significant differences between CCBT+MCBT and CCBT or between CCBT+MCI and
CCBT (p= 0.101 and 0.118, respectively).
TABLE 28 Clinical Global Impression: child – Improvement at assessment 2
Treatment allocation
Much/very much improved,
n (%)
Not much/very much improved,
n (%) Total, n (%)
CCBT 35 (63.64) 20 (36.36) 55
CCBT+MCBT 45 (80.36) 11 (19.64) 56
CCBT+MCI 46 (75.41) 15 (24.59) 61
Total 126 46 172
TABLE 29 Analysis of CGI-I at assessment 2
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.26 0.99 to 1.59 0.056
CCBT+MCI 1.18 0.93 to 1.52 0.170
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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TABLE 31 Proportion of children with at least a 2-point reduction in severity of their pre-treatment ADIS-C/P
primary diagnosis at assessment 2
Treatment n n (%) with a 2 or more point reduction p-valuea
CCBT 56 33 (58.9)
CCBT+MCBT 60 44 (73.3) 0.101
CCBT+MCI 62 45 (72.6) 0.118
a Chi-squared test, comparison with control group.
TABLE 30 Change in severity of child’s pre-treatment ADIS-C/P primary diagnosis at assessment 2, frequency (%)
Treatment –7 –6 –5 –4 –3 –2 –1 0 1 Total
CCBT 1 (1.8) 9 (16.1) 11 (19.6) 2 (3.6) 4 (7.1) 6 (10.7) 13 (23.2) 9 (16.1) 1 (1.8) 56
CCBT+MCBT 2 (3.3) 14 (23.3) 9 (15.0) 4 (6.7) 4 (6.7) 11 (18.3) 7 (11.7) 8 (13.3) 1 (1.7) 60
CCBT+MCI 2 (3.2) 17 (27.4) 8 (12.9) 4 (6.5) 2 (3.2) 12 (19.4) 14 (22.6) 3 (4.8) 0 (0.0) 62
Total 5 40 28 10 10 29 34 20 2 178
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FIGURE 5 Box plot of change in severity of child’s primary ADIS-C/P diagnosis at assessment 2 by treatment group.
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Presence of any Anxiety Disorder Interview Schedule anxiety diagnosis in
children at assessment 2
As shown in Table 32, the proportion of children with missing data was higher in the CCBT arm (21%);
the CCBT+MCBT arm (13%) and the CCBT+MCI arms (13%) were fairly similar.
As can be seen in Table 33, in the CCBT+MCBT and CCBT+MCI arms 18 and 25 children (30% and
40%), respectively, had recovered from all ADIS-C/P anxiety diagnoses at assessment 2. From the CCBT
arm, 16 participants (29%) had fully recovered.
Table 34 shows the results from log-binomial regression of the children’s recovery from all ADIS-C/P
anxiety diagnoses at assessment 2 adjusted for minimisation factors.
The estimated effect of CCBT+MCBT on ADIS-C/P anxiety diagnoses at assessment 2 compared with the
CCBT arm was RR 1.06 (0.63 to 1.78; p= 0.816). For those children receiving CCBT+MCI the adjusted RR
was 1.48 (95% CI 0.92 to 2.37; p= 0.102).
TABLE 32 Presence of any ADIS-C/P anxiety diagnosis in children at assessment 2 (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 15 (21.1) 16 (22.5) 40 (56.3) 71
CCBT+MCBT 9 (13.0) 18 (26.1) 42 (60.9) 69
CCBT+MCI 9 (12.7) 25 (35.2) 37 (52.1) 71
Total 33 59 119 211
TABLE 33 Presence of any ADIS-C/P anxiety diagnosis in children at assessment 2
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 16 (28.6) 40 (71.4) 56
CCBT+MCBT 18 (30.0) 42 (70.0) 60
CCBT+MCI 25 (40.3) 37 (59.7) 62
Total 59 119 178
TABLE 34 Analysis of recovery from any ADIS-C/P anxiety diagnosis in children at assessment 2
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.06 0.63 to 1.78 0.816
CCBT+MCI 1.48 0.92 to 2.37 0.102
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Analysis of change in child-reported questionnaire scores at assessment 2
Analyses of questionnaire results were conducted on the change scores from baseline to assessment 2
owing to the skewed distribution of the raw scores at assessment 2. The change scores were more
normally distributed.
The change scores were modelled using linear regression, adjusted for baseline scores and minimisation
factors. There were some outliers in the regression models, but these were not thought to be due to
incorrect completion of the questionnaires. Furthermore, their removal did not change the conclusions
from the regression.
Table 35 shows the adjusted means of the children’s responses in each treatment arm along with the
adjusted mean difference for CCBT+MCBT and CCBT+MCI in comparison with CCBT. For the SCAS-c
a significant difference was seen between CCBT+MCBT and CCBT (p= 0.031), with the CCBT arm seeing
a bigger reduction in total score on average. For the SMFQ-c a significant difference was seen between
CCBT+MCBT and CCBT (p= 0.004) and also CCBT+MCI and CCBT (p= 0.012); in both cases the
difference was in the opposite direction to what was expected, with the CCBT arm seeing a greater
reduction in the children’s scores than the treatment arms.
Appendix 5, Table 126, presents the summary statistics for questionnaire scores at baseline and assessment
2, along with the difference between baseline and assessment 2, for only those participants with data at
both time points who are included in Table 35.
TABLE 35 Adjusted analyses of change in child-reported questionnaires at assessment 2 (ITT analysis)
Questionnaire Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
SCAS-c total score CCBT 45 –19.68 (–23.48 to –15.89) Ref.
CCBT+MCBT 46 –13.71 (–17.49 to –9.92) 5.97 (0.54 to 11.41) 0.031
CCBT+MCI 52 –15.73 (–19.27 to –12.19) 3.96 (–1.28 to 9.19) 0.137
CAIS-c total score CCBT 44 –8.19 (–12.10 to –4.28) Ref.
CCBT+MCBT 45 –6.28 (–10.20 to –2.37) 1.91 (–3.73 to 7.55) 0.505
CCBT+MCI 53 –6.49 (–10.05 to –2.93) 1.70 (–3.63 to 7.03) 0.530
SMFQ-c total score CCBT 46 –5.03 (–6.35 to –3.71) Ref.
CCBT+MCBT 47 –2.25 (–3.57 to –0.93) 2.78 (0.88 to 4.68) 0.004
CCBT+MCI 54 –2.70 (–3.92 to –1.48) 2.33 (0.52 to 4.14) 0.012
SDQ-c conduct
subscale
CCBT 47 –0.61 (–1.08 to –0.14) Ref.
CCBT+MCBT 47 –0.52 (–1.00 to –0.05) 0.09 (–0.59 to 0.76) 0.803
CCBT+MCI 55 –0.50 (–0.94 to –0.07) 0.10 (–0.54 to 0.75) 0.748
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
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Analysis of change in mother-reported child symptoms at assessment 2
The results from the regression of the mothers’ questionnaires for child symptoms/impact are shown in
Table 36. There were no significant differences seen between the CCBT+MCBT and CCBT or between
CCBT+MCI and CCBT. Appendix 5, Table 127, presents a summary of the descriptive statistics.
Analysis of change in teacher-reported questionnaire scores at assessment 2
The analysis results of the change scores from the teachers’ questionnaires are shown in Table 37. The
numbers of respondents were small and there were no significant differences in any of the comparisons.
Appendix 5, Table 128, presents a summary of the descriptive statistics.
TABLE 36 Adjusted analyses of change in mother-reported questionnaires at assessment 2
Questionnaire Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
SCAS-c total score CCBT 36 –18.00 (–21.09 to –14.88) Ref.
CCBT+MCBT 39 –16.77 (–19.75 to –13.78) 1.22 (–3.15 to 5.59) 0.581
CCBT+MCI 38 –18.30 (–21.35 to –15.25) –0.32 (–4.77 to 4.14) 0.888
CAIS-c total score CCBT 33 –10.19 (–12.37 to –8.01) Ref.
CCBT+MCBT 35 –12.95 (–15.09 to –10.80) –2.76 (–5.86 to 0.34) 0.080
CCBT+MCI 31 –10.15 (–12.45 to –7.84) 0.04 (–3.20 to 3.28) 0.980
SMFQ-c total score CCBT 34 –4.60 (–6.03 to –3.18) Ref.
CCBT+MCBT 38 –5.66 (–7.03 to –4.29) –1.06 (–3.07 to 0.96) 0.301
CCBT+MCI 35 –5.64 (–7.07 to –4.22) –1.04 (–3.08 to 1.00) 0.314
SDQ-c conduct
subscale
CCBT 37 –0.65 (–1.06 to –0.24) Ref.
CCBT+MCBT 41 –0.74 (–1.12 to –0.35) –0.09 (–0.66 to 0.49) 0.763
CCBT+MCI 40 –0.84 (–1.23 to –0.45) –0.19 (–0.77 to 0.39) 0.515
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
TABLE 37 Adjusted analysis of change in teacher-reported questionnaires at assessment 2
Questionnaire Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
SCAS-t total score CCBT 7 –4.02 (–11.27 to 3.23) Ref.
CCBT+MCBT 14 –4.94 (–9.90 to 0.03) –0.92 (–10.69 to 8.85) 0.847
CCBT+MCI 12 –5.31 (–10.53 to –0.10) –1.29 (–10.86 to 8.27) 0.782
CAS-t total score CCBT 18 –0.86 (–2.32 to 0.60) Ref.
CCBT+MCBT 24 –1.96 (–3.22 to –0.70) –1.10 (–3.11 to 0.90) 0.275
CCBT+MCI 25 –1.26 (–2.48 to –0.04) –0.40 (–2.37 to 1.57) 0.684
SDQ-t conduct
subscale
CCBT 18 0.35 (–0.21 to 0.91) Ref.
CCBT+MCBT 22 –0.17 (–0.68 to 0.35) –0.52 (–1.30 to 0.27) 0.190
CCBT+MCI 23 –0.11 (–0.62 to 0.39) –0.46 (–1.24 to 0.31) 0.236
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
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Post-treatment follow-up
Child outcomes at 6-month follow-up
Presence of child’s Anxiety Disorder Interview Schedule primary diagnosis at
6-month follow-up
Table 38 shows the proportion of missing data within each treatment arm for the assessment of the child’s
primary diagnosis at 6 months post treatment. The CCBT arm has the highest proportion of missing
data (31%).
Table 39 shows the proportion of children who recovered from their primary ADIS-C/P anxiety diagnosis by
6 months. The CCBT+MCI arm had the highest proportion of recovered children (75%). The CCBT arm
had the lowest proportion of recovered children (59%).
Table 40 shows the results of the adjusted linear regression of the child’s primary diagnosis. The results
show no statistically significant difference between CCBT+MCBT or CCBT+MCI treatment arms in
comparison with CCBT.
TABLE 38 Presence of pre-treatment ADIS-C/P primary diagnosis at 6 months post treatment (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 22 (30.99) 29 (40.85) 20 (28.17) 71
CCBT+MCBT 16 (23.19) 34 (49.28) 19 (27.54) 69
CCBT+MCI 20 (28.17) 38 (53.52) 13 (18.31) 71
Total 58 101 52 211
TABLE 39 Presence of pre-treatment ADIS-C/P primary diagnosis at 6 months
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 29 (59.18) 20 (40.82) 49
CCBT+MCBT 34 (64.15) 19 (35.85) 53
CCBT+MCI 38 (74.51) 13 (25.49) 51
Total 101 52 153
TABLE 40 Analysis of pre-treatment ADIS-C/P primary anxiety diagnosis at 6 months
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.09 0.81 to 1.46 0.566
CCBT+MCI 1.26 0.97 to 1.64 0.077
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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As in all of the analyses reporting RRs in this report, a value > 1 implies a better outcome for the index
treatment arm compared with the control (CCBT) arm, if the value is < 1, the outcome is better for the
CCBT arm.
Child’s Clinical Global Impression – Improvement at 6 months
The proportion of missing data for child’s CGI-I assessment at 6 months was lower in the CCBT+MCBT
arm (23%) and similar in the CCBT (31%) and CCBT+MCI arms (28%) (Table 41).
The proportion of children who were ‘much/very much improved’ at 6 months is shown in Table 42. The
CCBT+MCI arm had the highest proportion (88%). CCBT and CCBT+MCBT were similar (80% and
77%, respectively).
The linear regression results in Table 43 show that there are no statistically significant differences between
treatment arms.
TABLE 41 Clinical Global Impression: child – Improvement at 6 months (including missing data)
Treatment allocation Missing, n (%)
Much/very much
improved, n (%)
Not much/very much
improved, n (%) Total, n (%)
CCBT 22 (30.99) 39 (54.93) 10 (14.08) 71
CCBT+MCBT 16 (23.19) 41 (59.42) 12 (17.39) 69
CCBT+MCI 20 (28.17) 45 (63.38) 6 (8.45) 71
Total 58 125 28 211
TABLE 42 Clinical Global Impression: child – Improvement at 6 months
Treatment
allocation
Much/very much improved,
n (%)
Not much/very much improved,
n (%) Total, n (%)
CCBT 39 (79.59) 10 (20.41) 49
CCBT+MCBT 41 (77.36) 12 (22.64) 53
CCBT+MCI 45 (88.24) 6 (11.76) 51
Total 125 28 153
TABLE 43 Analysis of CGI-I at 6 months
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 0.97 0.79 to 1.19 0.771
CCBT+MCI 1.16 0.94 to 1.33 0.216
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Presence of any Anxiety Disorder Interview Schedule anxiety diagnosis in
children at 6 months
As shown in Table 44, the proportion of missing data for any ADIS-C/P anxiety diagnosis was similar in
CCBT (31%) and CCBT+MCI (28%), but lower in MCBT (23%) children.
Table 45 shows the proportion of children recovering from all anxiety diagnoses by 6 months; and this is
the same in each group (47%).
The results of the linear regression of recovery from all ADIS-C/P anxiety diagnoses by 6 months are shown
in Table 46; there are no statistically significant differences between treatment groups.
TABLE 44 Presence of any ADIS-C/P anxiety diagnosis at 6 months (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 22 (30.99) 23 (32.39) 26 (36.62) 71
MCBT 16 (23.19) 25 (36.23) 28 (40.58) 69
CCBT+MCI 20 (28.17) 24 (33.80) 27 (38.03) 71
Total 58 72 81 211
TABLE 45 Presence of any ADIS-C/P anxiety diagnosis at 6 months
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 23 (46.94) 26 (53.06) 49
CCBT+MCBT 25 (47.17) 28 (52.83) 53
CCBT+MCI 24 (47.06) 27 (52.94) 51
Total 72 81 153
TABLE 46 Analysis of recovery from any ADIS-C/P anxiety diagnosis at 6 months
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.04 0.70 to 1.53 0.860
CCBT+MCI 1.04 0.71 to 1.55 0.814
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Severity of child’s primary Anxiety Disorder Interview Schedule diagnosis at
6 months
Figure 6 and Table 47 show the distribution of the change scores from baseline to 6 months for the
severity rating of the child’s primary diagnosis. As shown in Table 48, the proportion of children with a
reduction of 2 or more points is 74% in the CCBT arm, 70% in the CCBT+MCBT arm and 92% in the
CCBT+MCI arm. When comparing the CCBT+MCBT arm with CCBT there is no significant difference.
However, there is a significant difference between CCBT+MCI and CCBT (p= 0.013).
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FIGURE 6 Box plot of change in severity of child’s pre-treatment ADIS-C/P primary anxiety diagnosis at 6 months.
TABLE 47 Change in severity of child’s pre-treatment ADIS-C/P primary anxiety diagnosis at 6 months, frequency (%)
Treatment
allocation –7 –6 –5 –4 –3 –2 –1 0 1 Total
CCBT 0 (0.0) 12 (24.5) 10 (20.4) 3 (6.1) 3 (6.1) 8 (16.3) 4 (8.2) 6 (12.2) 3 (6.1) 49
CCBT+MCBT 2 (3.8) 16 (30.2) 10 (18.9) 1 (1.9) 2 (3.8) 6 (11.3) 11 (20.8) 5 (9.4) 0 (0.0) 53
CCBT+MCI 2 (3.9) 18 (35.3) 9 (17.7) 5 (9.8) 2 (3.9) 11 (21.6) 4 (7.8) 0 (0.0) 0 (0.0) 51
Total 4 46 29 9 7 25 19 11 3 153
TABLE 48 Proportion of children with at least a 2-point reduction in severity of their pre-treatment ADIS-C/P
primary anxiety diagnosis at 6 months
Treatment n n (%) with a 2 or more point reduction p-valuea
CCBT 49 36 (73.5)
CCBT+MCBT 53 37 (69.8) 0.682
CCBT+MCI 51 47 (92.2) 0.013
a Chi-squared test, comparison with control group.
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Analysis of questionnaire data at 6 month follow-up assessments
Analyses of questionnaire results were conducted on the change scores from baseline to the relevant time
point. The change scores were more normally distributed. The change scores were modelled using linear
regression, adjusted for baseline scores and minimisation factors.
In this section, only patients who are included in the analysis are included in the summary tables.
Adjusted analysis of change in child-reported questionnaire scores at
6 months (intention-to-treat analysis)
Table 49 shows the results for the analysis of the child-reported questionnaire scores, and the change in
scores from baseline to 6 months. For all four of the questionnaires there were no significant differences
between CCBT+MCBT and CCBT or between CCBT+MCI and CCBT. The adjusted mean scores for each
treatment group and every questionnaire are negative, which shows that all groups improved. A summary
of the descriptive statistics is given in Appendix 5, Table 136.
Adjusted analysis of change in mother-reported questionnaire scores at
6 months (intention-to-treat analysis)
Table 50 shows results of linear regression looking at mother-reported questionnaires about child
symptoms/impact. For the SDQ-p conduct subscale a significant difference was seen between the
CCBT+MCI and the CCBT arms (p= 0.022), with the CCBT+MCI arm seeing a bigger reduction in
score on average. A summary of the descriptive statistics is given in Appendix 5, Table 137.
Adjusted analysis of change in teacher-reported questionnaire scores at
6 months (intention-to-treat analysis)
The number of respondents was low. As shown in Table 51, no significant differences were seen.
A summary of descriptive statistics are given in Appendix 5, Table 138.
TABLE 49 Adjusted analysis of change in child-reported questionnaire scores at 6 months
Variable name Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
CAIS-c total score CCBT 38 –12.45 (–15.06 to –9.84) Ref. –
CCBT+MCBT 43 –11.02 (–13.50 to –8.54) 1.43 (–2.21 to 5.07) 0.4374
41 –10.75 (–13.29 to –8.21) 1.70 (–1.97 to 5.37) 0.3614
SCAS-c total score CCBT 41 –17.85 (–22.73 to –12.98) Ref. –
CCBT+MCBT 43 –16.59 (–21.35 to –11.83) 1.26 (–5.56 to 8.08) 0.7146
CCBT+MCI 41 –17.60 (–22.52 to –12.67) 0.26 (–6.77 to 7.28) 0.9427
SDQ-c conduct
subscale
CCBT 42 –0.88 (–1.35 to –0.42) Ref. –
CCBT+MCBT 44 –0.91 (–1.37 to –0.46) –0.03 (–0.68 to 0.62) 0.9245
CCBT+MCI 42 –0.81 (–1.28 to –0.34) 0.07 (–0.60 to 0.74) 0.8317
SMFQ-c total score CCBT 40 –3.81 (–5.33 to –2.29) Ref. –
CCBT+MCBT 44 –3.52 (–4.97 to –2.06) 0.30 (–1.82 to 2.42) 0.7828
CCBT+MCI 39 –3.97 (–5.52 to –2.41) –0.16 (–2.36 to 2.04) 0.8872
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
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TABLE 50 Adjusted analysis of change in mother-reported child symptoms questionnaire scores at 6 months
Variable name Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
CAIS-p total score CCBT 35 –9.25 (–12.12 to –6.37) Ref. –
CCBT+MCBT 37 –12.13 (–14.95 to –9.31) –2.88 (–6.92 to 1.16) 0.1599
CCBT+MCI 34 –9.69 (–12.68 to –6.70) –0.44 (–4.61 to 3.73) 0.8348
SCAS-p total score CCBT 36 –17.44 (–21.03 to –13.84) Ref. –
CCBT+MCBT 41 –16.62 (–20.00 to –13.25) 0.82 (–4.11 to 5.74) 0.7432
CCBT+MCI 38 –19.17 (–22.72 to –15.61) –1.73 (–6.86 to 3.40) 0.5050
SDQ-p conduct
subscale
CCBT 39 –0.47 (–0.86 to –0.09) Ref. –
CCBT+MCBT 42 –0.99 (–1.36 to –0.62) –0.51 (–1.05 to 0.02) 0.0600
CCBT+MCI 41 –1.11 (–1.49 to –0.73) –0.64 (–1.19 to -0.09) 0.0224
SMFQ-p total score CCBT 36 –4.25 (–5.82 to –2.67) Ref. –
CCBT+MCBT 38 –5.86 (–7.40 to –4.32) –1.61 (–3.83 to 0.61) 0.1542
CCBT+MCI 36 –4.90 (–6.49 to –3.30) –0.65 (–2.91 to 1.61) 0.5701
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
TABLE 51 Adjusted analysis of change in teacher-reported questionnaire scores at 6 months
Variable name Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
CAS-t total score CCBT 11 –1.43 (–3.85 to 0.99) Ref. –
CCBT+MCBT 17 –2.92 (–4.91 to –0.94) –1.50 (–4.65 to 1.66) 0.3432
CCBT+MCI 23 –1.40 (–3.02 to 0.23) 0.03 (–2.92 to 2.98) 0.9845
SCAS-t total score CCBT 4 –1.88 (–15.75 to 12.00) Ref. –
CCBT+MCBT 9 –15.07 (–22.85 to –7.29) –13.19 (–30.33 to 3.94) 0.1227
CCBT+MCI 15 –10.26 (–15.89 to –4.64) –8.39 (–24.79 to 8.01) 0.2955
SDQ-t conduct
subscale
CCBT 12 0.57 (–0.36 to 1.50) Ref. –
CCBT+MCBT 18 –0.21 (–0.98 to 0.57) –0.78 (–1.98 to 0.42) 0.1961
CCBT+MCI 22 0.31 (–0.37 to 1.00) –0.26 (–1.42 to 0.90) 0.6540
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
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Child outcomes at 12-month follow-up
Presence of child’s Anxiety Disorder Interview Schedule primary diagnosis at
12 months
Table 52 shows that the proportion of missing data for the assessment of the child’s primary diagnosis at
12 months is very similar in the CCBT (39%) and CCBT+MCI (35%) arms, but lower in the CCBT+MCBT
arm (28%).
Table 53 shows that recovery from primary diagnosis is very similar in the CCBT (72%) and CCBT+MCI
arms (74%), whereas in the CCBT+MCBT group it is lower (60%).
The results of the linear regression are shown in Table 54. The results show no statistically significant
difference between the CCBT+MCBT or CCBT+MCI treatment arms in comparison with CCBT.
TABLE 52 Presence of pre-treatment ADIS-C/P primary diagnosis at 12 months (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 28 (39.44) 31 (43.66) 12 (16.90) 71
CCBT+MCBT 19 (27.54) 30 (43.48) 20 (28.99) 69
CCBT+MCI 25 (35.21) 34 (47.89) 12 (16.90) 71
Total 72 95 44 211
TABLE 53 Presence of pre-treatment ADIS-C/P primary diagnosis at 12 months
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 31 (72.09) 12 (27.91) 43
CCBT+MCBT 30 (60.00) 20 (40.00) 50
CCBT+MCI 34 (73.91) 12 (26.09) 46
Total 95 44 139
TABLE 54 Analysis of pre-treatment ADIS-C/P primary anxiety diagnosis at 12 months
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 0.85 0.65 to 1.12 0.257
CCBT+MCI 1.04 0.82 to 1.30 0.766
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Child’s Clinical Global Impression – Improvement at 12 months
The proportion of 12-month CGI-I assessments that were missing is shown in Table 55. The CCBT arm
had 39% missing, CCBT+MCI had 35% missing and CCBT+MCBT had 28% missing.
As shown in Table 56, the proportion of children who were ‘much/very much improved’ was similar
between treatment groups; between 77% and 80%.
The results of the linear regression of CGI-I at 12 months are shown in Table 57; there are no statistically
significant differences between treatment groups.
TABLE 55 Clinical Global Impression: child – Improvement at 12 months (including missing data)
Treatment allocation Missing, n (%)
Much/very much
improved, n (%)
Not much/very much
improved, n (%) Total, n (%)
CCBT 28 (39.44) 33 (46.48) 10 (14.08) 71
CCBT+MCBT 19 (27.54) 39 (56.52) 11 (15.94) 69
CCBT+MCI 25 (35.21) 37 (52.11) 9 (12.68) 71
Total 72 109 30 211
TABLE 56 Clinical Global Impression: child – Improvement at 12 months
Treatment allocation
Much/very much
improved, n (%)
Not much/very much
improved, n (%) Total, n (%)
CCBT 33 (76.74) 10 (23.26) 43
CCBT+MCBT 39 (78.00) 11 (22.00) 50
CCBT+MCI 37 (80.43) 9 (19.57) 46
Total 109 30 139
TABLE 57 Analysis of CGI-I at 12 months
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 1.02 0.82 to 1.27 0.834
CCBT+MCI 1.05 0.85 to 1.30 0.628
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Presence of any Anxiety Disorder Interview Schedule anxiety diagnosis in
children at 12 months
As shown in Table 58, the proportion of missing data for all anxiety diagnoses at 12 months was lowest in
the CCBT+MCBT arm (28%). In the CCBT+MCI arm it is 35% and in the CCBT arm 39%.
The proportion of recovered children was similar in the CCBT arm (53%) and the CCBT+MCI arm (52%).
In the CCBT+MCBT arm the proportion was slightly lower at 46% (Table 59).
The results of the linear regression of recovery from all ADIS-C/P anxiety diagnoses by 12 months are
shown in Table 60. There are no statistically significant differences between treatment groups.
TABLE 58 Presence of any ADIS-C/P anxiety diagnosis at 12 months (including missing data)
Treatment allocation Missing, n (%) No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 28 (39.44) 23 (32.39) 20 (28.17) 71
CCBT+MCBT 19 (27.54) 23 (33.33) 27 (39.13) 69
CCBT+MCI 25 (35.21) 24 (33.80) 22 (30.99) 71
Total 72 70 69 211
TABLE 59 Presence of any ADIS-C/P anxiety diagnosis at 12 months
Treatment allocation No diagnosis, n (%) Diagnosis, n (%) Total, n (%)
CCBT 23 (53.49) 20 (46.51) 43
CCBT+MCBT 23 (46.00) 27 (54.00) 50
CCBT+MCI 24 (52.17) 22 (47.83) 46
Total 70 69 139
TABLE 60 Analysis of recovery from any ADIS-C/P anxiety diagnosis at 12 months
Parameter Adjusted RRa 95% CI p-valueb
Treatment CCBT Ref.
CCBT+MCBT 0.89 0.61 to 1.31 0.569
CCBT+MCI 1.01 0.70 to 1.45 0.972
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder and baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder.
b Analysis conducted using the modified Poisson regression framework with robust error variance.
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Severity of child’s pre-treatment Anxiety Disorder Interview Schedule primary
diagnosis at 12 months
By 12 months 77% of the control group, 74% of the CCBT+MCBT group and 87% of the CCBT+MCI
group children had seen an improvement of at least 2 points (Figure 7 and Tables 61 and 62).
There were no significant differences between the CCBT+MCBT and CCBT arms or between the
CCBT+MCI and CCBT arms (p= 0.760 and p= 0.210, respectively).
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FIGURE 7 Box plot of change in severity of child’s primary ADIS-C/P anxiety diagnosis at 12 months.
TABLE 61 Change in severity of child’s pre-treatment ADIS-C/P primary anxiety diagnosis at 12 months, frequency (%)
Treatment
allocation –7 –6 –5 –4 –3 –2 –1 0 1 Total
CCBT 3 (6.98) 10 (23.26) 9 (20.93) 5 (11.63) 2 (4.65) 4 (9.30) 7 (16.28) 1 (2.33) 2 (4.65) 43
CCBT+MCBT 3 (6.00) 10 (20.00) 12 (24.00) 1 (2.00) 3 (6.00) 8 (16.00) 6 (12.00) 7 (14.00) 0 (0.00) 50
CCBT+MCI 1 (2.17) 18 (39.1) 8 (17.39) 4 (8.70) 3 (6.52) 6 (13.04) 6 (13.04) 0 (0.00) 0 (0.00) 46
Total 7 38 29 10 8 18 19 8 2 139
TABLE 62 Proportion of children with at least a 2-point reduction in severity of their pre-treatment ADIS-C/P
primary anxiety diagnosis at 12 months
Treatment n n (%) with 2 or more point reduction p-valuea
CCBT 43 33 (76.7)
CCBT+MCBT 50 37 (74.0) 0.760
CCBT+MCI 46 40 (87.0) 0.210
a Chi-squared test, comparison with control group.
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Analysis of questionnaire data at 12-month follow-up assessments
Analyses of questionnaire results were conducted on the change scores from baseline to the relevant time
point owing to the skewed distribution of the raw scores at each time point. The change scores were more
normally distributed. The change scores were modelled using linear regression, adjusted for baseline scores
and minimisation factors.
In this section, only patients who are included in the analysis are included in the summary tables.
Adjusted analysis of change in child-reported questionnaire scores at
12 months (intention-to-treat analysis)
As shown in Table 63, no significant differences were seen. A summary of the descriptive statistics is given
in Appendix 5, Table 139.
Adjusted analysis of change in mother-reported questionnaire scores at
12 months (intention-to-treat analysis)
As shown in Table 64, no significant differences were seen. A summary of descriptive statistics is given in
Appendix 5, Table 140.
Adjusted analysis of change in teacher-reported questionnaire scores at
12 months (intention-to-treat analysis)
As shown in Table 65, no significant differences were seen. A summary of descriptive statistics is given in
Appendix 5, Table 141.
Note the small number of observations when looking at these results.
TABLE 63 Adjusted analysis of change in child-reported questionnaire scores at 12 months
Variable name Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
CAIS-c total score CCBT 29 –12.83 (–17.14 to –8.51) Ref. –
CCBT+MCBT 33 –9.25 (–13.41 to –5.09) 3.57 (–2.59 to 9.74) 0.2525
CCBT+MCI 37 –11.71 (–15.48 to –7.93) 1.12 (–4.59 to 6.83) 0.6978
SCAS-c total score CCBT 31 –18.11 (–23.18 to –13.03) Ref. –
CCBT+MCBT 34 –18.92 (–23.82 to –14.01) –0.81 (–7.96 to 6.34) 0.8225
CCBT+MCI 37 –17.98 (–22.59 to –13.38) 0.12 (–6.73 to 6.97) 0.9718
SDQ-c conduct
subscale
CCBT 31 –1.21 (–1.87 to –0.55) Ref. –
CCBT+MCBT 34 –0.94 (–1.58 to –0.30) 0.27 (–0.65 to 1.18) 0.5622
CCBT+MCI 38 –1.00 (–1.59 to –0.40) 0.21 (–0.68 to 1.10) 0.6373
SMFQ-c total score CCBT 28 –4.08 (–5.95 to –2.21) Ref. –
CCBT+MCBT 35 –4.20 (–5.91 to –2.49) –0.12 (–2.71 to 2.48) 0.9284
CCBT+MCI 37 –2.09 (–3.72 to –0.47) 1.99 (–0.48 to 4.46) 0.1132
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
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TABLE 64 Adjusted analysis of change in mother-reported questionnaire scores at 12 months
Variable name Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
CAIS-p total score CCBT 28 –9.50 (–12.44 to –6.56) Ref. –
CCBT+MCBT 27 –12.11 (–15.19 to –9.04) –2.61 (–6.88 to 1.66) 0.2270
CCBT+MCI 31 –12.15 (–14.99 to –9.32) –2.65 (–6.72 to 1.42) 0.1985
SCAS-p total score CCBT 30 –22.37 (–26.62 to –18.12) Ref. –
CCBT+MCBT 31 –16.36 (–20.58 to –12.15) 6.01 (–0.01 to 12.02) 0.0502
CCBT+MCI 33 –20.74 (–24.78 to –16.71) 1.62 (–4.27 to 7.51) 0.5850
SDQ-p conduct
subscale
CCBT 32 –1.04 (–1.56 to –0.53) Ref. –
CCBT+MCBT 32 –0.89 (–1.40 to –0.38) 0.16 (–0.57 to 0.89) 0.6685
CCBT+MCI 38 –0.85 (–1.31 to –0.38) 0.20 (–0.50 to 0.89) 0.5755
SMFQ-p total score CCBT 30 –5.14 (–6.81 to –3.48) Ref. –
CCBT+MCBT 29 –4.54 (–6.25 to –2.82) 0.61 (–1.82 to 3.04) 0.6194
CCBT+MCI 33 –5.97 (–7.55 to –4.39) –0.83 (–3.11 to 1.46) 0.4739
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
TABLE 65 Adjusted analysis of change in teacher-reported questionnaire scores at 12 months
Variable name Treatment n
Adjusteda mean change
(95% CI)
Adjusteda mean difference
(95% CI) p-value
CAS-t total score CCBT 9 –2.56 (–4.76 to –0.37) Ref. –
CCBT+MCBT 10 –0.04 (–2.23 to 2.14) 2.52 (–0.62 to 5.66) 0.1099
CCBT+MCI 12 –0.40 (–2.29 to 1.48) 2.16 (–0.77 to 5.09) 0.1391
SCAS-t total score CCBT 4 –7.90 (–17.17 to 1.37) Ref. –
CCBT+MCBT 4 –0.04 (–18.30 to 18.22) 7.86 (–12.83 to 28.55) 0.2437
CCBT+MCI 5 –11.90 (–23.14 to –0.66) –4.00 (–18.25 to 10.25) 0.3510
SDQ-t conduct
subscale
CCBT 9 –0.09 (–1.21 to 1.03) Ref. –
CCBT+MCBT 11 –0.27 (–1.30 to 0.75) –0.18 (–1.71 to 1.34) 0.8051
CCBT+MCI 12 0.41 (–0.54 to 1.36) 0.50 (–0.99 to 2.00) 0.4903
Ref., reference category.
a Adjusted for child age, child gender, type of child anxiety disorder (GAD, social phobia, SAD, other), baseline severity
(ADIS-C/P CSR) of the child’s primary anxiety disorder, baseline severity (ADIS-IV mother self-report) of the mother’s
primary anxiety disorder and baseline questionnaire score.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
Secondary research questions
The extent to which improvement in child anxiety was associated with changes in maternal anxiety and
parenting responses is shown in the following tables of correlations (see Tables 66–75). In each case
Pearson’s correlation coefficient (r), the p-value and the number of observations are shown. For each of
the three child anxiety variables that are used to correlate with other variables, a higher score implies a
worse outcome for the child (as we are looking at the change from baseline).
Associations between change in maternal anxiety and child anxiety
outcomes immediately post treatment (assessment 2)
Table 66 (assessment 1B) and Table 67 (assessment 2) show the correlations between child anxiety
(change in SCAS-c total score, change in CSR of primary diagnosis and CGI-I) and maternal anxiety
(change in CSR of primary diagnosis). In these tables none of the correlations are statistically different
from zero.
Similarly to before, the following table (Table 68) shows the correlations between the change in child
anxiety scores from baseline to assessment 2 (SCAS-c, CSR and CGI-I) and mother anxiety questionnaire
change scores (DASS-21).
TABLE 66 Correlation between child and mother anxiety scores at assessment 1B
Mother anxiety change scores (baseline to
assessment 1B)
Child anxiety change scores (baseline to assessment 1B)
SCAS-c CSR of primary diagnosis CGI-I
Change in CSR r 0.03295 0.06790 0.05102
p-value 0.6642 0.3419 0.4753
n 176 198 198
TABLE 67 Correlation between child and mother anxiety scores at assessment 2
Mother anxiety change scores (baseline to
assessment 2)
Child anxiety change scores (baseline to assessment 2)
SCAS-c CSR of primary diagnosis CGI-I
Change in CSR r 0.01689 0.03667 0.09354
p-value 0.8447 0.6339 0.2237
n 137 171 171
TABLE 68 Correlations between child and mother anxiety questionnaire change scores at assessment 2
Mother anxiety change scores (baseline to
assessment 2)
Change in child anxiety (baseline to assessment 2)
SCAS-c CSR of primary diagnosis CGI-I
DASS-21 anxiety r –0.06825 –0.0036 0.05363
p-value 0.5227 0.9710 0.5943
n 90 101 101
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Associations between change in maternal parenting responses and child
anxiety outcomes
Table 69 shows the correlations between the same child anxiety ratings and each of the behavioural
change scores at assessment 2. There are significant correlations between change in CSR and change in
overprotection (r= –0.1956; p= 0.0225), CGI-I and change in overprotection (r= –0.3123; p= 0.0002),
CGI-I and change in quality of relationship (r= –0.1097; p= 0.0450).
Similarly, Table 70 shows the correlations between the same child anxiety change scores and each of the
cognition change scores at assessment 2. None of the correlations are statistically different from zero.
TABLE 69 Correlation between change in child anxiety scores and change in mother behavioural change scores
(baseline to assessment 2)
Mother–child behavioural change scores
(baseline to assessment 2)
Child anxiety change scores (baseline to assessment 2)
SCAS-c CSR of primary diagnosis CGI-I
Positive behaviour r 0.00914 –0.01251 –0.06857
p-value 0.9220 0.8851 0.4294
n 117 136 135
Overprotection r 0.03525 –0.19558 –0.31226
p-value 0.7059 0.0225 0.0002
n 117 136 135
Promotion of avoidance r 0.02498 –0.04638 0.07694
p-value 0.7892 0.5918 0.3751
n 117 136 135
Intrusiveness r 0.14039 –0.01128 –0.02442
p-value 0.1311 0.8963 0.7786
n 117 136 135
Anxiety r –0.06341 –0.00024 –0.10791
p-value 0.4970 0.9978 0.2129
n 117 136 135
Quality of relationship r –0.03089 –0.15215 –0.17282
p-value 0.7409 0.0770 0.0450
n 117 136 135
POI r 0.17777 –0.00642 0.07565
p-value 0.0848 0.9479 0.4409
n 95 106 106
POI, Parent Over-Involvement Questionnaire.
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Associations between change in maternal anxiety and child anxiety
outcomes 6 and 12 months post treatment (assessments 3 and 4)
Tables 71 and 72 show correlations between change in child anxiety scores and change in mother anxiety
questionnaire scores from baseline to the 6- and 12-month post-treatment follow-up assessment.
At the 6-month time point none of the correlations were statistically significant. At 12 months, maternal
general anxiety (DASS-21) was significantly associated with change in the CSR of the child’s primary
diagnosis (p= 0.0195).
TABLE 70 Correlation between change in child anxiety scores and change in mother cognition change scores
(baseline to assessment 2)
Mother–child cognition change scores
(baseline to assessment 2)
Child anxiety change scores (baseline to assessment 2)
SCAS-c CSR of primary diagnosis CGI-I
Pre-task ‘scared’ r 0.15092 0.00701 0.16665
p-value 0.1122 0.9367 0.0581
n 112 131 130
Pre-task ‘anxious’ r –0.02832 0.01928 0.07960
p-value 0.7669 0.8270 0.3680
n 112 131 130
Pre-task ‘child in control’ r –0.03400 –0.04478 –0.08487
p-value 0.7219 0.6115 0.3370
n 112 131 130
Pre-task ‘mother in control’ r 0.17628 0.04862 0.04707
p-value 0.0630 0.5813 0.5949
n 112 131 130
TABLE 71 Correlations between change in child anxiety scores and change in mother anxiety questionnaire score
at 6 months (assessment 3)
Mother change scores (baseline to
6 months)
Child change scores (baseline to 6 months)
SCAS-c CSR of primary diagnosis CGI-I
DASS-21 anxiety r 0.08825 –0.06079 0.06979
p-value 0.3875 0.5359 0.4772
n 98 106 106
TABLE 72 Correlations between change in child anxiety scores and change in mother anxiety questionnaire score
at 12 months
Mother change scores (baseline to
12 months)
Child change scores (baseline to 12 months)
SCAS-c CSR of primary diagnosis CGI-I
DASS-21 anxiety r –0.05089 –0.25755 –0.05375
p-value 0.6624 0.0195 0.6315
n 76 82 82
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Observations of parental behaviours and cognitions were not made at the 6- and 12-month follow-up
assessments, so associations between change in these variables and longer-term outcomes were assessed
on the basis of maternal behavioural and cognition change scores at assessment 2 and child anxiety
outcomes at 6 and 12 months (Tables 73 and 74). Change in maternal overprotection at assessment 2 was
associated with CGI-I at 6 months (p= 0.044) and change in child anxiety symptoms (SCAS-c) at
12 months (p= 0.004). Change in maternal intrusiveness was significantly associated with child CGI-I
at 12 months (p= 0.009). In relation to maternal cognitions, change in pre-task expectations of how
much the mother would be in control of her child’s response was significantly associated with change in
child anxiety symptoms at 6 months (SCAS-c) (p= 0.022).
Parent-reported overinvolvement was assessed at all assessments so concurrent change in this variable
could be correlated with child outcomes at the 6- and-12 month assessments, as shown in Table 75.
There were no significant correlations.
TABLE 73 Correlation between change in child anxiety scores at 6 and 12 months and change in mother
behavioural change scores (baseline to assessment 2)
Mother–child behavioural
change scores (baseline to
assessment 2)
Child anxiety change scores (baseline
to 6 months)
Child anxiety change scores (baseline
to 12 months)
SCAS-c
CSR of
primary
diagnosis CGI-I SCAS-c
CSR of
primary
diagnosis CGI-I
Positive
behaviour
r 0.14050 –0.02741 0.02782 –0.00056 0.00176 0.03081
p-value 0.1489 0.7615 0.7581 0.9958 0.9850 0.7416
n 107 125 125 90 117 117
Overprotection r 0.12875 0.05708 –0.18019 0.30408 0.03819 –0.09012
p-value 0.1863 0.5272 0.0443 0.0036 0.6827 0.3339
n 107 125 125 90 117 117
Promotion
of avoidance
r 0.01996 –0.05951 0.03262 –0.02830 0.03669 0.05961
p-value 0.8383 0.5098 0.7180 0.7912 0.6945 0.5232
n 107 125 125 90 117 117
Intrusiveness r 0.03897 0.11560 –0.05094 –0.05594 –0.07602 –0.24017
p-value 0.6902 0.1992 0.5726 0.6005 0.4153 0.0091
n 107 125 125 90 117 117
Expressed anxiety r –0.09444 –0.10867 –0.11103 –0.14463 –0.02053 –0.16905
p-value 0.3333 0.2277 0.2177 0.1738 0.8261 0.0685
n 107 125 125 90 117 117
Quality of
relationship
r –0.03542 –0.09344 –0.06767 0.00020 –0.10428 –0.11616
p-value 0.7172 0.3000 0.4534 0.9985 0.2632 0.2123
n 107 125 125 90 117 117
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
Adverse events
Adverse events were defined as follows:
Adverse or unexpected events resulting in physical or psychological injury that arise from the
administration of research procedures or the provision of treatment within the trial. This will include
events such as breach of confidentiality, adverse therapeutic interventions, diagnostic error, improper
staff behaviour, falls and injury.
There were no adverse events.
TABLE 74 Correlation between change in child anxiety scores at 6 and 12 months and change in mother cognition
change scores (baseline to assessment 2)
Mother–child cognition
change scores (baseline to
assessment 2)
Child anxiety change scores (baseline to
6 months)
Child anxiety change scores (baseline
to 12 months)
SCAS-c
CSR of
primary
diagnosis CGI-I SCAS-c
CSR of
primary
diagnosis CGI-I
Pre-task ‘scared’ r 0.05618 0.13760 0.06005 0.14249 –0.05847 –0.02565
p-value 0.5711 0.1323 0.5129 0.1906 0.5384 0.7874
n 104 121 121 86 113 113
Pre-task
‘anxious’
r 0.00674 0.07552 –0.00865 –0.04708 –0.02433 –0.06011
p-value 0.9458 0.4103 0.9249 0.6669 0.7981 0.5271
n 104 121 121 86 113 113
Pre-task ‘child
in control’
r 0.06490 –0.16300 –0.05574 0.12284 0.00607 –0.01974
p-value 0.5127 0.0740 0.5437 0.2598 0.9492 0.8356
n 104 121 121 86 113 113
Pre-task
‘mother control’
r 0.22508 0.06698 0.03040 0.20293 –0.05837 0.01778
p-value 0.0216 0.4654 0.7406 0.0609 0.5391 0.8517
n 104 121 121 86 113 113
TABLE 75 Correlation between change in child anxiety scores and change in maternal-reported overprotection at
6 and 12 months
POI change scores SCAS-c CSR of primary diagnosis CGI-I
Baseline to 6-month follow-up r 0.11522 –0.05258 0.07649
p-value 0.2488 0.5854 0.4270
n 102 110 110
Baseline to 12-month follow-up r 0.09522 –0.06828 0.04747
p-value 0.3860 0.5201 0.6568
n 85 91 90
POI, Parent Over-Involvement Questionnaire.
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Chapter 4 Economic evaluation: cost–utility
analysis of treatment of childhood anxiety disorder in
the context of maternal anxiety disorder
Introduction
The aim of the economic evaluation was to assess the cost-effectiveness of the CCBT+MCBT and
CCBT+MCI treatment arms compared with the CCBT treatment arm. This design mirrored the study
research questions, and hence was equivalent to conducting two separate economic evaluations, that
is CCBT+MCBT versus CCBT, and CCBT+MCI versus CCBT. An incremental comparison between
CCBT+MCBT and CCBT+MCI was not a research question and the statistical and economic analyses
were not powered for this comparison. The primary economic analyses followed an ITT approach and
adopted a health service provider perspective. The economic analyses aligned with the primary aim
of the trial, namely to evaluate whether or not the CCBT treatment arm could be improved by the
addition of (i) treatment of maternal anxiety disorders (MCBT), or (ii) treatment focused on maternal
responses (MCI). Secondary economic analyses complemented the results of the primary analyses by
measuring additional mother and child resource use of health and personal social services beyond the
main costs of the treatment. Broader impacts on other sectors, including education and employment, were
also measured. Data were collected on time off school for children and time off work and usual activities
for mothers/carers.
Methods
The primary economic analyses for both comparisons consisted of a cost–utility analysis (CUA) conducted
from a health service provider perspective. Secondary economic analyses supplemented the primary results
by identifying, measuring and valuing resource use impacts from a wider social and personal social service
perspective in addition to measuring the impact on the education and employment sectors. Recent
methods guidance on the conduct, reporting and presentation of economic evaluations were adhered.75–77
Costs and outcomes were combined within a CUA framework and presented using incremental
cost-effectiveness ratios (ICERs) with uncertainty represented using the cost-effectiveness plane. The results
were also reported using net monetary benefit (NMB). Prices were reported in 2011/12 as the base year,
adjusted for inflation using Retail Price Index (RPI) 201278 or Hospital and Community Health Service
(HCHS) index 2011/1279 as appropriate. All statistical analyses were performed using Stata version 12.1.
Statistical significance was set at p-values < 0.05.
Identification and measurement of health and social care resource use
Patient-level resource use data, including all associated treatment costs, additional health and personal
social service costs, were identified and measured as an integral part of the trial data collection process.
Resource use data were collected via a ‘bottom up’ approach where detail on the intervention and control
resources used to deliver the CCBT+MCBT, CCBT+MCI and CCBT treatment arms were identified and
measured via the use of a specially designed ‘therapist resource use log’. This log was designed for trial
therapists to complete every time a contact was made. Details for all types of visit (e.g. client face-to-face
visit, phone contact, school visit) were collected by recording all resources used, duration of any contact
with the patient as well as other resources such as travel mileage, rail fares or other expenses incurred
during the contact. See Appendix 3, Health economic logs, for a copy of the therapist resource use log.
DOI: 10.3310/hta19380 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 38
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Creswell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
A patient-held ‘resource use’ diary was developed to capture any additional health and social care
resources used by the mother and child beyond the therapy sessions (see Appendix 3, Health economics
diary/patient-held resource use diary). The aim of the diary was to aid recall, that is for the use of mothers
as a means of recording relevant resource use information for them and their children during the time
between assessments (baseline to assessment 1B for mid-intervention; assessment 1B to assessment 2
for post intervention; assessment 2 to 6 months for the 6-month follow-up; 6 months to 12 months for
the 12-month follow-up), so that they might be able to complete the mid- and post-intervention
questionnaires more efficiently. The resource use diaries comprised three sections. The first section
included questions on use of primary and secondary care health services (except the main anxiety
intervention), of other social services (e.g. social worker contacts) and of services provided by government
bodies other than the NHS (e.g. education department). The second section aimed to collect information
on drug treatment by asking mothers whether or not they and/or their children made use of medications
and if the latter were GP prescribed or purchased ‘over-the-counter’. Finally, in a bid to capture broader
societal impacts on employment and education, the third section asked mothers to report how much time
they had to take off work and/or usual activities owing to ill health and how many days off school their
children had taken owing to ill health.
Valuation of health and social care resource use
For each trial participant (mother and child), all components of treatment costs stratified by category of
resource use were computed by multiplying units of resource use by their unit costs. These were then
summed over all resource use categories to obtain a total annual cost for each participant. Unit cost
sources included NHS reference costs and unit costs of community care.79–86 Unit costs can be found in
Appendix 3, Table 89. Primary economic analyses focused only on the NHS cost of the alternative anxiety
treatments; preliminary secondary analyses included also wider societal and further health and social care
costs and will be developed further to include cost of medications and time off work. Prescription cost
analysis87 and published literature will be used to identify unit costs of prescribed and ‘over-the-counter’
drugs, respectively, whereas time off work will be valued using the human capital approach, using the
median gross weekly earnings by age and sex.88 Values are expressed in 2011/12 UK pounds sterling (£).
Values available only in 2010/11 or earlier prices were adjusted for inflation using RPI 201278 or the HCHS
pay and price inflation index 2011/12.79 As the duration of the study was 12 months, discounting of future
costs and benefits was not required.
Identifying and measuring outcomes: quality-adjusted life-years
In line with National Institute for Health and Care Excellence (NICE) recommendations, outcomes in the
economic analyses were identified and measured using quality-adjusted life-years (QALYs). Data to
estimate QALYs for mothers were collected through the European Quality of Life-5 Dimensions (EQ-5D)
self-completion questionnaire,89 which was administered to mothers at baseline, assessment 1B
(mid-treatment), assessment 2 (post treatment), and at 6- and 12-month follow-ups. For children the
EQ-5D child-friendly version was used.90 The EQ-5D is a generic measure of health-related quality of life,
designed to estimate QALYs and widely used across disease areas. It contains five questions each
concerned with a different area or ‘domain’ of everyday life: mobility; self-care; usual activities such as
work, study, housework and leisure activities; pain/discomfort; and anxiety/depression. The answers to
these questions provide a description or profile of the respondent’s quality of life and a value is then
attached to each profile using the results of a large UK general population survey.91 The tariff was used to
estimate health-related quality of life (EQ-5D scores) for each child and mother at baseline, assessment 1B
(mid-treatment), assessment 2 (post treatment), and at 6- and 12-month follow-ups. These EQ-5D utilities
were then combined with duration spent in each health state to estimate QALY gain over the 12-month
period of the study, assuming linear changes of utility between measurements and linear interpolation to
identify the area under the curve for the 12-month period.92 QALYs were computed using the area under
the curve approach, weighting the 12-month period by utility measured on a scale from 0 to 1.92
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Reporting and presenting results
Within the primary economic analyses the mean volume of health-care resources associated with each arm
were estimated and reported together with their standard errors (CCBT+MCBT, CCBT+MCI and CCBT).
Mean differences were calculated using ordinary least squares (OLS) regression to reflect the trial
comparisons: first the incremental resources used by the CCBT+MCBT arm versus the CCBT arm, and
second the incremental resources used by the CCBT+MCI arm versus the CCBT arm. Differences in
resource use are reported alongside 95% CIs.
Within the secondary economic analyses, health-care services other than those associated with the
intervention, other personal social services, non-NHS resources and medication use, were investigated both
for the mother and the child in each arm using descriptive statistics on the available data. More specifically,
mean resource use volumes were reported with their SDs for mother and child separately over the following
periods: baseline to assessment 1B (mid-treatment); assessment 1B to assessment 2 (post treatment);
assessment 2 to 6 months follow-up; and from 6 months to 12 months follow-up.
In the primary analyses the total intervention cost per participant (mother and child) was estimated by
multiplying the volume of each item of resource used by the unit cost of that item, then summing each item
cost for each participant. Mean costs were estimated and reported together with their standard errors for
each trial arm. Statistical differences in mean cost estimates across trial arms (CCBT+MCBT vs. CCBT; and
CCBT+MCI vs. CCBT) were evaluated using OLS regression. Robustness checks were conducted using
generalized linear modelling estimates to account for skewedness of cost data. Similar analyses were
conducted in relation to wider health and social care costs in the preliminary secondary analyses. In those
cases, however, total cost per patient was first calculated over each period between measurements,
namely from baseline to assessment 1B (mid-treatment); from assessment 1B to assessment 2 weeks (post
treatment); from assessment 2 to 6 months follow-up; and from 6 months to 12 months follow-up, and then
summed for each patient in order to obtain a total cost over the 12-month period. Cost estimates were
calculated for mother and child separately and then combined into one variable.
In order to inform whether or not either intervention is cost-effective, current methods recommended by
NICE technology assessment guidance have been adopted to report and present the results of the
incremental costs and QALYs for each comparison (CCBT+MCBT vs. CCBT; CCBT+MCI vs. CCBT). The
methods recommended by NICE are to combine incremental costs and outcomes within an ICER and to
report the joint distribution of the bootstrapped ICERs on a cost-effectiveness plane to provide information
on the associated uncertainty around this point estimate. Currently NICE uses a threshold range of
£20,000–30,000 per QALY gained (i.e. any ICER within or below this range would be deemed a cost-effective
use of resources). Mean incremental cost of the intervention and mean child QALYs were combined within
an ICER for CCBT+MCBT versus CCBT and CCBT+MCI versus CCBT, respectively. Uncertainty around
matched costs and QALY dyads were explored using both a parametric (Fieller’s theorem93,94) and
non-parametric (bootstrap method95,96) approach. Within the bootstrap approach, uncertainty was
investigated using 1000 bootstrapped samples to generate multiple cost–effect pairs, and displayed and
analysed using cost-effectiveness acceptability curves (CEACs).97 CEACs show the probability of a treatment
being cost-effective given a wide range of willingness-to-pay threshold values for health gains. In addition, a
linear representation of the CEAC, incorporating values for societal willingness to pay, NMB, was calculated
for CCBT+MCBT and CCBT+MCI versus CCBT, respectively, as:
NMBi(λ) = λEi − C i, (1)
where Ei and Ci are the observed differences in effects (E) and costs (C), respectively, for patient ‘i’ and λ is
the societal willingness to pay for a health gain. Where NMB is positive, this suggests the intervention is a
worthwhile use of resources. The NMB framework can be seen as an alternative way of representing
the ICER.
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In the secondary analyses, days off school for the child and days off work and/or usual activities for the
mother due to ill health were investigated using descriptive statistics. Further analyses will be developed to
explore mean differences statistically and to include a valuation of lost productivity using the human capital
approach with standard valuations to avoid bias.98
Sensitivity analysis
Sensitivity analysis around key variables is performed in a bid to determine the key factors influencing
cost-effectiveness. A key question is uncertainty in the cost-effectiveness analysis related to the impact of
reducing the treatment costs of non-specific interventions. Hence, sensitivity analysis was conducted by
setting the treatment costs related to non-specific interventions to zero. Treatment costs related to
non-specific interventions included NDC and the FH control delivered to balance groups for therapist
contact. Exploring the impact of reducing these costs was intended to reflect what would happen in reality
if the interventions were adopted in current practice. Further sensitivity analysis will be developed by
altering other key assumptions to explore their consequences for the results at the 12-month follow-up.
In particular, an exploration of the incorporation of broader societal impacts on the cost-effectiveness
results will be carried out, as well as further exploration of the results of the cost-effectiveness analysis to
include combined child and maternal QALYs in the full CUA. The latter were not included in the primary
analyses (only the child QALYs) in order to mirror the main trial outcomes.
Handling missing data
The primary economic evaluation adopted an ITT approach and missing data on resource use and health
outcomes were imputed using two different methods. For face-to-face therapist contacts, where missing
data values were highly deterministic (i.e. readily identifiable and standardised given observed practice), a
conditional imputation method was conducted whereby missing data were estimated as an average of
know durations for that client and session type. For the other resource use (mainly supervision time), costs
(i.e. reward costs) and health outcomes (EQ-5D), where missing data were presented in higher
percentages, multiple imputation was performed using a chained equation procedure99 and 20 imputed
data sets were generated using the Stata command ‘mi impute chained’. Prediction equations for each
imputation variable were customised and allowed to differ. Conditional models for imputed variables are
specified in Appendix 3, Health economic supplementary material section 1.
Results
Data completeness
Data were missing because questionnaires were not fully completed at all time points. However, a high
percentage of complete data were obtained from the likely key drivers, the therapist log for the
intervention and control service costs (e.g. 76.8% complete for MCBT contact time). Complete EQ-5D data
from mothers and child-friendly EQ-5D data for children ranged from 47.9% to 91.3% for mother
and from 46.5% to 98.6% for children. Detailed percentages of missing data are presented in Appendix 3,
Tables 90 and 91 to maximise transparency and aid interpretation of results. A complete case analysis was
not possible owing to the high percentage of missing data across resource use and health outcomes.
Restricting the sample to those children who had the EQ-5D measured at each assessment reduced the
sample size to just above one-third of the initial sample (77 vs. 211). These results were underpowered and
are therefore unreliable hence not reported, but they are available from the authors on request.
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Resource use: therapy time
Utilising data obtained from the therapists’ log, Table 76 provides a detailed descriptive breakdown of the
specific components of health-care resources used across each trial’s arm (face-to-face contact with
patients, supervision time, preparation time, travel time and mileage). The principal resource used for the
intervention was the staff time that the therapists spent directly with the patient, preparation time and
travelling time.
Table 77 reports the incremental mean time differences in minutes between CCBT+MCBT and CCBT.
Although the total time difference between the groups is not statistically significant, individual items
including duration of treatment for maternal anxiety, travel time and mileage are all significantly higher in
the CCBT+MCBT arm.
Table 78 reports incremental differences between the CCBT+MCI and CCBT treatment arms. Total
time differences between the arms are not statistically significant; however, there are statistically significant
differences among individual items including time spent providing CCBT, MCBT/NDC, MCI/FH; treatment
and supervision time for MCBT/NDC; and treatment and supervision time for MCI/FH.
TABLE 76 Detailed treatment resource use volumes
Resource use item
CCBT+MCBT (n= 69),
mean (SD) (minutes)
CCBT+MCI (n= 71),
mean (SD) (minutes)
CCBT (n= 71), mean
(SD) (minutes)
CCBT 423.95 (143.26) 454.31 (147.13) 391.74 (183.95)
MCBT 380.79 (106.30) NA NA
Maternal counselling (NDC) NA 108.77 (20.27) 329.73 (110.05)
MCI treatment (MCI; mother only)a NA 399.79 (132.24) NA
MCI treatment (MCI; mother and child)a NA 58.94 (37.56) NA
FH 143.41 (65.11) NA 138.61 (70.85)
Supervision time for CCBT (therapist time) 26.22 (3.42)b 30.43 (3.77)b 26.22 (3.55)b
Supervision time for CCBT (supervisor time) 26.22 (3.42)b 30.43 (3.77)b 26.22 (3.55)b
Supervision time for MCBT/NDC
(therapist time)
46.03 (4.59)b 35.50 (5.09)b 52.21 (6.62)b
Supervision time for MCBT/NDC
(supervisor time)
46.03 (4.59)b 35.50 (5.09)b 52.21 (6.62)b
Supervision time for MCI/FH (therapist time) 8.77 (2.36)b 24.99 (2.55)b 9.09 (2.06)b
Supervision time for MCI/FH (supervisor time) 8.77 (2.36)b 24.99 (2.55)b 9.09 (2.06)b
Travel (duration) 317.13 (437.18) 221.48 (379.50) 191.08 (298.52)
Travel (mileage) 181.31 (260.03) 127.73 (231.39) 105.69 (180.75)
Other 33.04 (48.06) 20.61 (49.35) 30.26 (86.41)
Extra time associated to ‘not attended’
sessions (e.g. waiting time, phone call, etc.)
0.80 (4.67) 3.52 (17.14) 0.42 (3.56)
Reward (monetary only) £0.97 (2.14) £1.07 (2.34) £0.86 (2.14)
Parking (monetary only) £0.10 (0.84) £0.03 (0.24) £0
NA, not applicable.
a One child/mother belonging to the MCBT treatment arm also received MCI ‘mother only’ (minutes= 420) and ‘child and
mother’ treatment (minutes= 35) (see Chapter 2, Statistical analysis).
b Standard error in parentheses, as variable is multiply imputed or is derived from other multiply imputed variables.
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TABLE 77 Treatment resource use mean differences: CCBT+MCBT vs. CCBT
Resource use item
CCBT+MCBT
(n= 69), mean (SD)
(minutes)
CCBT (n= 71),
mean (SD)
(minutes)
Mean differences
(minutes):
CCBT+MCBT –CCBT
(95% CI) p-value
CCBT 423.95 (143.26) 391.74 (183.95) 32.21 (–22.99 to 87.41) 0.251
MCBT/NDC 380.79 (106.30) 329.73 (110.05) 51.06 (14.89 to 87.24) 0.006
MCI/FH 150.00 (72.94) 138.61 (70.85) 11.39 (–12.63 to 35.43) 0.350
Supervision time for CCBT
(therapist time)
26.22 (3.42)a 26.22 (3.55)a 0.0019596 (–9.10 to 9.10) 1.000
Supervision time for CCBT
(supervisor time)
26.22 (3.42)a 26.22 (3.55)a 0.0019596 (–9.10 to 9.10) 1.000
Supervision time for MCBT/NDC
(therapist time)
46.03 (4.59)a 52.21 (6.62)a –6.18 (–22.77 to 10.42) 0.456
Supervision time for MCBT/NDC
(supervisor time)
46.03 (4.59)a 52.21 (6.62)a –6.18 (–22.77 to 10.42) 0.456
Supervision time for MCI/FH
(therapist time)
8.77 (2.36)a 9.09 (2.06)a –0.32 (–5.88 to 5.24) 0.905
Supervision time for MCI/FH
(supervisor time)
8.77 (2.36)a 9.09 (2.06)a –0.32 (–5.88 to 5.24) 0.905
Preparation time and record
keeping
376.22 (192.47) 404.28 (191.75) –28.06 (–92.27 to 36.15) 0.39
Travel (duration) 317.13 (437.18) 191.08 (298.52) 126.05 (1.25 to 250.84) 0.048
Travel (mileage) 181.31 (260.03) 105.69 (180.75) 75.63 (0.97 to 150.29) 0.047
Other 33.04 (48.06) 30.26 (86.41) 2.78 (–20.68 to 26.24) 0.815
Extra time associated to ‘not
attended’ sessions (e.g. waiting
time, phone call, etc.)
0.80 (4.67) 0.42 (3.56) 0.37 (–1.01 to 1.76) 0.594
Total therapy resource useb
(minutes)
1843.98 (81.78)a 1661.18 (78.67)a 182.79 (–40.92 to 406.51) 0.108
a Standard error in parentheses, as variable is multiply imputed or is derived from other multiply imputed variables.
b Excluding travel mileage, which is not expressed in minutes.
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TABLE 78 Treatment resource use mean differences: CCBT+MCI vs. CCBT
Resource use item
CCBT+MCI (n= 71),
mean (SD) (minutes)
CCBT (n= 71),
mean (SD)
(minutes)
Mean differences
(minutes):
CCBT+MCI –CCBT
(95% CI) p-value
CCBT 454.31 (147.13) 391.74 (183.95) 62.57 (7.30 to 117.84) 0.027
MCBT/NDC 108.77 (20.27) 329.73 (110.05) –220.97 (–247.22 to –194.71) 0.000
MCI/FH 458.73 (148.85) 138.61 (70.85) 320.12 (281.45 to 358.80) 0.000
Supervision time for CCBT
(therapist time)
30.43 (3.77)a 26.22 (3.55)a 4.21 (–6.52 to 14.94) 0.436
Supervision time for CCBT
(supervision time)
30.43 (3.77)a 26.22 (3.55)a 4.21 (–6.52 to 14.94) 0.436
Supervision time for MCBT/NDC
(therapist time)
35.50 (5.09)a 52.21 (6.62)a –16.72 (–32.21 to –1.22) 0.035
Supervision time for MCBT/NDC
(supervision time)
35.50 (5.09)a 52.21 (6.62)a –16.72 (–32.21 to –1.22) 0.035
Supervision time for MCI/FH
(therapist time)
24.99 (2.55)a 9.09 (2.06)a 15.90 (9.30 to 22.49) 0.000
Supervision time for MCI/FH
(supervision time)
24.99 (2.55)a 9.09 (2.06)a 15.90 (9.30 to 22.49) 0.000
Preparation time and record
keeping
346.93 (157.95) 404.28 (191.75) –57.36 (–115.64 to 0.93) 0.054
Travel (duration) 221.48 (379.50) 191.08 (298.52) 30.39 (–82.89 to 143.68) 0.597
Travel (mileage) 127.73 (231.39) 105.69 (180.75) 22.05 (–46.85 to 90.94) 0.528
Other 20.61 (49.35) 30.26 (86.41) –9.65 (–32.99 to 13.70) 0.415
Extra time associated to ‘not
attended’ sessions (e.g. waiting
time, phone call, etc.)
3.52 (17.14) 0.42 (3.56) 3.10 (–1.01 to 7.21) 0.138
Total therapy resource useb
(minutes)
1796.18 (75.27)a 1661.18 (78.67)a 134.99 (–79.71 to 349.69) 0.216
a Standard error in parentheses, as variable is multiply imputed or is derived from other multiply imputed variables.
b Excluding travel mileage, which is not expressed in minutes.
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Cost of therapy
Resource differences in time for CCBT+MCBT versus CCBT are translated into cost differences in Table 79
below and reveal a borderline statistically significant difference in total cost between the groups, with
CCBT+MCBT being £233.55 more expensive than the CCBT arm.
Resource differences in time for CCBT+MCI versus CCBT are translated into cost differences in Table 80
and reveal a borderline statistically significant difference in total cost between the groups, with the
CCBT+MCI arm being £233.16 more expensive that the CCBT arm.
TABLE 79 Treatment cost mean differences: CCBT+MCBT vs. CCBT
Costa
CCBT+MCBT
(n= 69), mean (SD)
CCBT (n= 71),
mean (SD)
Mean differences:
CCBT+MCBT –CCBT (95% CI) p-value
CCBT £621.65 (210.07) £574.42 (269.72) £47.23 (–£33.72 to £128.17) 0.251
MCBT/NDC £558.37 (155.87) £483.50 (161.38) £74.87 (£21.83 to £127.91) 0.006
MCI/FH £219.96 (106.96) £203.24 (103.88) £16.71 (–£18.52 to £51.95) 0.350
Supervision time for
CCBT (therapist time)
£17.11 (2.23)b £17.11 (2.32)b £0.001 (–£5.94 to £5.94) 1.000
Supervision time for
CCBT (supervision time)
£30.93 (4.03)b £30.92 (4.19)b £0.002 (–£10.73 to £10.74) 1.000
Supervision time for
MCBT/NDC
(therapist time)
£30.04 (2.99)b £34.07 (4.32)b –£4.03 (–£14.87 to £6.80) 0.456
Supervision time for
MCBT/NDC
(supervision time)
£54.29 (5.41)b £61.59 (7.80)b –£7.29 (–£26.88 to £12.29) 0.456
Supervision time for
MCI/FH (therapist time)
£5.72 (1.54)b £5.93 (1.35)b –£0.21 (–£3.84 to £3.42) 0.905
Supervision time for
MCI/FH (supervision time)
£10.34 (2.79)b £10.72 (2.43)b –£0.38 (–£6.94 to £6.18) 0.905
Preparation time and
record keeping
£245.49 (125.58) £263.80 (125.11) –£18.31 (–£60.21 to £23.59) 0.389
Travel (duration) £206.93 (285.26) £124.68 (194.78 £82.24 (£0.82 to £163.67) 0.048
Travel (mileage) £97.91 (140.42) £57.07 (97.60) £40.84 (£0.52 to £81.16) 0.047
Other £21.56 (31.36) £19.75 (56.39) £1.81 (–£13.50 to £17.12) 0.815
Extra time associated to
‘not attended’ sessions
(e.g. waiting time,
phone call, etc.)
£0.52 (3.05) £0.28 (2.32) £0.24 (–£0.66 to £1.15) 0.594
Rewards £3.95 (0.46)b £4.22 (0.48)b –£0.27 (–£1.72 to £1.18) 0.763
Parking £0.10 (0.84) £0 NA £0.10 (–£0.10 to £0.30) 0.312
Treatment total cost £2124.85 (84.98)b £1891.30 (87.14)b £233.55 (–£6.81 to £473.92) 0.057
NA, not applicable.
a Time delivering treatments (CCBT, MCBT/NDC, MCI/FH) was cost at the therapist–client contact hourly rate, whereas the
other therapist’s time was cost at the therapist standard hourly rate.
b Standard error in parentheses, as variable is multiply imputed or is derived from other multiply imputed variables.
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TABLE 80 Treatment cost mean differences: CCBT+MCI vs. CCBT
Costa
CCBT+MCI
(n= 71),
mean (SD)
CCBT (n= 71),
mean (SD)
Mean differences:
CCBT+MCI –CCBT+MCBT
(95% CI) p-value
CCBT £666.18 (215.74) £574.42 (269.72) £91.75 (£10.71 to £172.80) 0.027
MCBT/NDC £159.49 (29.72) £483.50 (161.38) –£324.01 (–£362.51 to –£285.51) 0.000
MCI/FH £672.65 (218.26) £203.24 (103.88) £469.41 (£412.69 to £526.13) 0.000
Supervision time for CCBT
(therapist time)
£19.85 (2.46)b £17.11 (2.32)b £2.75 (–£4.25 to £9.75) 0.436
Supervision time for CCBT
(supervision time)
£35.89 (4.44)b £30.92 (4.19)b £4.96 (–£7.69 to £17.62) 0.436
Supervision time for
MCBT/NDC (therapist time)
£23.16 (3.32)b £34.07 (4.32)b –£10.91 (–£21.02 to –£0.80) 0.035
Supervision time for
MCBT/NDC
(supervision time)
£41.87 (6.00)b £61.59 (7.80)b –£19.72 (–£37.99 to–£1.44) 0.035
Supervision time for MCI/FH
(therapist time)
£16.31 (1.66)b £5.93 (1.35)b £10.37 (£6.07 to £14.68) 0.000
Supervision time for MCI/FH
(supervision time)
£29.48 (3.01)b £10.72 (2.43)b £18.75 (£10.97 to £26.53) 0.000
Preparation time and
record keeping
£226.37 (103.06) £263.80 (125.11) –£37.42 (–£75.46 to £0.61) 0.054
Travel (duration) £144.52 (247.62) £124.68 (194.78) £19.83 (–£54.09 to £93.75) 0.597
Travel (mileage) £68.97 (124.95) £57.07 (97.60) £11.90 (–£25.30 to £49.11) 0.528
Other £13.45 (32.20) £19.75 (56.39) –£6.30 (–£21.53 to £8.94) 0.415
Extra time associated to
‘not attended’ sessions
(e.g. waiting time, phone
call, etc.)
£2.30 (11.19) £0.28 (2.32) £2.02 (–£0.66 to £4.70) 0.138
Reward £3.96 (0.49)b £4.22 (0.48)b –£0.26 (–£1.77 to £1.25) 0.727
Parking £0.03 (0.24) £0 £0.03 (–£0.03 to £0.08) 0.319
Treatment total cost £2124.46 (83.06)b £1891.30 (87.14)b £233.16 (–£6.81 to £473.92) 0.054
a Time delivering treatments (CCBT, MCBT/NDC, MCI/FH) was cost at the therapist client contact hourly rate, while the
other therapist’s time was cost at the therapist standard hourly rate.
b Standard error in parentheses, as variable is multiply imputed or is derived from other multiply imputed variables.
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Cost of additional health, personal social and non-NHS services
The total cost variable for use in the CUA comparing CCBT+MCBT with CCBT and CCBT+MCI with
CCBT was derived using the treatment costs only. Limited data were available from the additional health
and social service use patient diaries and three monthly resource use questionnaires (see Appendix 3,
Tables 92–115) owing to small numbers completed (reported in Appendix 3, Table 91). The results from
these analyses provide an indication of the broad health and social care resources used by this group.
Tables 81 and 82 report a summary of these results for CCBT+MCBT versus CCBT and for CCBT+MCI
versus CCBT. Further, detailed sensitivity analyses using chained equations to impute missing data will
consider this wider societal perspective. The analyses will include these health and social care resources
and costs beyond the resources/cost of the treatment, as well as resource use/cost from other sectors of
the economy (e.g. education). Furthermore, additional information on productivity loss (i.e. days off school
for children, and days off work and usual activities for mothers) will be included in these sensitivity
analyses (see Appendix 3, Tables 112–115).
TABLE 81 Cost of other health and social care resources and other non-NHS services: child, mother and overall
(available data only) – CCBT+MCBT vs. CCBT
Cost n
CCBT+MCBT,
mean (SD) n
CCBT,
mean (SD)
Mean differences:
CCBT+MCBT –CCBT (95% CI) p-value
Child
Baseline to
assessment 1B
35 £191.10 (281.97) 32 £148.01
(302.32)
£43.10 (–£99.46 to £185.66) 0.548
Assessment 1B to
assessment 2
17 £202.02 (648.96) 20 £121.76
(369.93)
£80.25 (–£265.66 to £426.18) 0.641
Assessment 2 to
assessment 3
32 £161.53 (267.83) 30 £385.78
(1043.20)
–£224.25 (–£605.70 to £157.19) 0.244
Assessment 3 to
assessment 4
23 £103.47 (158.66) 30 £327.45
(1178.54)
–£223.98 (–£721.84 to £273.88) 0.371
Total over 12 months
(child)
54 £327.26 (546.50) 51 £560.16
(1803.80)
–£232.90 (–£742.72 to £276.90) 0.367
Mother
Baseline to
assessment 1B
35 £145.32 (189.04) 32 £223.66
(429.56)
–£78.33 (–£237.89 to £81.22) 0.330
Assessment 1B to
assessment 2
17 £202.95 (272.91) 20 £382.62
(867.47)
–£179.66 (–£625.18 to £265.85) 0.418
Assessment 2 to
assessment 3
32 £194.44 (323.03) 30 £313.20
(886.12)
–£118.76 (–£453.43 to £215.91) 0.481
Assessment 3 to
assessment 4
23 £299.35 (537.12) 30 £206.27
(614.93)
£93.09 (–231.09 to 417.27) 0.567
Total over 12 months
(mother)
54 £400.81 (622.99) 51 £595.95
(1987.14)
–£195.13 (–£758.53 to £368.25) 0.494
Child and mother
Total over 12 months
(child and mother)
54 £728.07 (860.19) 51 £1156.11
(281.97)
–£428.048 (–£1453.25 to £597.16) 0.410
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Quality-adjusted life-years
Table 83 reports the results of the child EQ-5D utility values and QALYs for CCBT+MCBT versus CCBT.
There are no statistically significant differences in QALYs at 12 months.
Table 84 reports the results of the child EQ-5D utility values and QALYs for CCBT+MCI versus CCBT.
There are no statistically significant differences in QALYs at 12 months.
Table 85 reports the results of the mother EQ-5D utility values and QALYs for CCBT+MCBT versus CCBT.
There are no statistically significant differences in QALYs at 12 months.
Table 86 reports the results of the mother EQ-5D utility values and QALYs for CCBT+MCI versus CCBT.
There are no statistically significant differences in QALYs at 12 months.
TABLE 82 Cost of other health and social care resources and other non-NHS services: child, mother and overall
(available data only) – CCBT+MCI vs. CCBT
Cost n
CCBT+MCI,
mean (SD) n
CCBT,
mean (SD)
Mean differences:
CCBT+MCI –CCBT (95% CI) p-value
Child
Baseline to assessment 1B 47 £172.17
(390.05)
32 £148.01
(302.32)
£24.16 (–£138.91 to £187.24) 0.769
Assessment 1B to
assessment 2
25 £120.25
(330.03)
20 £121.76
(369.93)
–£1.51 (–£212.19 to £209.17) 0.989
Assessment 2 to
assessment 3
31 £89.51
(169.73)
30 £385.78
(1043.20)
–£296.28 (–£676.18 to £83.63) 0.124
Assessment 3 to
assessment 4
23 £132.54
(258.41)
30 £327.45
(1178.54)
–£194.90 (–£698.31 to £308.51) 0.441
Total over 12 months
(child)
60 £282.03
(586.32)
51 £560.16
(1803.80)
–£278.139 (–£767.21 to £210.93) 0.262
Mother
Baseline to assessment 1B 47 £122.15
(232.82)
32 £223.66
(429.56)
–£101.512 (–£250.56 to £47.54) 0.179
Assessment 1B to
assessment 2
25 £129.19
(259.35)
20 £382.62
(867.47)
–£253.42 (–£621.46 to £114.61) 0.172
Assessment 2 to
assessment 3
31 £82.67
(127.86)
30 £313.20
(886.12)
–£230.53 (–£552.31 to £91.25) 0.157
Assessment 3 to
assessment 4
23 £151.26
(213.60)
30 £206.27
(614.93)
–£55.01 (–£324.56 to £214.55) 0.684
Total over 12 months
(mother)
60 £250.21
(311.15)
51 £595.95
(1987.14)
–£345.74 (–£861.08 to £169.59) 0.186
Child and mother
Total over 12 months
(child and mother)
60 £311.15
(814.58)
51 £1156.11
(281.97)
–£623.88 (–£1595.28 to £347.52) 0.206
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TABLE 83 Child EQ-5D utility values and QALYs gained: CCBT+MCBT vs. CCBT
Time of assessment
CCBT+MCBT (n= 69),
mean (SE)
CCBT (n= 71),
mean (SE)
Mean differences:
CCBT+MCBT –CCBT (95% CI) p-value
EQ-5D utility values
Baseline 0.706 (0.028) 0.684 (0.036) 0.022 (–0.070 to 0.113) 0.641
Assessment 1B 0.727 (0.030) 0.773 (0.034) –0.046 (–0.135 to 0.042) 0.300
Assessment 2 0.798 (0.028) 0.862 (0.028) –0.065 (–0.144 to 0.015) 0.108
6-month follow-up 0.823 (0.033) 0.840 (0.034) –0.018 (–0.116 to 0.081) 0.723
12-month follow-up 0.821 (0.038) 0.862 (0.034) –0.042 (–0.150 to 0.067) 0.440
QALYs gained
Baseline to
assessment 1B
0.110 (0.004) 0.112 (0.004) –0.002 (–0.013 to 0.009) 0.741
Assessment 1B to
assessment 2
0.117 (0.004) 0.126 (0.004) –0.009 (–0.019 to 0.002) 0.097
Assessment 2 to
6 months
0.156 (0.005) 0.164 (0.005) –0.008 (–0.023 to 0.007) 0.291
6–12 months 0.411 (0.015) 0.426 (0.015) –0.015 (–0.059 to 0.030) 0.508
Total over 12 months 0.794 (0.022) 0.827 (0.024) –0.033 (–0.101 to 0.035) 0.332
SE, standard error.
TABLE 84 Child EQ-5D utility values and QALYs gained: CCBT+MCI vs. CCBT
Time of assessment
CCBT+MCI (n= 71),
mean (SE)
CCBT (n= 71),
mean (SE)
Mean differences:
CCBT+MCI –CCBT (95% CI) p-value
EQ-5D utility values
Baseline 0.729 (0.036) 0.684 (0.036) 0.045 (–0.058 to 0.147) 0.393
Assessment 1B 0.798 (0.026) 0.773 (0.034) 0.025 (–0.059 to 0.109) 0.559
Assessment 2 0.867 (0.023) 0.862 (0.028) 0.004 (–0.068 to 0.076) 0.904
6-month follow-up 0.897 (0.023) 0.840 (0.034) 0.057 (–0.026 to 0.139) 0.175
12-month follow-up 0.864 (0.031) 0.862 (0.034) 0.001 (–0.083 to 0.086) 0.973
QALYs gained
Baseline to
assessment 1B
0.118 (0.004) 0.112 (0.004) 0.005 (–0.006 to 0.017) 0.370
Assessment 1B to
assessment 2
0.128 (0.003) 0.126 (0.004) 0.002 (–0.007 to 0.012) 0.637
Assessment 2 to
6 months
0.170 (0.004) 0.164 (0.005) 0.006 (–0.007 to 0.018) 0.358
6–12 months 0.440 (0.012) 0.426 (0.015) 0.015 (–0.021 to 0.050) 0.424
Total over 12 months 0.855 (0.018) 0.827 (0.024) 0.028 (–0.030 to 0.086) 0.342
SE, standard error.
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TABLE 85 Mother EQ-5D utility values and QALYs gained: CCBT+MCBT vs. CCBT
Time of assessment
CCBT+MCBT (n= 69),
mean (SE)
CCBT (n= 71),
mean (SE)
Mean differences:
CCBT+MCBT –CCBT (95% CI) p-value
EQ-5D utility values
Baseline 0.833 (0.022) 0.816 (0.025) 0.017 (–0.050 to 0.084) 0.613
Assessment 1B 0.848 (0.022) 0.810 (0.036) 0.038 (–0.044 to 0.120) 0.358
Assessment 2 0.865 (0.026) 0.842 (0.030) 0.022 (–0.060 to 0.103) 0.597
6-month follow-up 0.861 (0.026) 0.855 (0.026) 0.007 (–0.069 to 0.082) 0.860
12-month follow-up 0.824 (0.030) 0.841 (0.034) –0.017 (–0.101 to 0.067) 0.689
QALYs gained
Baseline to
assessment 1B
0.129 (0.003) 0.125 (0.004) 0.004 (–0.005 to 0.014) 0.384
Assessment 1B to
assessment 2
0.132 (0.003) 0.127 (0.004) 0.005 (–0.006 to 0.015) 0.381
Assessment 2 to
6 months
0.166 (0.004) 0.163 (0.004) 0.003 (–0.011 to 0.016) 0.690
6–12 months 0.421 (0.011) 0.424 (0.013) –0.003 (–0.036 to 0.031) 0.878
Total over 12 months 0.848 (0.019) 0.839 (0.023) 0.009 (–0.050 to 0.068) 0.763
SE, standard error.
TABLE 86 Mother EQ-5D utility values and QALYs gained: CCBT+MCI vs. CCBT
Time of assessment
CCBT+MCI (n= 71),
mean (SE)
CCBT (n= 71),
mean (SE)
Mean differences:
CCBT+MCI –CCBT (95% CI) p-value
EQ-5D utility values
Baseline 0.799 (0.028) 0.816 (0.025) –0.017 (–0.091 to 0.058) 0.655
Assessment 1B 0.822 (0.027) 0.810 (0.036) 0.012 (–0.079 to 0.104) 0.789
Assessment 2 0.843 (0.027) 0.842 (0.030) 0.0003 (–0.082 to 0.083) 0.995
6-month follow-up 0.829 (0.026) 0.855 (0.026) –0.026 (–0.097 to 0.045) 0.474
12-month follow-up 0.857 (0.029) 0.841 (0.034) 0.016 (–0.067 to 0.100) 0.696
QALYs gained
Baseline to
assessment 1B
0.125 (0.004) 0.125 (0.004) –0.0003 (–0.011 to 0.010) 0.950
Assessment 1B to
assessment 2
0.128 (0.004) 0.127 (0.004) 0.001 (–0.011 to 0.013) 0.869
Assessment 2 to
6 months
0.161 (0.004) 0.163 (0.004) –0.002 (–0.015 to 0.010) 0.705
6–12 months 0.422 (0.012) 0.424 (0.013) –0.002 (–0.036 to 0.032) 0.893
Total over 12 months 0.835 (0.021) 0.839 (0.023) –0.004 (–0.065 to 0.057) 0.894
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Cost–utility analysis
Table 87 and Figures 8–10 report the results of the CUA from a health-care perspective for CCBT+MCBT
compared with CCBT. The bootstrapped ICERs for this comparison are shown in the cost-effectiveness
plane in Figure 8. With higher mean costs (albeit statistically insignificant) and lower mean utility (albeit
statistically insignificant) differences between the groups, Figure 8 reveals that, given current thresholds
for commonly accepted levels of cost-effectiveness (£20,000–30,000), CCBT+MCBT is not likely to
be a cost-effective alternative to CCBT. The CEAC shown in Figure 9 reveals that the probability that
CCBT+MCBT will be cost-effective in comparison with CCBT is < 10%. The NMB curve (see Figure 10)
confirms that CCBT+MCBT confers no monetary benefit over CCBT for a broad range of societal
willingness-to-pay thresholds and would not be deemed cost-effective given commonly accepted
threshold values representing value for money.
TABLE 87 Cost–utility analysis (health service perspective): ITT approach – CCBT+MCBT vs. CCBT
CUA results CCBT+MCBT (n= 69), mean (SE) CCBT (n= 71), mean (SE)
Cost of intervention £2124.85 (84.98) £1891.30 (87.14)
QALY gain 0.794 (0.022) 0.827 (0.024)
Incremental cost (95% CI) £233.55 (–£6.81 to £473.92)
Incremental QALY gain (95% CI) –0.033 (–0.101 to 0.035)
ICER, incremental cost per QALY gain –£7077
(95% CI) bootstrap method Lower limit, £12,373; upper limit, –£91
(95% CI) Fieller’s method Lower limit, £10,000; upper limit, £187
NMB for WTP= £20,000 –0.033 × £20,000 – £233.55= –£893.55
NMB for WTP= £30,000 –0.033 × £30,000 – £233.55= –£1223.55
SE, standard error; WTP, willingness to pay.
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FIGURE 8 Cost-effectiveness plane showing bootstrapped replicates of the ICER: CCBT+MCBT vs. CCBT. LL, lower
limit; PE, point estimate; UL, upper limit.
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FIGURE 9 Cost-effectiveness acceptability curve showing the probability that the intervention is cost-effective at
different willingness-to-pay thresholds: CCBT+MCBT vs. CCBT.
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FIGURE 10 Net monetary benefit curve and limit curves: CCBT+MCBT vs. CCBT. LL, lower limit; UL, upper limit.
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Table 88 and Figures 11–13 present the results of the CUA from a health-care perspective for CCBT+MCI
compared with CCBT. The bootstrapped ICERS for this comparison are shown in the cost-effectiveness
plane in Figure 11. With higher mean costs (albeit statistically insignificant) and higher mean utility (albeit
statistically insignificant) differences between the groups, Figure 11 reveals that, given the distribution of
the ICERS, CCBT+MCI is highly likely to be a cost-effective alternative to CCBT. The CEAC shown in
Figure 12 reveals that, given current NICE thresholds for accepted levels of willingness to pay for an extra
QALY (£20,000–30,000), the probability that CCBT+MCI will be cost-effective in comparison with CCBT is
around 75%. The NMB curve (see Figure 13) confirms that CCBT+MCI confers additional monetary
benefit over CCBT alone and would be deemed a cost-effective alternative given commonly accepted
threshold values representing value for money.
TABLE 88 Cost–utility analysis (health service perspective): ITT approach – CCBT+MCI vs. CCBT
CUA results CCBT+MCI (n= 71), mean (SE) CCBT (n= 71), mean (SE)
Cost of intervention £2124.46 (83.06) £1891.30 (87.14)
QALYs 0.855 (0.018) 0.827 (0.024)
Incremental cost (95% CI) £233.16 (–£6.81 to £473.92)
Incremental benefit, QALY gain (95% CI) 0.028 (–0.030 to 0.086)
ICER, incremental cost per QALY gain £8327
(95% CI) bootstrap method Lower limit, –£173; upper limit, –£11,021
(95% CI) Fieller’s method Lower limit, –£95; upper limit, –£8881
NMB for WTP= £20,000 0.028 × £20,000 – £233.16= £326.84
NMB for WTP= £30,000 0.028 × £30,000 – £233.16= £606.84
SE, standard error; WTP, willingness to pay.
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FIGURE 11 Cost-effectiveness plane showing bootstrapped replicates of the ICER: CCBT+MCI vs. CCBT. LL, lower
limit; PE, point estimate; UL, upper limit.
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FIGURE 12 Cost-effectiveness acceptability curve showing the probability that the intervention is cost-effective at
different willingness-to-pay thresholds: CCBT+MCI vs. CCBT.
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FIGURE 13 Net monetary benefit curve and limit curves: CCBT+MCI vs. CCBT. LL, lower limit; UL, upper limit.
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Sensitivity analysis
A key question of uncertainty in the cost-effectiveness analysis related to the impact of reducing the
treatment costs of non-specific interventions. Hence, sensitivity analysis was conducted by setting
the treatment costs related to non-specific interventions to zero. Treatment costs related to non-specific
interventions included NDC and a generic FH control intervention delivered to balance groups for therapist
contact. Although this analysis was conducted with the intention to reflect what would happen in reality
if the interventions were adopted in current practice, it relied on the strong assumption that the non-specific
interventions had no impact at all on the child anxiety outcomes. By increasing the cost difference between
interventions and control, but maintaining the difference in effects invariant (as counterfactual outcomes
in absence of non-specific interventions could not be measured), no evidence was found that either
CCBT+MCBT or CCBT+MCI would offer any added value for money in improving child anxiety outcomes
beyond what was already suggested in the primary analyses. Detailed results are reported in Appendix 3,
Tables 116 and 117, and Figures 14–19.
Further sensitivity analysis will be developed by altering other key assumption to explore their
consequences for the results at 12 months follow-up. In particular, an exploration of the incorporation of
broader societal impacts and of the combined child and maternal QALYs on the cost-effectiveness results
will be carried out.
Limitations of the data
The high level of missing data in the follow-up health and social care resource use beyond the treatment
costs is a limitation for this economic evaluation. If the health and personal social service costs reported for
the CCBT+MCBT versus CCBT comparison were representative of this population and included in the ICER,
as they typically would be, the costs in the CCBT arm would increase by £428, thereby placing CCBT+MCBT
into the lower cost/lower effectiveness zone of the cost-effectiveness plane (south west) and a different
scenario to the cost-ineffective scenario arising when treatment only costs were included in the ICER. If the
health and social care resources reported for the CCBT+MCI versus CCBT comparison were representative
of this population and included in this analysis, the costs in the control arm would increase by £624. This
would have placed the CCBT+MCI arm in the realms of being highly cost-effective (south-east quadrant of
the cost-effectiveness place), that is dominating the CCBT arm and being both less costly and more effective,
a clear win–win scenario. Another limitation of the data was the high percentage of missing data. This was
dealt with using appropriate data imputation techniques; however, imputation cannot account for potentially
non-random reasons for missing data.
Discussion
The aim of the economic evaluation was to assess the cost-effectiveness of the CCBT+MCBT and
CCBT+MCI treatment arms in relation to the CCBT treatment arm from a health service perspective.
The economic analyses aligned with the primary aim of the trial, namely to evaluate whether or not CCBT
could be improved by the addition of (i) treatment of maternal anxiety disorders (MCBT), or (ii) treatment
focused on maternal responses (MCI). Combining the total treatment costs with maternal and child QALYs
revealed that, within commonly accepted levels of value for money (i.e. £20,000–30,000 per extra QALY
gained), CCBT+MCBT was not likely to be a cost-effective alternative to CCBT. However, combining the
total treatment costs with child QALYs revealed that in the comparison of the CCBT+MCI with CCBT
treatment arms, the CCBT+MCI treatment arm was highly likely to be a cost-effective alternative to the
CCBT arm. A limitation of these analyses, however, was that the resource use and costs of additional health
and personal social services, beyond the current treatment costs, were not included in the primary analyses
owing to very small sample sizes for these data components. Insufficient statistical power meant that
conclusions could not be drawn about the impact of these additional costs on the overall cost-effectiveness.
These additional data, however, do provide insights about the type and range of services this group of
children and mothers use. Children undergoing treatment for anxiety disorders can be seen to be accessing
a broad range of services beyond treatment from GPs, including social workers, psychologists, psychiatrists,
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education welfare officers, family liaison officers, teachers, paediatricians, audiologists, ophthalmology,
accident and emergency (A&E), dieticians, physiotherapists, mental health workers and ‘other services’.
Notwithstanding the limited evidence these small sample sizes convey, comparisons of CCBT+MCBT and
CCBT+MCI with the CCBT treatment arm reveal increasing costs prevalent in the CCBT arm in the majority
of the assessment periods. Furthermore, counting the number of services accessed by each group it can be
seen that overall participants in the CCBT arm were accessing approximately one-third more services than
those in the CCBT+MCBT and CCBT+MCI arms. In addition, the total costs are always higher in the CCBT
arm for both comparisons. If these differences translated into actual differences then this would only
increase the likelihood of the CCBT+MCBT and CCBT+MCI arms being more cost-effective than the CCBT
arm. It is only by replicating these data collection exercises with larger samples that these results can be
confirmed or refuted. On a cautionary note, however, it is important to outline that increased use of services
may not represent an inferior quality-of-life outcome owing to the benefits of increased awareness about
the health and well-being advantages of accessing additional services.
Broader impacts on other sectors, including impacts on education, employment and impacts on leisure
time including time off school for children and time off work and usual activities for their mothers,
were also presented but not included in the primary analyses. Further analyses will explore the impact of
these effects on a broader societal perspective.
Conclusions
These CUAs have shown that when adopting a health service perspective, only the addition of MCI to
standard CCBT is highly likely to represent a cost-effective use of resources for these mother/child pairs
within commonly accepted thresholds of cost-effectiveness. Further, analyses reveal that when adopting a
health service perspective only the addition of MCBT to standard CCBT is unlikely to be a cost-effective
use of resources for these mother/child pairs. However, the latter result should be interpreted with caution
because of the high percentage of missing data in some variables which, despite being dealt with using
appropriate imputation techniques, may still be viewed as a shortcoming. However, further analysis
incorporating the additional health and social care costs has indicated that, depending on the
representativeness of these data, there are possible improvements in the cost-effectiveness of both
CCBT+MCBT and CCBT+MCI depending on the assumptions made about these costs. Further analysis
of the data exploring inclusion of the additional health and personal social service costs and employment
and educational impacts using multiple imputations within sensitivity analyses may provide further
insight to the cost-effectiveness of these interventions. This economic evaluation provides insight to the
broad range of services accessed by this client group, hence it is recommended that future economic
evaluations in this area incorporate data collection on this full range of services to fully capture the impact
of new interventions.
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Chapter 5 Discussion and conclusions
Summary of findings
Children with anxiety disorders whose mothers are also highly anxious have been shown to have a
poorer response to treatment than those whose mothers are not anxious,9,100 yet the impact on children
of treating the maternal anxiety has been unclear. Further, the clinical impact on children with anxiety
disorders of targeting potentially anxiogenic maternal behaviours has not previously been evaluated
systematically. The current study set out to address both these issues in a large RCT.
There was some evidence that the MCBT and MCI treatments were successful in altering the maternal factors
which they were designed to address. Specifically, MCBT conferred short-term benefits in maternal recovery
from primary diagnoses. However, by the post-treatment assessment, when children in all treatment arms had
received CCBT, mothers in all arms had experienced a good level of recovery from their primary disorder and
differences between treatment arms were no longer apparent. It is important to note that there were no
significant differences between treatment arms on maternal-reported symptoms of anxiety at any time
point. For the CCBT+MCI treatment arm there was evidence of change in maternal overprotection and
expectations relating to a lack of child coping with challenge. There were no differences between treatment
arms in change in other potentially anxiogenic parenting responses (such as expressed anxiety and
positive behaviours).
Despite the success in changing some aspects of maternal anxiety and parenting responses, adding neither
treatment of maternal anxiety (MCBT) nor treatment of maternal responses (MCI) conferred a significant
benefit on children on the basis of the primary child treatment outcomes. Although both adjunct treatments
achieved higher child recovery and global improvement rates post treatment than the group in which neither
maternal anxiety nor potentially anxiogenic parenting received specific therapeutic attention, the advantages
were neither statistically significant nor consistent across treatment arms and outcome measures.
There was some evidence of an advantage for the CCBT+MCI treatment arm on the primary outcomes at
the 6-and 12-month follow-up assessments, but this did not reach statistical significance. There was a
significant advantage of CCBT+MCI over CCBT on change in child anxiety severity at the 6-month
follow-up, and a similar pattern existed at the 12-month follow-up (although it was no longer statistically
significant). There was a general lack of significant differences between treatment arms on child-,
mother- and teacher-reported anxiety symptom questionnaires. Where statistically significant differences
did exist, these were contrary to expectations, with children in the CCBT group reporting a greater reduction
in symptoms of anxiety and low mood than children in the CCBT+MCI arm at the post-treatment
assessment. In contrast, mothers in the CCBT+MCI arm reported a greater reduction in child conduct
problems at the 12-month follow-up assessment than mothers in the CCBT arm.
The secondary research questions considered whether or not improvement in child anxiety was significantly
associated with change in (i) maternal anxiety, and (ii) maternal parenting responses. No significant
associations were found between change in maternal anxiety and change in child anxiety symptoms,
severity or improvement at the mid-treatment, post-treatment and 6-month follow-up assessments.
Contrary to expectations, greater change in maternal anxiety symptoms was associated with less change
in the severity of the child’s primary anxiety diagnosis. It is important to note that a large number of
correlations were conducted to examine this research question and the lack of a consistent pattern
of results highlights the fact that no clear conclusions can be drawn. In relation to maternal parenting
responses, significant associations were found between change in maternal behaviours and change in child
anxiety, most commonly for maternal overprotection. Specifically, and contrary to expectations, a greater
increase in overprotection was associated with a greater reduction in the severity of the child’s primary
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anxiety diagnosis post treatment and global improvement at both the post-treatment and the 6-month
follow-up assessments. These indices are both assessor rater; when child symptom ratings were used the
opposite pattern was found, with a greater reduction in maternal overprotection being associated with
greater reduction in child anxiety symptoms. The difference in the pattern of findings according to who is
reporting on child anxiety is interesting and warrants further investigation, but for now clear conclusions
about mechanisms of change cannot be drawn.
Economic evaluation
The CUAs demonstrated that, when adopting a health service perspective, the addition of MCI to standard
CCBT is highly likely to represent a cost-effective use of resources for these mother/child pairs within
commonly accepted thresholds of cost-effectiveness. Further, analyses reveal that when adopting a health
service perspective the addition of MCBT to standard CCBT is unlikely to be a cost-effective use of resources
for these mother/child pairs. Those cost-effectiveness results should be interpreted with caution owing to the
high percentage of missing data on some variables which, despite being dealt with using appropriate
imputation techniques, may still be viewed as a shortcoming. Furthermore, analysis incorporating the
additional health and social care costs has indicated that, depending on the representativeness of these
data, there are possible improvements in the cost-effectiveness of both CCBT+MCBT and CCBT+MCI
depending on the assumptions made about these costs. Further analysis of the data exploring inclusion of
the additional health and personal social service costs and employment and educational impacts using
multiple imputations within sensitivity analyses may provide further insight to the cost-effectiveness of these
interventions. The economic evaluation provides insight into the broad range of services accessed by this
client group; hence, it is recommended that future economic evaluations in this area incorporate data
collection on this full range of services when evaluating new interventions.
Strengths and limitations
The study had several notable strengths, including the referred clinical sample, the use of reliable, blind
raters to make assessments of child and maternal anxiety and maternal behaviours before and after
treatment, and a design which allowed for isolating the effects of specifically targeting maternal anxiety
and parenting responses. A further strength of the study was the inclusion of non-specific interventions
designed to balance therapist contact. However, the data collected for health economic analyses indicated
that therapist contact did not end up entirely balanced within each phase of treatment. Most notably,
more therapist time was spent delivering the eight sessions of MCBT treatment than the eight sessions of
NDC that were delivered in the CCBT arm. Similarly, the MCI treatment took more time to deliver than the
FH-oriented control. In both cases this may have resulted from the more directive treatment manuals in
the MCBT and MCI treatments requiring longer sessions, or from therapist difficulties in maintaining
engagement in the NDC and FH treatments so moving through the material more quickly. This suggestion
is consistent with the fact that the highest rate of dropout was found during the eight-session NDC
phase of treatment. Despite these differences, the overall time and cost of interventions across the entire
treatment period was not significantly different across arms, supporting a good balance overall in therapist
contact across treatment arms.
The strengths of the study need to be considered in the light of various other limitations. Although we
allowed for 20% loss to follow-up, by the 1-year post-treatment assessment retention was down to 61%
in the CCBT condition. This limits the conclusions that can be drawn about differences between treatment
conditions in the longer term. Although there were no clear baseline differences between completers
and those who dropped out, it is of concern that the greatest amount of dropout occurred during the
eight-session maternal counselling phase. Therefore, this form of intervention appears not to have been an
acceptable treatment approach for some families. This finding presents a challenge for future research;
the inclusion of non-specific interventions presents a conservative test of the specific effects of particular
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interventions but requires the delivery of credible, alternative interventions. Whether longer-term dropouts
over-represented those with good or bad treatment outcomes cannot be determined, although the
sensitivity analyses that were conducted suggest that this was not the case. Our impression was that, in
some cases, those that dropped out from follow-up assessments did so because they felt that their child
had made a good recovery and had ‘moved on’ (and so did not want them to have to take part in a long
diagnostic assessment). Future studies might benefit from an abridged follow-up assessment which places
a minimal burden on participants. The degree to which long-term outcome was also influenced by
involvement with help seeking elsewhere is also unclear. Although families agreed not to initiate any other
treatment during the course of the intervention, they may have sought help elsewhere during the
follow-up period. However, as indicated in the economic analyses (see Appendix 3, Tables 91–111), use of
other resources was low across all treatment arms.
The lack of additional health and social care resource use beyond the treatment costs is a limitation for the
economic evaluation presented here. Unfortunately there was a large amount of missing data on this
measure which precluded its inclusion in these analyses. However, preliminary analysis incorporating the
limited data available on the additional health and social care costs has indicated that, depending on
the representativeness of these data, there are possible improvements in the cost-effectiveness of both
CCBT+MCBT and CCBT+MCI depending on the assumptions made about these costs. Further analysis of
the data exploring inclusion of the additional health and personal social service costs and employment and
educational impacts using multiple imputations within sensitivity analyses may provide further insight to
the cost-effectiveness of these interventions.
Other limitations include the relatively restricted demographic characteristics of the participating group, who
were predominantly of non-minority ethnicity and relatively high socioeconomic status (SES), although this
was lower than in a comparable trial on the basis of parent education.19 Our study population also had
somewhat higher rates of child- and parent-rated anxiety levels than in similar studies.19 In terms of marital
status, the population was representative of the wider population.101 We elected to focus on middle
childhood (ages 7–12 years) and intervening with mothers as a methodological expediency as it is likely that
the nature of parental influences on child anxiety varies with child age102,103 and parent gender;34 however, as
a result, the findings cannot be generalised to young children or adolescents or to interventions with fathers
or other caregivers. The extent to which characteristics of other parental figures (e.g. paternal anxiety and
parenting responses) moderate treatment outcomes warrants further examination. In our trial each phase of
treatment was delivered by a different therapist, this meant that there was a very large number of different
combinations of therapists (116 combinations) which precluded us from examining therapist effects.
The study also included children and mothers with a broad range of anxiety disorders. There is emerging
evidence that generic treatment approaches, of the sort provided in the study, may be more beneficial for
some child anxiety disorders than others104 and that particular potentially anxiogenic parental responses may
be disorder specific.64,105 Both of these sets of findings suggest that further work needs to be done which
takes account of the precise form of parental and child anxiety, as well as particular forms of parenting
responses. The inclusion of mothers with a broad range of disorders also meant that it was most appropriate
for a transdiagnostic anxiety treatment to be delivered. Although there is evidence for the effectiveness of
this approach (both here and in previous studies),38 it is unclear if disorder-specific treatments would have
conferred greater benefits in terms of maternal anxiety. Furthermore, anxiety disorders are commonly
comorbid with depression;32 the extent to which maternal depression moderates treatment outcomes in the
context of maternal anxiety disorders warrants further attention. Finally, although we recruited a referred
clinical population, their experience of treatment will have been very different from routine child mental
health services because of the intensive research assessments and the adjunct interventions that were
essential for our research purposes. Further insights in to the experiences of patients and therapists
participating in this trial would be of value.
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Interpretation of results
The findings suggest that adding specific interventions targeting maternal anxiety or the MCIs to individual CBT
for children with anxiety disorders in the context of maternal anxiety disorder do not confer significant benefits
in terms of child outcomes when compared with individual CBT (supplemented with non-specific therapist
support); although some cost–benefit may obtain from the addition of an intervention to target the MCI.
Our findings, in relation to the treatment of parental anxiety disorder, are consistent with those obtained
in a recent study by Hudson and colleagues.19 Their study also specifically focused on children with anxiety
disorders who had a parent with an anxiety disorder, and they also failed to find a significant benefit of
the addition of parental anxiety management to CCBT. The findings also run contrary to the idea that
changing parental responses is necessary for successful treatment of child anxiety disorder in the context of
parental anxiety disorder.23 Notably, however, the CCBT treatment arm in the current study performed
considerably better than expected: immediately post treatment, 48% of children were free of their primary
anxiety disorder, and 64% were ‘much’ or ‘very much’ improved; a year after treatment, 72% were free of
their primary diagnosis and 77% were ‘much’/‘very much’ improved. These outcomes are particularly
notable given the relatively brief nature of the CCBT intervention.106 They are also higher than the 33% of
children (with a parent with an anxiety disorder) who were free of their primary anxiety disorder in the
study reported by Hudson and colleagues.19 Indeed, the success rates reported here are similar to those
found from more intensive (14-session) CBT for children with anxiety disorders, regardless of parental
anxiety disorder status, where 60% and 72% were ‘much’/’very much’ improved at post treatment55
and 6-month follow-up,107 respectively. The lack of consistent differences between groups on clinical
outcomes and the failure to find consistent, significant associations between the hypothesised mechanisms
of change and child outcomes, may suggest that the association that has been commonly found between
maternal anxiety disorder and child treatment outcomes may be the result of some third factor, for
example other stressors experienced by the family, or shared associations with particular child or maternal
comorbidities. The fact that we obtained higher child outcomes than expected following CCBT suggests
that it is possible that this third factor variable was addressed to some extent by the generic support
received by all mothers in this trial.
One consideration in making sense of the lack of main effects of the two active adjunct interventions
(MCI/MCBT) is statistical power, given the higher than anticipated success rate on the CCBT arm. However,
the extent of differences found between our treatment arms was below our a priori criteria for clinical
significance (30% more children free of their anxiety diagnoses). The unexpectedly high rate of recovery
within the CCBT group in the current study is unlikely to be a function of particular features of our sample,
as our study population was a referred sample with systematically confirmed anxiety diagnoses, comparable
to other clinic samples in the literature. One possible explanation may lie in the potential added value of the
non-specific interventions. These both provided some level of parental support. Although the design used for
the current study was appropriate for determining whether or not the MCBT and MCI interventions conferred
specific benefits, controlling for therapist contact time using non-specific interventions is a conservative
approach and the effects of the non-specific treatments are unclear. The absence of a significant main effect
of either CCBT+MCBT or CCBT+MCI also needs to be considered in the light of the degree to which the
adjunctive interventions were successful in altering their respective targets. In the one previous study that
assessed the impact of adding CBT for parental anxiety disorders to CBT for child anxiety disorders,12 the
failure to find differences in child outcomes was attributed to the fact that the parental CBT did not confer a
benefit in terms of reducing parental anxiety compared with when only the children received CBT (i.e. 35.5%
vs. 32.7% of mothers were free of their primary anxiety disorder, respectively). In the current study, a more
intensive CBT intervention was delivered to the mothers and, as predicted, CCBT+MCBT was associated
with a significant reduction in the frequency of maternal anxiety disorder compared with when mothers
received NDC (58.5% vs. 36.5% diagnosis free). However, by the end of the CCBT treatment phase there
were no group differences in maternal anxiety disorder, with all groups showing high rates of recovery from
maternal anxiety disorder (52–66%). The fact that a marked reduction in anxiety disorders across all groups
was found following CCBT is consistent with recent findings indicating that reduction in child anxiety
promotes reduction in parental anxiety.25
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This study is the first of which we are aware to report on observational assessments of parental responses
before-and-after treatment for child anxiety disorders. We were able to rigorously evaluate the extent to
which the MCI intervention successfully altered maternal responses to her child when confronted with a
challenge. These assessments provided evidence that, in terms of a reduction in overprotective behaviours,
the MCI treatment was indeed successful. It is notable that this observation-based finding was confirmed by
maternal self-report data. The MCI intervention was also associated with change in maternal cognitions
associated with confidence in child coping (i.e. reduced predictions regarding child fear and increased
predictions regarding child control). Despite these positive benefits of the MCI intervention, no significant
benefit to child outcomes was conferred on primary outcome measures (although MCI added to CCBT
seemed to represent good value for money). One possible reason for this may be that the changes were not
of sufficient magnitude to be of benefit in terms of the clinical outcomes. Another possibility is that the
factors that did change are not central to the maintenance of child anxiety. Indeed, although scores on
the self-report maternal overprotection scale used have been found to be associated with the development
of child anxiety,108 others have found that they do not discriminate clinically anxious children from their
non-anxious peers.66 It will be important to evaluate whether the association between maternal anxiety
disorder and child treatment outcomes is in fact mediated by other shared factors, for example other stressors
experienced by the family, which might have been addressed to some extent by the generic support received
by all mothers in this trial. It is of interest that no specific benefit was apparent for the MCI intervention on
the measures of maternal expressed anxiety, intrusiveness or positive behaviours. Although it is, of course,
possible that the intervention was ineffective with respect to these dimensions, it is also possible that these
findings reflect a lack of sensitivity of the laboratory-based observational tasks. It is also possible that
these parental behaviours changed equally across groups in response to improvements in child anxiety.13
Although there were no significant differences between treatment arms on the primary outcome measures
at the post-treatment assessment, an advantage for CCBT+MCI was found on indices of change in
anxiety disorders severity and an advantage which approached significance in terms of being free of the
primary anxiety diagnosis at the 6-month follow-up assessment. There was also a trend for an advantage
of CCBT+MCI over the CCBT arm in terms of the proportion of children who were free of all their anxiety
diagnoses. These findings are consistent with the health economic outcomes which suggest that the
CCBT+MCI is a cost-effective use of resources in comparison with the CCBT intervention. As the inclusion
of two non-specific interventions within the CCBT arm would be expected to reduce its cost-effectiveness,
sensitivity analyses were conducted in which zero costs were attributed to the non-specific interventions.
This is a conservative test given that the non-specific interventions might be expected to confer some
benefit to children and mothers, yet there was still evidence to support the cost-effectiveness of the
CCBT+MCI intervention in this context. As noted above, the mechanisms by which CCBT+MCI conferred
a cost–benefit advantage remain unclear.
It is notable that there was also a trend for CCBT+MCBT to have an advantage over CCBT in terms of
general improvement post treatment. However, differences between arms were not consistent across time
points or measures. Thus, although there is a possibility that MCBT helped support the generalisation of
benefits in the short term, this speculation received only weak support.
Some unexpected findings should also be noted. In particular, on the basis of child self-reported anxiety
symptoms, the CCBT+MCBT group did less well than the CCBT group at the post-treatment assessment.
Both the CCBT+MCI and CCBT+MCBT groups also reported less of a reduction in low mood than the
CCBT groups. None of these findings were maintained at the later assessment (although CCBT+MCBT
had the poorest overall outcomes by the 12-month assessment); however, they are surprising given the
content of the child treatment was the same across groups. Whether or not the full course of NDC
(eight sessions) received by the mothers in the CCBT group led to some short-term benefit in terms of
children’s perceptions of their symptoms remains unclear. There were also some unexpected findings in
relation to the secondary research questions, which addressed the extent to which change in maternal
anxiety and parenting responses was associated with change in child anxiety. However, as the pattern of
findings was not consistent across measures and assessment time points no clear conclusions can be drawn.
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It is important to note that the sample size for this study was based on providing enough power to assess the
primary outcomes. Other outcomes are secondary and, owing to the large number of tests, the results must
be interpreted with caution.
Implications for health care
l The novel intervention that focused on modifying maternal parenting responses was associated with
some benefit to children and mothers with anxiety disorders, and is likely to be cost-effective (although
the latter result needs to be considered with caution because of the high percentage of missing data
in the economic analyses). Incorporating effective measures to address maternal cognitions and
behaviours when interacting with her child may improve health outcomes for children with anxiety
disorders in the context of maternal anxiety disorder.
l We can be confident that supplementing individual CCBT with CBT to target the maternal anxiety
disorder is unlikely to confer substantial health benefits and is unlikely to be cost-effective (although
the latter result needs to be considered with caution owing to the high percentage of missing data in
the economic analyses). Given the intensity of this intervention and its general lack of effectiveness we
think it is unlikely that supplementing CCBT with this intervention will improve child outcomes.
Implications for future research
l Given that CCBT alone was sufficient for a good number of patients, it is possible that a benefit of the
CCBT+MCI and CCBT+MCBT interventions may be enhanced in particular contexts, for example in
the context of particular maternal or child anxiety disorders or high levels of severity. Future research
that directly addresses these possibilities is warranted.
l The relatively low level of association between change in parental anxiety and responses and child
anxiety may suggest that other factors may account for the modest treatment outcomes typically found
among children with anxiety disorders who have mothers with anxiety disorders (such as genetic or
broader social/environmental factors). Future research is warranted to address these issues.
l The economic evaluation provides insight as to the broad range of services accessed by this client
group, hence it is recommended that future economic evaluations in this area incorporate data
collection on this full range of services when evaluating new interventions.
DISCUSSION AND CONCLUSIONS
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Appendix 1 Patient and public involvement
Public involvement in the conduct of the research
A member of the public was a full member of the TSC from initiation to completion of the trial. This lay
member was identified by contacting parents of children that had received treatment for anxiety disorders
at the University of Reading/Berkshire Healthcare NHS Foundation Trust/Berkshire Child Anxiety Clinic. The
individual appointed was the only parent to express an interest who was available to commit to ongoing
participation and so no selection process was needed. The lay member’s contributions to the conduct
of the trial included reviewing information sheets for children and parents, providing feedback on the study
protocol and providing guidance on strategies for successful recruitment. This proved invaluable, particularly
in providing advice on how to best inform potential participants about the trial and recruitment strategies.
Lessons learned
We benefited from the commitment of our one lay representative; however, we were unable to secure a
commitment from other potential lay members, and two general practitioners who gave agreement to join
the TSC were ultimately unable to attend meetings. We clearly recognise the value of patient and public
involvement at all stages of the research process so will include more comprehensive costings to cover the
expenses/lost earnings associated with patient and public involvement and will be more explicit in forming
patient and public involvement relationships (e.g. through honorary appointments) in future grants.
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Appendix 2 Mother and child anxiety trial
study protocol
Treatment of Child Anxiety Disorder in the Context of Maternal Anxiety: 
A Randomised Controlled Trial
Trial Acronym: MACh  (i.e. mother and child anxiety treatment study)
RATIONALE: The outcome from CBT for children with anxiety disorders is highly variable. 
A major factor contributing to this is likely to be the presence of maternal anxiety and the 
associated disturbances in mother-child interactions and maternal behaviours. Where parental 
anxiety has been addressed in treatment research it has been difficult to assess its contribution 
to child outcome. Similarly, where therapeutic measures to address parent-child interactions 
have been included, it has not been possible to determine the specific role of such measures in 
the treatment package employed. 
The trial is a three-arm RCT which aims to determine the extent to which treatments of 
maternal anxiety and mother-child interactions enhance standard cognitive behaviour therapy 
for children (CCBT) who have anxiety disorders in the context of maternal anxiety disorder 
(a group who currently show a poor response to treatment). Index children will receive CCBT 
with either additional treatment for maternal anxiety or specific measures to address features 
of mother-child interactions; and their outcome will be compared to that of children 
receiving standard individual CCBT (together with appropriate control conditions)
A. Background
Childhood Anxiety Disorders
Anxiety disorders are the most common form of psychopathology in children. They have a 
significant adverse impact on children’s general socio-emotional functioning and commonly 
persist into adulthood.
Treatments of childhood anxiety disorders
Following advances in the development of successful cognitive behavioural therapies (CBT) 
for adult anxiety disorders (e.g. Clark & Fairburn, 1996), CBT for child anxiety disorders has 
now been developed. Although there is still some uncertainty over the optimal form of such 
intervention, recent systematic reviews of outcome research indicate that the general CBT 
approach produces significant therapeutic benefit in this patient group. However, it is clear 
from these reviews, and from the individual treatment trials, that outcome is highly variable, 
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with a significant proportion of patients retaining their anxiety diagnoses following treatment 
(i.e. 16-61%; James, Soler & Wetherall, 2006).
Predictors of Treatment Outcome
There has been little research into the factors that predict response to CBT in anxious 
children, although, in addition to severity of child anxiety, two factors are likely to be 
especially significant: anxiety in the mother, and features of mother-child interactions. 
i. Anxiety in mothers.
It has been known for some time that the rate of anxiety disorder amongst the parents of 
anxious children is raised (Last et al, 1987; Last et al, 1991), but the extent of this elevation 
has been uncertain and the implications for treatment outcome of child anxiety have not been 
fully considered. Recent research of our own has addressed this issue. In a consecutive series 
of children referred for treatment of an anxiety disorder, two thirds of the mothers were found 
to have a current DSM-IV anxiety disorder (with no elevated rate of current disorder amongst 
the fathers), almost three times the base rate (Cooper et al, 2006). Furthermore, follow up of 
the children after treatment revealed a significant association between child response and 
level of maternal anxiety (Cooper et al, in press). 
ii. Mother-child interactions
Specific features of mother-child interactions have been implicated in the maintenance of 
child anxiety, in particular, an over-controlling and over-protective maternal style (see Rapee, 
1997; Wood et al, 2003) and associated maternal cognitions and expectations about child 
competence (Creswell et al, 2006). Notably, strong associations have been found between 
level of maternal anxiety and both maternal behaviours (e.g. Whaley et al, 1999; Bogels & 
van Melick, 2004) and maternal expectations of child competence (Wheatcroft & Creswell, 
2007). It appears that the disturbances in mother-child interactions which serve to maintain 
child anxiety are, at least in part, themselves driven by maternal anxiety. These conclusions 
are supported by the findings of further research by our group. We have been conducting a 
prospective study of 250 infants born to mothers with anxiety disorders and control mothers 
to investigate the intergenerational transmission of anxiety disorders. Recent data from both 
this study (Murray et al, 2007), and from an associated experimental study (DeRosnay et al, 
2006), have shown that a lack of both appropriate modelling and support, both features of 
mothers with anxiety disorders, are associated with the development of anxiety in offspring. 
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Implications for optimal treatment outcomes
In so far as CBT treatments of child anxiety disorder commonly require the day-to-day 
prosecution of treatment regimes to be managed by the mother (e.g. mothers are typically 
required to model positive responses to fear provoking stimuli and to prompt and reinforce 
their child’s positive responses), the mother’s own anxiety and the associated disturbances in 
mother-child interactions are likely to militate against optimal treatment delivery. Although 
the CBT treatments developed to date for the treatment of child anxiety do acknowledge the 
importance of both parental anxiety and parenting (e.g. Barrett et al, 1996; Mendlowitz et al, 
1999; Nauta et al, 2003; Spence et al, 2000), there has been no systematic evaluation of an 
intervention in which both maternal anxiety and mother-child interactions are specifically 
addressed. There is, therefore, a need for the development and evaluation of a CBT treatment 
for child anxiety disorder in which maternal anxiety and associated disturbances in mother-
child interactions are systematically targeted.
Rationale for the trial
The outcome from CBT for children with anxiety disorders is highly variable. Major factors 
contributing to this are likely to be the presence of maternal anxiety and associated 
disturbances in mother-child interactions and maternal behaviours. Where parental anxiety 
has been addressed in treatment research (e.g. Barrett et al, 1996; Mendlowitz et al, 1999; 
Nauta et al, 2003; Spence et al, 2000), for several methodological reasons, it has been 
difficult to assess its contribution to child outcome. It is notable, however, that in the single 
study in which treatment of parental anxiety was systematically varied, child anxiety outcome 
was better where therapeutic measures to address parental anxiety symptoms were included 
(Cobham et al, 1998). Whilst this is a finding of critical importance, since the treatment did 
not significantly alter levels of parental anxiety it remains unclear what aspect of the 
treatment effected the clinical improvement in the children. Similarly, where therapeutic 
measures to address parent-child interactions have been included (e.g. Wood et al, 2006), it 
has not been possible to determine the specific role of such measures in the complex 
treatment package employed. A controlled trial in which both factors – treatment of maternal 
anxiety and measures to address mother-child interactions - are systematically varied, would 
produce data of both clinical utility and scientific importance.
Research Questions
In an RCT for child anxiety occurring in the context of maternal anxiety, the principal 
questions are:  
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1. Is the impact of child CBT (CCBT) enhanced by first providing CBT to the mother
for her own anxiety?  
2. Is the impact of CCBT enhanced by the addition of therapeutic measures designed to 
improve mother-child interactions?  
Secondary questions are:  
a. Is sustained improvement in child anxiety significantly associated with a reduction in 
maternal anxiety? 
b. Is sustained improvement in child anxiety significantly associated with improvements 
in maternal modelling, encouragement, over-controlling/over-protective behaviour, and 
associated cognitions?  
B. Summary
The aim of the trial is to establish the relative effectiveness of treatments of (i) maternal 
anxiety and (ii) key features of mother-child interactions for children with anxiety disorders 
who have a mother with current anxiety disorder. All treatments will be in addition to 
individual Cognitive Behaviour Therapy administered to all children.
Patients who consent to join the trial (participants) will be randomised to one of three 
conditions: (i) Child Cognitive Behaviour Therapy (CCBT) plus Cognitive Behaviour 
Therapy for Maternal Anxiety (MCBT); (ii) CCBT plus treatment targeting the Mother-Child 
Interaction (MCI), (iii) CCBT plus control conditions (see below).
Condition CCBT+MCBT CCBT+MCI CCBT
Standard child 
treatment
CCBT
(child: 8 sessions)
CCBT
(child: 8 sessions)
CCBT
(child: 8 sessions)
Treatment of 
maternal anxiety
MCBT
(mother: 8 sessions)
Counselling control
(mother: 2 sessions)
Counselling control
(mother: 8 sessions)
Treatment of mother-
child interactions
Family Health 
Control
(child and mother: 2 
sessions; mother: 2 
sessions)
MCI
(child and mother: 2 
sessions; mother: 8 
sessions)
Family Health 
Control
(child and mother: 2 
sessions; mother: 2 
sessions)
Total therapist Child: 8 sessions Child: 8 sessions Child: 8 sessions
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contact Mother: 10 sessions
Child and mother: 2 
sessions
Mother: 10 sessions
Child and mother: 2 
sessions
Mother: 10 sessions
Child and mother: 2 
sessions
CCBT: Individual CBT for child anxiety; MCBT: Individual CBT for maternal anxiety; MCI: 
Mother-child interaction treatment
C. Eligibility
The trial is open to children with a current primary diagnosis of a major anxiety disorder 
(Generalised Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Panic 
Disorder/Agoraphobia, Specific Phobia, as long as co-morbid with another anxiety disorder) 
whose mother also has a current major anxiety disorder. 
1. Inclusion Criteria
Child:
(i) Aged 7 to 12 years;
(ii) Primary diagnosis of DSM-IV generalised anxiety disorder, social phobia, separation 
anxiety disorder, panic disorder/agoraphobia or specific phobia (if co-morbid with another 
anxiety disorder).
Mother: 
(i) Primary carer;
(ii) Current maternal DSM-IV anxiety disorder. 
2. Exclusion Criteria
Participants will not be eligible if the following criteria are met.
Child:
(i) Significant physical1 or intellectual impairment (including ASD)2;
(ii) Current prescription of psychotropic medication (or, if psychotropic medication is 
prescribed, it should have been at a stable dose for at least one month with agreement to 
maintain that dose throughout the study);
1 Where physical disability would impede treatment delivery (e.g. significant speech/ hearing impairment).
2 Significant intellectual impairment will be determined by children being registered within local learning 
disability services. Children will be excluded if they have a current diagnosis of an Autistic Spectrum Disorder 
(ASD). In case of undiagnosed ASD, a preliminary assessment will be made at the initial assessment (see 
Section S). 
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(iii) Previously received six or more sessions of systematically administered Cognitive-
Behaviour Therapy for an anxiety disorder;
Mother:
(i) Significant intellectual impairment3;
(ii) Severe comorbid disorder (e.g. severe major depressive disorder, psychosis, 
substance/alcohol dependence); 
(ii) Prescription of psychotropic medication (Or, if psychotropic medication is prescribed, it 
should have been at a stable dose for at least one month with agreement to maintain that dose 
throughout the study);
3 Significant intellectual impairment will be determined by the mother being registered within local learning 
disability services.
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D. Trial Procedures
1. Recruitment schedule
1. Suspected anxiety disorder in child 
2.
3.
Child aged 7- 12 years
Absence of significant physical or intellectual 
impairment (including ASD) in child
Assessment by trial assessors at local CAMHS
Does child have current anxiety disorder (Generalised Anxiety Disorder, 
Social Phobia, Separation Anxiety Disorder, Panic Disorder +/- Agoraphobia), specific 
phobia if co-morbid
YES 
Does mother have current 
anxiety disorder? 
NO
Refer back to CAMHS 
with detailed assessment 
report
YES
Invite to take part in MRC Trial.
Does the family agree?
NO
Treatment as Usual 
(Group CBT)
YES
Trial protocol
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2. Treatment Interventions
There will be two stages of treatment intervention in the trial:
(1) Individual Cognitive Behavioural Treatment for maternal anxiety (MCBT), or control
a. Individual CBT for maternal anxiety
This will consist of an eight session (one hour each) intervention for mothers delivered by a 
clinical psychologist (or equivalent) over eight-weeks. Sessions will take place in the 
participants’ local CAMHS, within their home, or at the University of Reading. The CBT 
programme will follow a manualised transdiagnostic treatment for adult anxiety disorders 
(Shafran, unpublished manuscript). 
b. Control: Supportive Counselling
This will consist of either two or eight sessions (one hour each) of supportive counselling 
(see figure 1), delivered by a clinical psychologist (or equivalent) over eight-weeks. Sessions 
will take place in the participants’ local CAMHS, within their home, or at the University of 
Reading. The supportive counselling programme will follow a manualised treatment 
(Borkovec & Costello, 1993).
(2) Individual Cognitive Behavioural Treatment for child anxiety (CCBT) with Mother 
Child Interaction treatment (MCI) or control
Individual CBT for child anxiety
All participating children will receive an eight session (one hour each) intervention based on 
the Cool Kids programme (Rapee, 2000), delivered by a clinical psychologist (or equivalent) 
over eight-weeks. Sessions will take place in the participants’ local CAMHS, within their 
home, or at the University of Reading.
a. Mother-Child Interaction Treatment
This intervention consists of 10 sessions: eight with the mother alone and two with the 
mother and child together. This is a novel intervention which specifically targets anxiogenic 
features of mother-child interactions. Specifically it aims to enhance maternal cognitions 
associated with child competence, reduce maternal overcontrol/overprotection, and enhance 
maternal warmth and encouragement. This is achieved through a combination of specific 
materials from existing family interventions for childhood anxiety (Rapee & Wignall, 2000; 
Wood et al, 2006) and video-feedback techniques developed and piloted by the trial 
investigators (Stein et al, 2006; Creswell et al, in press). This intervention is provided by a 
clinical psychologist (or equivalent) in parallel with the CCBT sessions. Sessions will 
generally take place in the participants’ local CAMHS, within their home, or at the University 
of Reading. The two mother and child sessions will be conducted within the laboratory at the 
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University of Reading, as these involve the mother and child completing structured tasks 
which are video-recorded for feedback purposes.
b. Control: Family Lifestyle Management
This will consist of four sessions, two with the mother alone and two with the mother and 
child together. These sessions will focus on promoting a healthy lifestyle with a focus on 
family diet and exercise, based on existing packages applied within school settings (British 
Dietetic Association, 2003). This intervention is provided by a clinical psychologist (or 
equivalent) in parallel with the CCBT sessions. Sessions will generally take place in the 
participants’ local CAMHS, within their home, or at the University of Reading.
For all treatment conditions, therapists will routinely rate the extent to which participants 
adhere to the intervention (e.g. completion of in-session and homework exercises, session 
attendance).
How the second stage interventions run in parallel is illustrated in Section R.
E. Randomisation
Following confirmation of eligibility and informed consent, participants will be randomised 
to treatment condition. Randomisation will be performed centrally by facsimile contact at the 
Centre for Statistics in Medicine, Oxford (CSM). This will be performed/coordinated by the 
Trial Statistician. The randomisation programme will include a minimisation algorithm to 
ensure balanced allocation of participants across the three treatment groups for the following 
potential prognostic factors: child age, child gender, type of child anxiety disorder (GAD, 
Social Phobia, SAD, Other) and baseline severity (ADIS Clinician Severity Rating) of child 
and mother’s primary anxiety disorder. To reduce the possibility of outcome measure events 
occurring after randomisation and before treatment, intervention will start within 2 weeks of 
randomisation.
F. Routine Care Outside of the Trial
Participants (mothers and children) will be asked not to engage in other psychological 
interventions during the course of the trial. They will also be asked not to initiate 
psychotropic medication and if psychotropic medication is prescribed, this should have been 
at a stable dose for at least one month with agreement to maintain that dose throughout the 
study. Referrers (Local CAMHS) and General Practitioners will be informed of this 
requirement.
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G. Serious and Unexpected Adverse Events
There are no adverse side-effects of the interventions being delivered. Successful treatment of 
anxiety may involve some distress, however this will be managed and contained by qualified 
clinical psychologists, receiving regular expert supervision. Although substantial clinical 
benefits are anticipated from the interventions, some children and mothers can be expected to 
not respond to the interventions. Where children continue to meet criteria for a current 
anxiety disorder at the six month post treatment assessment, they will be invited to participate 
in a group intervention for anxious children or referred back to their local CAMHS team 
following clinical review and liaison. If other significant difficulties emerge these will be 
discussed with referrer from the local CAMHS team.
H. Assessment of Outcome
1. Primary outcomes
The primary outcome is child anxiety (assessed both categorically [i.e. diagnosis] and 
continuously [i.e. symptoms]). Diagnostic status will be assessed by the ADIS for DSM-IV: 
C/P administered to both the mother and child. Assessors will be blind to treatment condition. 
Assessors’ beliefs about treatment condition will be formally assessed. Child anxiety 
symptoms will be assessed using questionnaires (SCAS; Spence, 1998) administered to the 
child, the mother and the child’s teacher. These measures will be administered post-
treatment, and at 6 and 12 month follow-up assessments.
2. Secondary outcomes
Maternal anxiety will be assessed categorically using the ADIS (DSM-IV) and continuously 
using questionnaires (i.e. DASS, Lovibond & Lovibond, 1995; PSWQ, Meyer et al, 1990; 
SIAS and SPS, Mattick & Clark, 1998). These measures will be administered post-treatment, 
and at 6 and 12 month follow-up assessments.
Maternal interactive behaviours will be assessed by filming the mother assisting the child 
perform an anxiety provoking task and applying standardised ratings of anxiogenic 
behaviours (i.e. modelling, lack of encouragement, overcontrol/overprotection). Interactive 
behaviours will be coded by independent, trained, reliable raters. Coders will be blind to the 
purpose and conditions of the trial. Maternal cognitions will be assessed by a standardised 
interview. These measures will be conducted at the post-treatment assessment.
See Section S for a full assessment schedule.
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3. Health Economic Assessment
An economic evaluation will be undertaken integral to the main trial. The evaluation will 
adhere to guidelines for good economic evaluation practice as outlined in the reference case 
by Gold et al (1996). The economic analysis will estimate the incremental cost and 
effectiveness of each of CCBT/MCBT and CCBT/MCI in relation to the control group as 
well as their relative costs. Patient level resource use data, including all health and social care 
costs (staff costs for provision of CCBT, MCBT, MCI, and the control interventions, GP 
costs, referrals, and other relevant services identified) as well as leisure and productivity 
estimates for the parents will be collected within trial forms and valued using appropriate unit 
costs. Staff training costs and the costs of staff supervision will also be identified and 
allocated pro-rata. The outcome measure for the cost-effectiveness analysis will be the ADIS 
as well as a measure of ‘days off school avoided’. In line with recent recommendations from 
the National Institute for Health and Clinical Excellence (NICE) the economic evaluation will 
also include generic quality of life instruments, the child friendly EuroQol EQ-5D (EuroQol, 
1990; Hennesy & Kind, 2002) and HUI2 outcome measure (Feeny et al, 1995), on which 
normative data are available. Measures of the impact of anxiety disorders will also be 
included, using questionnaires administered to the child and mother (CAIS; Langley et al, 
2004) and teacher (School Adjustment/ Teacher Report Form; Achenbach, 1986). These 
instruments will be administered at baseline, following treatment and at 6 and 12 months 
follow up. 
I. Power and Sample Size
A total sample size of 210 pairs of anxious children with anxious mothers will be recruited 
into the trial. This sample size is based on calculations relating to the primary outcome of 
child anxiety diagnosis for the principal questions.
i. Efficacy of CCBT/MCBT: 
Comparison of Group 1 and the Control Group. To detect an absolute difference of 30% in 
success (i.e. absence of child anxiety diagnosis) post-treatment for CCBT/MCBT compared 
with control (40% to 70%), with 90% power at the 5% significance level (two sided) would 
require 56 patients per treatment group. This difference is based on reported effect of CBT 
with parental anxiety management in children where at least one parent had high anxiety 
(Cobham et al, 1998).
ii. Efficacy of CCBT/MCI: 
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Comparison of Group 2 and the Control Group. Assuming that the response to treatment in 
the control group is 40% (from Cobham et al, 1998) and the minimum clinical difference in 
response due to MCI is 30%, 56 patients per group are required to enable us to detect this 
difference with 90% power at the 5% significance level. 
Thus, 56 patients are required in each of the three randomised groups. Accounting for a 20% 
loss to follow up would require 210 children in total to be recruited to the study. No formal
comparison will be made between Groups 1 and 2 (CCBT/MCBT and CCBT/MCI). The 
sample size has been estimated as if two independent trials were conducted, with no 
adjustment for multiple testing, as recommended by Machin et al (1997). 
A difference of 30% in the proportion of anxiety-free children following completion of the 
treatment is considered to be the minimum that would be clinically worthwhile taking into 
account the increased resources required and change to service delivery that would be 
required if either of these interventions were found to be effective and implemented in 
practice.
J. Data Management
Data management will be consistent with MRC Guidelines for Good Clinical Practice in 
Clinical Trials (MRC, 1998) and with the Data Protection Act (1998). Principal investigators 
will ensure that all personnel are familiar and comply with the MRC guidelines, particularly 
section 5.9 ‘Data handling and record keeping’ and section 7 ‘Documentation’.
1. Identifying information
After providing consent, participants will be given a unique, sequential, study identifier. This 
will be used for randomisation and data entry purposes.
2. Data entry
Data will be entered in to desktop computers, fitted with SPSS for Windows v13 as standard 
allowing for an immediate interactive message to be displayed if an invalid data entry is 
made. The Trial Manager will arrange appropriate quality assurance checks.
3. Backing up of data
Immediately after every episode of data entry, data will be backed up onto a portable USB 
drive, which will be securely stored locally. These files will be backed up on to a password-
protected system on a weekly basis. A hard copy will be printed and stored locally compliant 
with Data Protection Act (1998).
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K. Data Analysis
The principal comparisons will be performed on an intention-to-treat basis. The results from 
the trial will be presented as comparative summary statistics (difference in proportion of 
anxiety-free children or mean anxiety level) with 95% confidence intervals. The analysis and
reporting of results will follow the general principles of Consolidated Standards of Reporting 
Trials (CONSORT; Moher et al, 2001). 
The primary analysis will focus on the effect of the intervention following completion of 
treatment (post-treatment/16 week assessment).  Analysis of the 6 and 12 month outcome 
data will utilize all outcome assessments (post treatment, 6 and 12 months) using multilevel 
repeated measures analysis, to establish maintenance of change. 
Child anxiety diagnosis (ADIS for DSM-IV C/P): The proportion of anxiety-free children in 
the two groups following treatment will be compared using the Chi squared test. Testing for a 
treatment effect after adjustment for minimisation factors will be conducted using multiple 
logistic regression.   
Child anxiety symptoms: Change in anxiety scores following treatment will be analysed using 
multiple linear regression with baseline score and minimisation factors entered as covariates.  
We will formally assess the distribution of the change in anxiety scores for evidence of 
departure from normality.  If necessary, data will either be transformed or analysed using a 
non-parametric equivalent. Change in anxiety scores at 6 and 12 months will be analysed 
using a multilevel repeated measures analysis, adjusted for baseline anxiety score and 
minimisation covariates.
The secondary research questions will be explored using univariate tests (e.g. Chi squared 
test, t-test and correlation) to examine whether the particular factors identified are associated 
with sustained improvement in child anxiety. Multiple logistic and linear regression will be 
adopted to investigate the independent factors predictive of sustained improvement in child 
anxiety. 
A comprehensive statistical analysis plan will be produced prior to any data being seen.
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L. Management Structure
1. Trial Management
The Trial Management Group (TMG) comprises the five grant holders, the clinical director 
(LW) and the Trial Manager (RG). The group will meet periodically throughout the trial as 
requested by the Principal applicant (PJC).
The day to day administration of the trial will be the overall responsibility of the principal 
applicant (PJC) who will monitor all aspects of recruitment, treatment and assessment, as 
well as the budget. 
The child anxiety clinics will be under the direction of the Clinical Director (LW). She will 
coordinate all clinical referrals, and, together with her assistant, carry out initial clinical 
assessments of all referred children. Where both child and mother are found to have a current 
anxiety disorder, the trial manager (RG) will recruit to the trial and, in liaison with the trial 
statistician (NA), will ensure randomisation to treatment condition and assign to the 
appropriate therapists. The Trial Manager will also coordinate and supervise the maternal and 
child assessments. Assessment and coding of the mother-child interactions will be the under 
the supervision of Professor Lynne Murray. 
Professor Roz Shafran (Reading) will train and supervise the adult therapists providing 
treatment to mothers. The therapists providing the non-directive counseling (control 
condition) will be supervised by an experienced counseling practitioner and supervisor to 
ensure adherence to protocol. The Clinical Director (LW) will supervise the two child 
therapists delivering CCBT to the children and the mother-child interaction treatment as well 
as the healthy lifestyle sessions (control). Professor Alan Stein will provide supervision to Dr 
Willetts on the interaction treatment. 
The Trial Manager (RG) will have responsibility for the data file which will be handed over 
to the Trial statistician for analysis. The Trial Manager will also liaise with Dr McIntosh to 
ensure that all health economic data are collected appropriately. 
2. Trial Steering Committee (TSC)
Overall responsibility for the trial will lie with the Trial Steering Committee comprising: 
Professor Jonathon Hill (Chair), Dr Gavin Malloch (MRC), Dr Natasha Conner and Vicky 
Taylor (Berkshire Healthcare NHS Foundation Trust), Dr Pasco Fearon (Reading) and a 
consumer representative. Their function is to maintain the overall integrity of the trial, to 
receive and consider reports from both the Trial Management Group and IDMEC and take 
action if appropriate. The Trial Steering Committee will meet before the trial is initiated and 
then every 6 months throughout the trial.
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3. Independent Data Monitoring and Ethics Committee (IDMEC)
The Independent Data Monitoring and Ethics Committee will be chaired by Professor 
Jonathon Geddes (Oxford). Other members are Dr Craig Ramsay (Aberdeen) and a 
representative from Berkshire Healthcare NHS Foundation Trust). The Trial statistician will
also attend meetings to present reports. The IDMEC will monitor: recruitment to the trial, 
protocol adherence and serious adverse events as well as the difference between trial 
treatments on the primary outcome measures. The IDMEC will consider reports prepared by 
the Trial Statistician and any other relevant studies published during the timeframe of the 
trial. Recommendations of IDMEC will be passed on to the Chair of the Steering Committee. 
The Data Monitoring and Ethics Committee will meet throughout the trial as determined by 
the Chair.
M. Indemnity
University of Reading indemnity will apply:
i. To meet the potential legal liability of the University of Reading for harm to participants 
arising from the management and design of the research.
ii. To meet the potential legal liability of the investigators/collaborators arising from harm to 
participants in the conduct of the research.
iii. For payment of compensation in the event of harm to the research participants where no 
legal liability arises.
N. Ethics
Berkshire Local Research Ethics Committee has given a favourable opinion of this study 
(07/H0505/156), as has the University of Reading Research Ethics Committee (07/48). All 
aspects of the study will be conducted in line with MRC Guidelines for Good Clinical 
Practice in Clinical Trials (MRC, 1998).
O. Informed Consent
Information about the trial will be provided to both the mother and child in person from the 
Clinical Director (LW) as well as in written information. A copy will be provided for the 
participants to keep. Written consent will be obtained from parents by the Clinical Director 
(LW). Assent will be obtained from children. Following treatment completion, participants 
will be asked whether they would be happy for video-taped material to be used for teaching 
and training purposes. Where participants agree, separate written consent will be obtained.
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P. Publications and Ancillary Studies
1. Publications
A meeting of the Trial Management Group will be held on completion of the study to allow 
discussion of the main results among the collaborators. The results will then be presented to a 
combined meeting of the TSC and IDMEC for comment. Public presentations pertaining to 
the main trial must not be made without the prior agreement of the Trial Management Group.
2. Ancillary studies
Ancillary studies will be conducted by Dr Cathy Creswell (MRC Clinician Scientist 
Fellowship, Reading), Mr Ray Percy (PhD student, Reading) and Dr Thalia Eley (Institute of 
Psychiatry, London), in collaboration with Peter Cooper. The protocols for these studies will 
be referred to the Trial Steering Committee, whose responsibility is to safeguard the integrity 
of the trial, for final approval. Any further proposals for ancillary studies should initially be 
referred to the Trial Management group for consideration. Studies considered appropriate by 
the TMG will then be submitted to the TSC for final approval. In principle it is preferable for 
the trial to be kept as simple as possible with few further add-on studies.
Q. Proposed Timetable
Main tasks Proposed timetable
Finalise protocols May- November 2007
Submit Ethics & Trust approval August 2007
Register Trial 
Receipt of MRC award
In post:
Cathy Creswell (Trial Manager; MRC)
Lucy Willetts (Clinic Manager; 
NHS/MRC)
1 September 2007
Ethics Outcomes November 2007
Invite referrals from East and West Berks 
(establish wait-list for assessments)
September- December 2007
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Recruit remaining University & Trust 
staff
Establish satellite clinics
Convene Trial Steering Committee and 
IDMEC
Training University and Trust staff January – February 2008
Initiation of assessments January 2008
Initiation of treatment March 2008
Recruitment ends 30 August 2010
Treatments end 31 January 2011
Trials end 30 June 2012
Recruitment assessments will be conducted from January 2008 until end of August 2010 (32 
month), therefore we aim to recruit 6-7 new cases to the trial every month.
R. Stage 2 Treatment (CCBT/MCI/FH) Outline
Week CCBT
(child 8 sessions)
MCI
(mother 8; mother& 
child 2)
FH
(mother 2; mother 
& child 2)
1 Session 1 Introduction- 1.
Getting to know each 
other
2. Psychoeducation
Mother
1. Introduction-
psycho-education and 
rationale. 
Mother
1. Introduction-
healthy family 
lifestyle
2 Session 2 1. Update & review
2. How I feel depends 
Mother
1. Update & Review
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on what I think; 
Detective Thinking
2. Promoting 
autonomy (i):Self-
help skills: giving 
choices, allowing 
struggle, attention
(ii) Feedback on video 
from research 
assessment: highlight 
parental positive 
impact on child 
through autonomy 
granting, 
encouragement, 
modelling, cognitions 
re child coping) 
3 Session 3 1. Update & review
2. How I feel depends 
on what I think; 
Detective Thinking 
Practice
Mother
1. Update & Review
2. Promoting 
autonomy 
(i) Alternative 
strategies: managing 
child’s anxious 
thoughts
4 Session 
4A
1. Update & review
2. Rewards 
Mother
1. Update & review
2. Promoting 
autonomy: 
encouraging brave 
behaviour; inc CALM 
strategy (reflective 
listening, selective 
attention , planned 
Mother & Child
Family diet
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ignoring), positive 
encouragement 
(verbal and 
nonverbal), modelling 
brave behaviours
4 Session 
4B
Mother  & Child
Video Task: setting 
up an exposure 
hierarchy
5 Session 5 1.Update &review
2. Problem solving
Mother
1. Update & Review
2. Video feedback (to 
highlight successful 
autonomy granting).
3. Promoting 
autonomy: Family 
problem-solving
6 Session 
6A
1. Update & review
2. Practice
Mother
1. Update and review
2. Promoting 
autonomy:  New roles
Mother & Child
Family exercise
6 Session 
6B
Mother & Child
Challenging task
7 Session 7 1. Update & review
2. Practice
Mother
1. Update & Review
2. Video feedback (to 
highlight successful 
autonomy granting, 
modelling, 
encouragement 
(verbal/nonverbal), 
positive cognitions re 
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child coping). 
8 Session 8 1. Update & review
2. You did it
Mother
1. Update & Review
2. You did it- what 
helped? Future plans/ 
Relapse Prevention
Mother
Healthy family 
lifestyle
Review and 
summary
S. Assessment Schedule
l clinical assessment
Conducted within local CAMH 
service
Structured clinical interviews:
1. Anxiety Disorders Interview Schedule-
Child/Parent version (ADIS-C/P)
2. Anxiety Disorders Interview Schedule (ADIS) 
(Mother self-report)
Questionnaires:
1. Spence Children’s Anxiety Scale –parent/child 
version (SCAS-c/p)
2. Child Anxiety Impact Scale- parent/child version 
(CAIS-c/p)
3. Depression Anxiety Stress Scales (DASS)
4. Penn State Worry Inventory
5. Mattick Social Phobia Scale and Social Interaction 
Assessment Scale (SPS, SIAS)
6. Over-involvement questionnaire (POI) parent self-
report
7. Social Communication Questionnaire (SCQ)
8.The Short Moods and Feelings Questionnaire-
Child/Parent version (SMFQ-C/P)
9.The Strengths and Difficulties Questionnaire -
Child/Parent version (SDQ-C/P)
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Research assessment 1. (pre-
treatment)
Conducted at University of Reading
1. Laboratory assessment of mother-child interaction 
and associated cognitions
2. Spence Children’s Anxiety Scale-teacher report 
(SCAS-T)
3. Teacher Report Form (TRF)
4. Teacher report- child adjustment to school
5. Health economic assessments (EQ-5D, HUI-2,
diaries)
Research assessment 1b. (mid-
treatment)
Conducted at University of Reading/ 
Local CAMH service
Structured clinical interviews:
1. Anxiety disorders Interview Schedule-
Child/Parent version (ADIS-C/P)
2. Anxiety Disorders Interview Schedule (ADIS) 
(Mother self-report)
Questionnaires:
1. Spence Children’s Anxiety Scale –parent/child 
version (SCAS-c/p)
2. Child Anxiety Impact Scale- parent/child version 
(CAIS-c/p)
3. Depression Anxiety Stress Scales (DASS)
4. Penn State Worry Inventory
5. Mattick (SPS, SIAS)
6. Over-involvement questionnaire (POI) parent self-
report
7. The Short Moods and Feelings Questionnaire-
Child/Parent version (SMFQ-C/P)
8. The Strengths and Difficulties Questionnaire -
Child/Parent version (SDQ-C/P)
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9. Therapy Questionnaire
10. Health economic assessments (EQ-5D, HUI-2,
diaries)
Research assessment 2 (post-
treatment)
Conducted at University of Reading
Structured clinical interviews:
1. Anxiety Disorders Interview Schedule-
Child/Parent version (ADIS-C/P)
2. Anxiety Disorders Interview Schedule (ADIS) 
(Mother self-report)
Questionnaires:
1. Spence Children’s Anxiety Scale –parent/child 
version (SCAS-c/p)
2. Child Anxiety Impact Scale- parent/child version 
(CAIS-c/p)
3. Depression Anxiety Stress Scales (DASS)
4. Penn State Worry Inventory
5. Mattick (SPS, SIAS)
6. Over-involvement questionnaire (POI) parent self-
report
7. The Short Moods and Feelings Questionnaire-
Child/Parent version (SMFQ-C/P)
8. The Strengths and Difficulties Questionnaire -
Child/Parent version (SDQ-C/P)
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9. Health economic assessments (EQ-5D, HUI-2,
diaries)
Other
1. Laboratory assessment of mother-child interaction 
and associated cognitions
Research assessment 3 (6 months 
post-treatment)
Conducted at University Of Reading/ 
Local CAMH service
Structured clinical interviews:
1. Anxiety Disorders Interview Schedule-
Child/Parent version (ADIS-C/P)
Questionnaires:
1. Spence Children’s Anxiety Scale –parent/child 
version (SCAS-c/p)
2. Child Anxiety Impact Scale- parent/child version 
(CAIS-c/p)
3. Depression Anxiety Stress Scales (DASS)
4. Penn State Worry Inventory
5. Mattick (SPS, SIAS)
6. Over-involvement questionnaire (POI) parent self-
report
7. The Short Moods and Feelings Questionnaire-
Child/Parent version (SMFQ-C/P)
8. The Strengths and Difficulties Questionnaire -
Child/Parent version (SDQ-C/P)
9. Spence Children’s Anxiety Scale-teacher report 
(SCAS-T)
10. Teacher Report Form (TRF)
11. Teacher report- child adjustment to school
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12. Health economic assessments (EQ-5D, HUI-2,
diaries)
Research assessment  4 (12 months 
post-treatment)
Conducted at University Of Reading/ 
Local CAMH service
Structured clinical interviews:
1. Anxiety disorders Interview Schedule-
Child/Parent version (ADIS-C/P)
Questionnaires:
1. Spence Children’s Anxiety Scale –parent/child 
version (SCAS-c/p)
2. Child Anxiety Impact Scale- parent/child version 
(CAIS-c/p)
3. Depression Anxiety Stress Scales (DASS)
4. Penn State Worry Inventory
5. Mattick (SPS, SIAS)
6. Over-involvement questionnaire (POI) parent self-
report
7. The Short Moods and Feelings Questionnaire-
Child/Parent version (SMFQ-C/P)
8. The Strengths and Difficulties Questionnaire -
Child/Parent version (SDQ-C/P)
9. Spence Children’s Anxiety Scale-teacher report 
(SCAS-T)
10. Teacher Report Form (TRF)
11. Teacher report- child adjustment to school
12. Health economic assessments (EQ-5D, HUI-2,
diaries)
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Appendix 3 Health economic measures
Health economic logs
Log for recording resources used, and duration of,
any clinical contact
Important: Please complete a new log every time a 
contact is made (client visit, phone contact, school 
visit e.t.c.)
Patient ID:  
Date:
Type of contact Session No. Duration of contact
Maternal CBT
Maternal Counselling
Child CBT
MCI
Healthy Living
Supervision time 
(time spent 
discussing this 
particular patient)
Preparation time & 
record keeping
MaCh ECONOMIC LOG
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Other* (please state)
* Please record all phone contact, school visits, home visits and 
any other types of visit.
Additional Resources used (Staff only)
Please record below any travel mileage, rail fares or other 
expenses incurred during this contact
_______________________________________________
____
_______________________________________________
____
_______________________________________________
____
_______________________________________________
_
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f 
wo
rk
 a
nd
 t
im
e 
of
f 
sc
ho
ol
 f
or
ch
ild
re
n.
 I
n 
or
de
r 
to
 d
o 
th
is
 w
e 
wo
ul
d 
lik
e 
yo
u 
to
 u
se
 t
hi
s 
di
ar
y 
to
 r
ec
or
d 
yo
u 
an
d 
yo
ur
 c
hi
ld
‛s
 u
se
 o
f 
su
ch
 s
er
vi
ce
s,
 a
nd
 
tr
ea
tm
en
ts
 t
ha
t 
yo
u 
an
d 
yo
ur
 c
hi
ld
 h
av
e 
ha
d.
 
Th
is
 is
 a
 'D
ia
ry
' (
or
 r
ec
or
d)
 o
f 
yo
ur
 u
se
 o
f 
se
rv
ic
es
, m
ed
ic
at
io
ns
 a
nd
 t
im
e 
of
f 
wo
rk
an
d 
sc
ho
ol
 b
et
we
en
 n
ow
 a
nd
 y
ou
r 
ne
xt
 a
ss
es
sm
en
t 
ap
po
in
tm
en
t,
 f
or
 a
ny
 c
au
se
.  
It
 is
 f
or
 y
ou
r 
us
e 
on
ly
, t
o 
fi
ll 
in
 e
ac
h 
ti
m
e 
yo
u 
co
m
e 
in
to
 c
on
ta
ct
 w
it
h 
an
y 
of
 t
he
 h
ea
lt
h 
pr
of
es
si
on
al
s 
or
 
us
e 
an
y 
of
 t
he
 f
ac
ili
ti
es
 li
st
ed
 o
ve
r 
th
e 
pa
ge
.  
W
e 
wo
ul
d 
al
so
 li
ke
 y
ou
 t
o 
ke
ep
 a
 r
ec
or
d 
of
 a
ny
 p
re
sc
ri
pt
io
n 
dr
ug
s 
an
d 
m
ed
ic
at
io
ns
 t
ak
en
 
as
 w
el
l a
s 
da
ys
 o
ff
 w
or
k 
an
d 
sc
ho
ol
.  
Fo
r 
ex
am
pl
e:
  I
f 
yo
u 
or
 y
ou
r 
ch
ild
 v
is
it
s 
th
e 
GP
 s
ur
ge
ry
 w
e 
wo
ul
d 
lik
e 
yo
u 
to
 t
ic
k 
on
e 
of
 t
he
 c
ir
cl
es
on
 t
he
 li
ne
 'F
am
ily
 D
oc
to
r 
(G
P)
'. 
O
ne
 t
ic
k 
= 
on
e
vi
si
t.
   
 I
f 
yo
u 
ar
e 
pr
es
cr
ib
ed
 a
 d
ru
g 
th
en
 w
e 
wo
ul
d 
lik
e 
to
 k
no
w 
th
e 
na
m
e 
of
 it
 a
nd
 w
he
th
er
 it
 is
 f
or
 y
ou
 o
r 
yo
ur
 c
hi
ld
.  
  
Th
is
 D
ia
ry
 c
ov
er
s 
th
e 
pe
ri
od
 f
ro
m
 S
tu
dy
 E
nt
ry
 t
o 
yo
ur
 n
ex
t 
tr
ia
l a
ss
es
sm
en
t.
 A
t 
yo
ur
 n
ex
t 
as
se
ss
m
en
t 
we
 w
ill
 a
sk
 y
ou
 a
bo
ut
 y
ou
r
‘re
so
ur
ce
 u
se
‛ d
ur
in
g 
th
is
 t
im
e 
pe
ri
od
. P
le
as
e 
re
m
em
be
r 
to
 b
ri
ng
 y
ou
r 
di
ar
y 
al
on
g 
to
 t
hi
s 
ap
po
in
tm
en
t 
so
 t
ha
t 
yo
u 
m
ay
 u
se
 i
t 
to
 
co
m
pl
et
e 
th
is
 q
ue
st
io
nn
ai
re
.
W
e 
wi
ll 
gi
ve
 y
ou
 n
ew
 d
ia
ri
es
 e
ve
ry
 t
im
e 
a 
‘re
so
ur
ce
 u
se
‛ q
ue
st
io
nn
ai
re
 h
as
 b
ee
n 
co
m
pl
et
ed
 s
o 
th
at
 yo
u 
ca
n 
us
e 
th
e 
di
ar
y 
to
 k
ee
p 
a 
re
co
rd
 
of
 y
ou
r 
us
e 
of
 s
er
vi
ce
s 
re
ad
y 
to
 c
om
pl
et
e 
th
e 
ne
xt
 q
ue
st
io
nn
ai
re
. 
N
.B
: P
le
as
e 
do
 n
ot
in
cl
ud
e 
an
y 
ap
po
in
tm
en
ts
 r
el
at
ed
 t
o 
th
e 
st
ud
y 
it
se
lf
 s
uc
h 
as
 t
he
 t
he
ra
py
 s
es
si
on
s.
Be
rk
sh
ir
e 
Ch
ild
 A
nx
ie
ty
 C
lin
ic
U
ni
ve
rs
it
y 
of
 R
ea
di
ng
Be
rk
sh
ir
e 
Re
se
ar
ch
 E
th
ic
s 
re
fe
re
nc
e 
nu
m
be
r:
 0
7/
H
05
05
/1
56
-1
57
-1
76
U
ni
ve
rs
it
y 
of
 R
ea
di
ng
 E
th
ic
s 
re
fe
re
nc
e 
nu
m
be
r:
 0
7/
48
-4
9-
50
Ve
rs
io
n 
1.4
(3
1.
07
.0
8)D
ia
ry
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St
ar
ti
ng
 f
ro
m
 w
he
n 
yo
u 
en
te
re
d 
th
e 
tr
ia
l, 
sh
ou
ld
 y
ou
 o
r 
yo
ur
 c
hi
ld
 c
om
e 
in
to
 c
on
ta
ct
 w
it
h 
an
y 
of
 t
he
 p
eo
pl
e/
fa
ci
lit
ie
s 
lis
te
d 
be
lo
w,
 p
le
as
e 
ti
ck
 o
ne
 o
f 
th
e 
ci
rc
le
s.
Y
O
U
:  
If 
th
e 
co
nt
ac
t/v
is
it 
w
as
fo
r y
ou
rs
el
f,
tic
k 
on
e 
of
 th
e 
ci
rc
le
s i
n 
th
is
 se
ct
io
n:
Y
O
U
R
 C
H
IL
D
:
If 
th
e 
co
nt
ac
t/v
is
it 
w
as
fo
r y
ou
r c
hi
ld
, 
tic
k 
on
e 
of
 th
e 
ci
rc
le
s i
n 
th
is
 se
ct
io
n:
Fa
m
ily
 D
oc
to
r (
G
P)
   
 
So
ci
al
 W
or
ke
r
Pr
ac
tic
e 
nu
rs
e
Ps
yc
ho
lo
gi
st
Ps
yc
hi
at
ris
t
C
om
m
un
ity
 P
sy
ch
ia
tri
c 
N
ur
se
Ed
uc
at
io
n 
W
el
fa
re
 O
ff
ic
er
Ed
uc
at
io
na
l P
sy
ch
ol
og
is
t
Fa
m
ily
 L
ia
is
on
 O
ff
ic
er
 (S
ch
oo
l)
Te
ac
he
r (
ot
he
r t
ha
n 
us
ua
l c
on
ta
ct
)
Pa
ed
ia
tri
ci
an
 (c
hi
ld
re
n’
s d
oc
to
r)
   
   
   
A
ud
io
lo
gy
 
Sp
ee
ch
 a
nd
 la
ng
ua
ge
O
pt
ha
lm
ol
og
y
H
os
pi
ta
l A
&
E 
de
pa
rtm
en
t
O
cc
up
at
io
na
l T
he
ra
pi
st
 
Pa
ed
ia
tri
c 
D
ie
tic
ia
n
Pa
ed
ia
tri
c 
Ph
ys
io
th
er
ap
is
t
Pa
ed
ia
tri
c 
Pl
ay
 S
pe
ci
al
is
t
Fa
m
ily
 T
he
ra
pi
st
C
om
m
un
ity
 C
hi
ld
re
n’
s N
ur
se
C
hi
ld
 &
 A
do
le
sc
en
t M
en
ta
l H
ea
lth
 N
ur
se
Pr
im
ar
y 
M
en
ta
l H
ea
lth
 W
or
ke
r
H
ou
si
ng
 D
ep
ar
tm
en
t
C
iti
ze
ns
 A
dv
ic
e 
B
ur
ea
u
Fa
m
ily
 c
en
tre
H
om
e-
st
ar
t
A
lc
oh
ol
 o
r d
ru
g 
co
un
se
lli
ng
 
O
th
er
 (p
le
as
e 
sp
ec
ify
) *
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_
O
th
er
 (p
le
as
e 
sp
ec
ify
) *
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_
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* 
If
 y
ou
 c
an
 o
nl
y 
re
m
em
be
r 
th
e 
na
m
e 
of
 t
he
 p
er
so
n 
yo
u 
sa
w 
th
en
 p
le
as
e 
wr
it
e 
th
e 
na
m
e 
do
wn
.
D
ru
g 
Tr
ea
tm
en
ts
In
 t
hi
s 
fo
llo
wi
ng
 s
ec
ti
on
 w
e 
wo
ul
d 
lik
e 
to
 k
no
w 
wh
et
he
r 
yo
u 
or
 y
ou
r 
ch
ild
 h
av
e 
be
en
 p
re
sc
ri
be
d,
 o
r 
pu
rc
ha
se
d,
 a
ny
 d
ru
gs
 o
r 
m
ed
ica
ti
on
s.
Pl
ea
se
 k
ee
p 
a 
re
co
rd
 b
el
ow
 o
f 
an
y 
dr
ug
s/
m
ed
ic
at
io
ns
 a
nd
 w
he
th
er
 it
 w
as
 p
re
sc
ri
be
d 
by
 y
ou
r 
GP
 o
r 
pu
rc
ha
se
d 
yo
ur
se
lf:
D
ru
g 
na
m
e
Pr
es
cr
ip
ti
on
D
ur
at
io
n 
of
 T
re
at
m
en
t
Fo
r 
yo
ur
se
lf
 o
r 
yo
ur
 c
hi
ld
 (
ci
rc
le
)
__
__
__
__
__
_
Ye
s/
N
o
__
__
__
__
__
__
__
__
__
Yo
ur
se
lf
/c
hi
ld
__
__
__
__
__
_
Ye
s/
N
o
__
__
__
__
__
__
__
__
__
Yo
ur
se
lf
/c
hi
ld
__
__
__
__
__
_
Ye
s/
N
o
__
__
__
__
__
__
__
__
__
Yo
ur
se
lf
/c
hi
ld
__
__
__
__
__
_
Ye
s/
N
o
__
__
__
__
__
__
__
__
__
Yo
ur
se
lf
/c
hi
ld
T
im
e 
of
f 
wo
rk
 a
nd
 S
ch
oo
l
Fi
na
lly
, w
e 
ar
e 
in
te
re
st
ed
 in
 w
he
th
er
 y
ou
 h
av
e 
ta
ke
n 
an
y 
ti
m
e 
of
f 
wo
rk
 o
r 
yo
ur
 u
su
al
 a
ct
iv
it
ie
s 
an
d 
wh
et
he
r 
yo
u 
ch
ild
 h
as
 h
ad
 t
o 
ha
ve
 
da
ys
 o
ff
 s
ch
oo
l d
ue
 t
o 
ill
 h
ea
lt
h.
If
 y
ou
 a
re
in
 p
ai
d 
em
pl
oy
m
en
t 
pl
ea
se
 k
ee
p 
a 
re
co
rd
 o
f 
th
e 
da
ys
 o
ff
 w
or
k 
yo
u 
ta
ke
 d
ue
 t
o 
yo
u 
or
 y
ou
r 
ch
ild
‛s 
ill
 h
ea
lt
h:
Pl
ea
se
 t
ic
k 
on
e 
ci
rc
le
 f
or
 e
ve
ry
 d
ay
 y
ou
 t
ak
e 
of
f 
du
e 
to
 il
l h
ea
lt
h:
 
If
 y
ou
 a
re
 n
ot
in
 p
ai
d 
em
pl
oy
m
en
t 
pl
ea
se
 k
ee
p 
a 
re
co
rd
 o
f 
th
e 
da
ys
, i
f 
an
y,
 o
f 
yo
ur
 u
su
al
 a
ct
iv
it
ie
s 
yo
u 
ha
ve
 h
ad
 t
o 
gi
ve
 u
p 
du
e 
to
 y
ou
 o
r 
yo
ur
 c
hi
ld
‛s 
ill
 h
ea
lt
h:
 
Pl
ea
se
 t
ic
k 
on
e 
ci
rc
le
 f
or
 e
ve
ry
 d
ay
 y
ou
 t
ak
e 
of
f 
yo
ur
 u
su
al
 a
ct
iv
it
ie
s 
(e
.g
. c
hi
ld
 c
ar
e,
 h
ob
bi
es
, s
ho
pp
in
g)
: 
Yo
ur
 C
hi
ld
: 
T
im
e 
of
f 
Sc
ho
ol
Pl
ea
se
 k
ee
p 
a 
re
co
rd
 o
f 
th
e 
nu
m
be
r 
of
 w
ho
le
 d
ay
s 
yo
ur
 c
hi
ld
 h
as
 o
ff
sc
ho
ol
N
um
be
r 
of
ha
lf
da
ys
 o
ff
 s
ch
oo
l
T
ra
ve
l 
Co
st
s
Fi
na
lly
, i
f 
yo
u 
ha
ve
 in
cu
rr
ed
 a
ny
 t
ra
ve
l e
xp
en
se
s 
si
nc
e 
yo
ur
 la
st
 a
ss
es
sm
en
t 
as
 a
 r
es
ul
t 
of
 t
he
 t
re
at
m
en
t 
we
 h
av
e 
pr
ov
id
ed
 p
le
as
e 
en
te
r 
th
e 
ap
pr
ox
im
at
e 
am
ou
nt
:
N
b:
 P
le
as
e 
do
n‛t
 d
iv
ul
ge
 t
he
 n
um
be
r 
of
 t
re
at
m
en
t 
se
ss
io
ns
 y
ou
 h
av
e 
re
ce
iv
ed
 t
o 
yo
ur
 r
es
ea
rc
h 
as
si
st
an
ts
! 
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Your use of Health and Social Services in the last 8 weeks
SERVICES THAT YOU AND YOUR CHILD HAVE USED IN THE LAST 8 WEEKS
Have you or your child had any visits or visited any of the following 
services since you joined the study? If so, please write the number of
visits for yourself or your child in the appropriate box. If you cannot 
remember the exact number of visits, don‛t worry, please just give your 
best guess.  Please ignore any services that you have not used. If you 
have used the diary about your use of services we sent you at the 
beginning of the study then please use that to fill in the answers below. 
Please do not include any appointments related to the trial itself such as 
the CBT therapy sessions. Thank you.
Visits to/from Yourself       Your Child 
Example     GP 1 3
Family Doctor (GP) 
Social Worker 
Practice nurse
Psychologist
Psychiatrist
Community Psychiatric Nurse
Education Welfare Officer
Educational Psychologist
Family Liaison Officer (School)
Teacher (other than usual contact)
Paediatrician (children’s doctor) 
Obstetrician (woman’s doctor)
Audiology
Speech and language
Opthalmology 
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Hospital A & E Department
Occupational Therapist
Paediatric Dietician
Paediatric Physiotherapist
Paediatric Play Specialist
Family Therapist
Community Children’s Nurse
Child & Adolescent Mental Health Nurse
Housing Department
Citizens Advice Bureau
Family Centre
Home-start
Alcohol or drug counselling
Other (Please specify)
Drug treatments
In this following section we would like to know whether you or your child 
have been prescribed, or purchased, any drugs or medications in the last 
8 weeks.
Please note the name of the drug/medication and whether it was 
prescribed by your GP or purchased yourself:
Drug name Prescription  Duration of treatment For yours
___________ Yes/No _______________      Yourself/child
___________ Yes/No _______________         Yourself/child
___________ Yes/No _______________         Yourself/child
___________ Yes/No _______________         Yourself/child
Time off work and School
Finally, we are interested in whether you have taken any time off work or
your usual activities and whether you child has had to have days off 
school due to ill health in the last 8 weeks.
Are you in paid employment? Yes/No (circle)
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If yes, have you taken time off work in the last 8 weeks due to ill health? 
Yes/No (circle)
If yes, please state how many: Days
If you are not in paid employment please state the number of days, if any, 
of your usual activities (e.g. child care, hobbies, shopping) you have had to 
give up in the last 8 weeks due to ill health:                     Days
Time off school
Has your child had to have days off school in the last 8 weeks due to ill 
health? Yes/No (circle)
If yes, please state how many:                       Days
Travel costs
Finally, if you have incurred any travel expenses in the last 8weeks as a result
of your CBT treatment please enter the approximate amount:     
Thank you for completing this questionnaire. If you have any queries 
or concerns please do not hesitate to contact *****   Tel:                 
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TABLE 89 Unit costs
Item Unit cost (£) Source Notes
Family doctor (GP
consultation in surgery)
40 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 10.8b. Cost including
qualifications, excluding other
direct care staff costs
Social worker 74 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 11.3. Cost per hour of
face-to-face contact, including
qualifications
Practice nurse (nurse
consultation in surgery)
13.69 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 10.6. Cost including
qualifications, excluding other
direct care staff costs and based
on duration of contact of
15.5 minutes
Psychologist 136 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 9.5. Cost per hour of client
contact (includes A to E: A=wages/
salary; B= salary oncosts;
C=qualifications; D=overheads;
E= capital overheads)
Consultant: psychiatrist 383 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 15.7. Cost per face-to-face
contact, including qualifications
Community psychiatrist nurse
(nurse – mental health)
76 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 10.2. Cost per hour of
face-to-face contact
(including qualifications)
Education welfare officer 20.44 Local Government Earnings Survey
2011/12 – Observed Pay Rates.
URL: www.local.gov.uk/web/guest/
local-government-intelligence/-/
journal_content/56/10171/
3015313/ARTICLE-TEMPLATE
(accessed 22 April 2013)
Education welfare officer, median
annual gross pay (FTE). Unit cost
calculated using information on
local government pension
schemes and employer National
Insurance contributions. Adjusted
for inflation using RPI
Educational psychologist 37.29 Local Government Earnings Survey
2011/12 – Observed Pay Rates.
URL: www.local.gov.uk/web/guest/
local-government-intelligence/-/
journal_content/56/10171/
3015313/ARTICLE-TEMPLATE
(accessed 22 April 2013)
Educational psychologist, median
annual gross pay (FTE). Unit cost
calculated using information on
local government pension
schemes and employer National
Insurance contributions. Adjusted
for inflation using RPI
Family liaison officer (school)
(approximated with family
support worker)
49 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 11.8. Costs per hour of
client-related work
Teacher 35.41 Department of Education. Statistical
First Release. School Workforce in
England, November 2011. URL:
www.education.gov.uk/rsgateway/
DB/SFR/s001062/sfr06–2012v7.pdf
(accessed 16 April 2013)
Table 9a. Average salary (£) in
total, publicly funded school.
Salary oncosts have been
included in the calculation of the
unit cost. Adjusted for inflation
using RPI
continued
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TABLE 89 Unit costs (continued )
Item Unit cost (£) Source Notes
Paediatrician: outpatient
department – paediatrics
225 National Schedule of Reference
Costs Year: ‘2011–2012’.
URL: www.gov.uk/government/
publications/nhs-reference-costs-
financial-year-2011-to-2012
(accessed 18 April 2013)
NHS trusts. Consultant led, first
attendance, non-admitted, face
to face. Service code: 420
Audiology: outpatient
department – paediatric
audiological medicine (A),
audiological medicine (B),
audiology (C)
110 National Schedule of Reference
Costs Year: ‘2011–2012’.
URL: www.gov.uk/government/
publications/nhs-reference-costs-
financial-year-2011-to-2012
(accessed 18 April 2013)
As above. Weighted average
of (A), (B) and (C). (A) service
code 254; (B) service code 310;
(C) service code 840
Speech and language
(community speech and
language therapist)
33 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 9.3. Cost
including qualifications
Ophthalmology: outpatient
department –ophthalmology
(A), paediatric ophthalmology
(B), medical ophthalmology
(C), orthoptics (D),
optometry (E)
107 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
As above. Weighted average of
(A), (B), (C) and (D). (A) service
code 130; (B) service code 216;
(C) service code: 460; (D) service
code 655; (E) service code 662
Hospital A&E department 108 National Schedule of Reference
Costs Year: ‘2011–2012’.
URL: www.gov.uk/government/
publications/nhs-reference-costs-
financial-year-2011-to-2012
(accessed 18 April 2013)
A&E services: no leading to
admitted. Weighted average of
all services in the category
Occupational therapist 33 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 9.2. Cost including
qualifications
Paediatric dietitian 34 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 13.4. Cost including
qualifications
Paediatric physiotherapist 74 National Schedule of Reference
Costs Year: ‘2011–2012’.
URL: www.gov.uk/government/
publications/nhs-reference-costs-
financial-year-2011-to-2012
(accessed 18 April 2013)
Community physiotherapy
services: child, one-to-one
services, service code N5C1
Paediatric play specialist 11.55 Local Government Earnings Survey
2011/12 – Observed Pay Rates.
URL: www.local.gov.uk/web/guest/
local-government-intelligence/-/
journal_content/56/10171/
3015313/ARTICLE-TEMPLATE
(accessed 22 April 2013)
Playworker, median annual gross
pay (FTE). Unit cost calculated
using information on local
government pension schemes
and employer National Insurance
contributions. Adjusted for
inflation using RPI
Family therapist (family
support worker)
49 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 11.8. Costs per hour of
client-related work
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TABLE 89 Unit costs (continued )
Item Unit cost (£) Source Notes
Community children’s nurse 93 National Schedule of Reference
Costs Year: ‘2011–2012’.
URL: www.gov.uk/government/
publications/nhs-reference-costs-
financial-year-2011-to-2012
(accessed 18 April 2013)
Community nursing services:
nursing services for children,
service code CN101
Child and adolescent mental
health worker
68 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 12.6. Generic
single-disciplinary CAMHS
Primary mental health worker 68 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 12.6. Generic
single-disciplinary CAMHS
Housing department 19.81 Local Government Earnings Survey
2011/12 – Observed Pay Rates.
URL: www.local.gov.uk/web/guest/
local-government-intelligence/-/
journal_content/56/10171/
3015313/ARTICLE-TEMPLATE
(accessed 22 April 2013)
Housing officer, median annual
gross pay (FTE) England. Unit cost
calculated using information on
local government pension
schemes and employer National
Insurance contributions. Adjusted
for inflation using RPI
Citizens advice bureau 15.50 Office for National Statistics (UK).
Labour Market, Earnings by
Industry. Patterns of Pay: Results
from the Annual Survey of Hours
and Earnings, 1997–2012.
URL: www.ons.gov.uk/ons/
taxonomy/search/index.html?
nscl=Earnings+by+Industry&nscl-
orig=Earnings+by+Industry&
content-type=Dataset&content-
type=Reference+table&
sortDirection=DESCENDING&
sortBy=pubdate (accessed on
19 April 2013)
Table 5_SIC07. Full-time
employees’ pay by industry sector
(SIC 2007), United Kingdom,
April 2008–12. Industry sector:
other service activities. Unit cost
calculated using information on
stakeholders pension schemes
and employer National
Insurance contributions
Family centre (family
support worker
49 Personal Social Services Research
Unit. Unit Costs of Health and
Social Care 2012. Kent:
University of Kent; 2012
Table 11.8. Costs per hour of
client-related work
Home-Start 95.59 McIntosh E, Barlow J, Davis H,
Stewart-Brown. Economic
evaluation of an intensive
home visiting programme: a
cost-effectiveness analysis from a
societal perspective. J Publ Health
2009;3:423–33
Table 1, p. 427. Price inflated to
2011/12 prices using the
HCHS index
Other health and social care
resource use
81.12 Authors’ calculations Average of all other unit costs
Therapist: newly qualified
clinical psychologist
39.15 (per
hour); 87.98
(per hour of
client contact)
Health & Social Care Information
Centre. NHS Staff Earnings,
Estimates – April–June 2012.
URL: www.hscic.gov.uk/catalogue/
PUB07388 (accessed
23 April 2013)
Table 3. Basic pay and earnings
for Agenda for Change Band 7
(spine point 26), and calculated
according to the methodology
adopted in Personal Social
Services Research Unit. Unit Costs
of Health and Social Care 2012.
Kent: University of Kent; 2012.
Table 9.5
continued
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TABLE 89 Unit costs (continued )
Item Unit cost (£) Source Notes
Supervisor £70.77 (per
hour) £159.03
(per hour of
client contact)
Health & Social Care Information
Centre. NHS Staff Earnings,
Estimates – April–June 2012.
URL: www.hscic.gov.uk/catalogue/
PUB07388 (accessed
23 April 2013)
Table 3. Basic pay and earnings
for Agenda for Change Band 8b
(spine point 41), and calculated
according to the methodology
adopted in Personal Social
Services Research Unit. Unit Costs
of Health and Social Care 2012.
Kent: University of Kent; 2012.
Table 9.5
Mileage allowance £0.54 per mile NHS Employers. NHS Terms and
conditions of service handbook.
Amendment number 25 – Pay
Circular (AforC) 1/2012. URL: www.
nhsemployers.org/∼/media/
Employers/Documents/Pay%20and
%20reward/AfC_tc_of_service_
handbook_fb.pdf (accessed
12 November 2013)
Car (all types of fuel), annual
mileage up to 3500 miles
(standard rate)
CAMHS, Child and Adolescent Mental Health Services; FTE, full-time equivalent; GP, general practitioner; SIC, standard
industrial classification.
All costs in 2011/12 prices. For 2010/11 prices adjusted for inflation using RPI 2012 or HCHS 2011/12 as appropriate.
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Health economic supplementary material section 1
Conditional models for multiple imputation using chained equations
Variable imputed: each category of supervision time.
Covariates in the model:
l treatment allocation
l minimisation factors, that is child age, child gender, type of child anxiety disorder (GAD, social phobia,
SAD, other)
l baseline severity (ADIS-IV CSR) of the child’s primary anxiety disorder
l baseline severity (ADIS-IV mother self-report) of the mother’s primary anxiety disorder
l mothers’ baseline depression (DASS-21 – depression)
l child baseline depression symptoms (SMFQ-c, child-reported)
l child behavioural problems (SDQ conduct, mother-reported)
l baseline presence of child social phobia
l all other categories of supervision time.
Variable imputed: total rewards.
Covariates in the model:
l treatment allocation
l minimisation factors, that is child age, child gender, type of child anxiety disorder (GAD, social phobia,
SAD, other).
Variable imputed: baseline EQ-5D for child and mother.
Covariates in the model:
l treatment allocation
l minimisation factors, that is child age, child gender, type of child anxiety disorder (GAD, social phobia,
SAD, other)
l baseline severity (ADIS-IV CSR) of the child’s primary anxiety disorder
l baseline severity (ADIS-IV mother self-report) of the mother’s primary anxiety disorder
l mothers’ baseline depression (DASS-21 – depression)
l child baseline depression symptoms (SMFQ-c, child-reported)
l child behavioural problems (SDQ conduct, mother-reported)
l baseline presence of child social phobia.
Variable imputed: follow-up measurements of child and mother EQ-5D.
Covariates in the model:
l treatment allocation
l minimisation factors, that is child age, child gender, type of child anxiety disorder (GAD, social phobia,
SAD, other)
l measurement of outcomes at previous time points.
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TABLE 90 Health economic data completeness
Item CCBT+MCBT, %a CCBT+MCI, %b CCBT, %c
CCBT time 34.8 25.4 38
MCBT time 23.2 NA NA
MCI time NA 33.8 NA
NDC time NA 2.8 8.5
FH time 27.5 NA 11.3
Supervision time for CCBT 42.03 47.89 33.80
Supervision time for CCBT 13.04 NA NA
Supervision time for MCI NA 42.25 NA
Supervision time for NDC time NA 73.24 59.15
Supervision time for FH 79.71 NA 74.65
Total cost rewards 75.36 70.42 81.69
Child: EQ-5D score – baseline 1.45 2.82 5.63
Child: EQ-5D score – assessment 1B 13.04 8.45 21.13
Child: EQ-5D score – assessment 2 33.33 21.13 32.39
Child: EQ-5D score – 6-month follow-up 36.23 39.44 40.85
Child: EQ-5D score – 12-month follow-up 50.72 46.48 53.52
Mother: EQ-5D score – baseline 8.70 9.86 15.49
Mother: EQ-5D score – assessment 1B 33.33 28.17 38.03
Mother: EQ-5D score – assessment 2 37.68 40.85 43.66
Mother: EQ-5D score – 6-month follow-up 37.68 40.85 43.66
Mother: EQ-5D score – 12-month follow-up 50.72 46.48 52.11
NA, not applicable.
a Percentage calculated with respect to the 69 patients in trial arm 1.
b Percentage calculated with respect to the 71 patients in trial arm 2.
c Percentage calculated with respect to the 71 patients in trial arm 3.
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TABLE 91 Response rates of patient-held resource use diaries
Section CCBT+MCBT, %a CCBT+MCI, %b CCBT, %c
Other health and social care resources: child and mother – period
‘baseline to assessment 1B’
50.7 66.2 45.1
Medication use: child and mother – period ‘baseline to
assessment 1B’
39.1 39.4 32.4
Other health and social care resources: child and mother – period
‘assessment 1B to assessment 2’
24.6 35.2 28.2
Medication use: child and mother – period ‘assessment 1B to
assessment 2’
18.8 32.4 26.8
Other health and social care resources: child and mother – period
‘assessment 2- to 6-month follow-up’
46.4 43.6 42.3
Medication use: child and mother – period ‘assessment 2- to
6-month follow-up’
46.4 43.6 42.3
Other health and social care resources: child and mother – period
‘6–12 months follow-up’
28.9 26.8 29.6
Medication use: child and mother – period ‘6–12 months follow-up’ 33.3 32.4 42.3
a Percentage calculated with respect to the 69 patients in trial arm 1.
b Percentage calculated with respect to the 71 patients in trial arm 2.
c Percentage calculated with respect to the 71 patients in trial arm 3.
TABLE 92 Other health and social care resources: child – period between assessment 1A (baseline) and assessment
1B (mid-treatment)
Resource use (contacts): child
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor 1.11 (1.59) 0.36 (0.76) 0.5 (0.80)
Social worker 0.13 (0.88) 0.25 (1.41)
Practice nurse 0.03 (0.17) 0.09 (0.28) 0.06 (0.25)
Psychologist 0.09 (0.50) 0.13 (0.74) 0.06 (0.25)
Education welfare officer 0.021 (0.15) 0.13 (0.71)
Educational psychologist 0.06 (0.34) 0.04 (0.21)
Family liaison officer 0.11 (0.68) 0.04 (0.29)
Teacher 0.34 (1.21) 0.62 (3.10) 0.66 (2.50)
Paediatrician 0.2 (0.63) 0.15 (0.47)
Audiology 0.06 (0.34)
Speech and language 0.03a (0.17) 0.02 (0.15) 0.06 (0.25)
Ophthalmology 0.06 (0.24) 0.04 (0.20)
Hospital A&E department 0.11 (0.47) 0.09 (0.28) 0.06 (0.35)
Occupational therapist 0.09 (0.51)
Paediatric physiotherapist 0.06 (0.32)
Community children’s nurse 0.14 (0.85)
Child and adolescent mental health worker 0.02 (0.15)
Primary mental health worker 0.03 (0.18)
Other 0.57b (1.03) 0.79c (1.59) 0.71c (1.36)
Observations 35 47 32
a Only 22 observations.
b Only 29 observations.
c Only 22 observations.
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TABLE 93 Other health and social care resources: mother – period between assessment 1A (baseline) and
assessment 1B (mid-treatment)
Resource use (contacts): mother
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor 1.74 (2.19) 1.04 (1.52) 1.41 (3.24)
Social worker 0.13 (0.88) 0.09 (0.53)
Practice nurse 0.23 (0.49) 0.11 (0.31) 0.22 (0.75)
Psychologist 0.16 (0.57)
Psychiatrist 0.04 (0.29) 0.03 (0.18)
Community psychiatrist nurse 0.22 (1.24)
Education welfare officer 0.02 (0.15) 0.03 (0.18)
Family liaison officer 0.22(1.24)
Teacher 0.23 (0.60) 0.15 (0.72) 0.28 (0.81)
Paediatrician 0.06 (0.25)
Ophthalmologist 0.14 (0.60)
Hospital A&E department 0.09 (0.28) 0.11 (0.37) 0.03 (0.18)
Family therapist 0.06 (0.35)
Community children nurse 0.13 (0.88)
Primary mental health worker 0.03 (0.18)
Housing department 0.02 (0.15) 0.03 (0.18)
Citizens Advice Bureau 0.03 (0.17)
Other 0.77a (1.54) 0.14b (0.58) 0.91c (1.85)
Observations 35 47 32
a Only 22 observations.
b Only 29 observations.
c Only 22 observations.
TABLE 94 Consumption of medications: mother and child – period between assessment 1A (baseline) and
assessment 1B (mid-treatment)
Resource use: medications
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Mother’s consumption of prescription medications 0.70 (1.10) 0.89 (1.20) 0.78 (1.28)
Mother’s consumption of ‘over-the-counter’ medications 0.15 (0.46) 0.18 (0.55) 0
Child’s consumption of prescription medications 0.48 (0.89) 0.46 (0.84) 0.35 (0.49)
Child’s consumption of ‘over-the-counter’ medications 0.11 (0.32) 0.36 (0.62) 0.22 (0.85)
Observations 27 28 23
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TABLE 95 Other health and social care resources: child – period between assessment 1B (mid-treatment) and
assessment 2 (post treatment)
Resource use (contacts): child
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor 0.24 (0.44) 0.64 (1.04) 0.3 (0.47)
Social worker 0.76 (3.15) 0.4 (1.8)
Practice nurse 0.12 (0.49) 0.08 (0.28)
Psychologist 0.32 (1.6)
Education welfare officer 0.18 (0.73)
Family liaison officer 0.04 (0.2)
Teacher 0.24 (0.56) 0.24 (0.83) 0.2 (0.70)
Paediatrician 0.06 (0.24) 0.08 (0.4)
Speech and language 0.06 (0.24)
Ophthalmology 0.04 (0.2)
Hospital A&E department 0.06 (0.24) 0.04 (0.2)
Other 0.25a (0.77) 0.29b (0.77)
Observations 17 25 20
a Only 16 observations.
b Only 17 observations.
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TABLE 96 Other health and social care resources: mother – period between assessment 1B (mid-treatment) and
assessment 2 (post treatment)
Resource use (contacts): mother
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor 1.06 (1.71) 0.8 (0.96) 1.9 (4.94)
Social worker 0.25 (0.79)
Practice nurse 0.06 (0.24) 0.12 (0.33) 0.1 (0.45)
Psychologist 0.4 (1.63)
Community psychiatrist nurse 0.04 (0.2) 1.05 (4.70)
Education welfare officer 0.29 (0.85)
Educational psychologist 0.04 (0.2)
Family liaison officer 0.04 (0.2) 1.2 (4.71)
Teacher 0.12 (0.49) 0.08 (0.4) 0.1 (0.31)
Audiology 0.24 (0.66)
Ophthalmology 0.04 (0.2)
Hospital A&E department 0.2 (0.89)
Occupational therapist 0.18 (0.73)
Housing department 0.41 (1.70) 0.08 (0.28)
Citizens Advice Bureau 0.05 (0.22)
Other 1.77a (3.32) 0.38b (1.53) 1.16c (2.36)
Observations 17 25 20
a Only 13 observations.
b Only 21 observations.
c Only 19 observations.
TABLE 97 Consumption of medications: mother and child – period between assessment 1B (mid-treatment) and
assessment 2 (post treatment)
Resource use: medications
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Mother’s consumption of prescription medications 0.46 (0.78) 0.96 (1.46) 0.63 (1.38)
Mother’s consumption of ‘over-the-counter’ medications 0.31 (0.63) 0.17 (0.39) 0.05 (0.23)
Child’s consumption of prescription medications 0.38 (0.65) 0.30 (0.63) 0.11 (0.32)
Child’s consumption of ‘over-the-counter’ medications 0.31 (0.48) 0.17 (0.39) 0.05 (0.23)
Observations 13 23 19
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TABLE 98 Other health and social care resources: child – period between assessment 2 (post treatment) and
assessment 3 (6-month follow-up)
Resource use (contacts): child
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor 0.66 (1.10) 0.45 (0.77) 0.93 (1.80)
Social worker 0.73 (2.90)
Practice nurse 0.13 (0.43) 0.07 (0.37)
Psychologist 0.13 (0.71) 0.17 (0.75)
Psychiatrist 0.03 (0.18)
Education welfare officer 0.19 (0.90)
Educational psychologist 0.07 (0.37)
Family liaison officer 0.03 (0.18) 0.87 (3.88)
Teacher 0.38 (1.13) 0.35 (1.14) 0.6 (2.43)
Paediatrician 0.19 (0.60) 0.13 (0.50) 0.10 (0.55)
Audiology 0.03 (0.18) 0.10 (0.40)
Ophthalmology 0.03 (0.18) 0.1 (0.40)
Hospital A&E department 0.16 (0.37) 0.06 (0.25) 0.07 (0.25)
Paediatric dietitian 0.03 (0.18) 0.27 (1.46)
Paediatric physiotherapist 0.03 (0.18) 0.03 (0.18)
Paediatric play specialist 0.19 (1.06)
Community children’s nurse 0.03 (0.18)
Child and adolescent mental health worker 0.23 (1.10)
Other 0.83a (1.53) 0.36b (0.92) 0.63c (1.63)
Observations 32 31 30
a Only 12 observations.
b Only 11 observations.
c Only 16 observations.
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TABLE 99 Other health and social care resources: mother – period between assessment 2 (post treatment) and
assessment 3 (6-month follow-up)
Resource use (contacts): mother
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor 1.34 (1.75) 0.81 (1.05) 1.77 (3.94)
Social worker 0.4 (2.19)
Practice nurse 0.16 (0.45) 0.26 (0.58) 0.13 (0.43)
Psychologist 0.17 (0.75)
Psychiatrist 0.06 (0.25) 0.03 (0.18)
Community psychiatrist nurse 0.31 (1.77) 0.2 (1.10)
Education welfare officer 0.25 (0.92) 0.07 (0.7)
Educational psychologist 0.03 (0.18)
Family liaison officer 0.03 (0.17) 0.73 (3.83)
Teacher 0.41 (1.50) 0.16 (0.73) 0.07 (0.37)
Audiology 0.13 (0.50) 0.10 (0.54) 0.13 (0.73)
Ophthalmology 0.06 (0.25)
Hospital A&E department 0.13 (0.42) 0.06 (0.25) 0.07 (0.26)
Occupational therapist 0.17 (0.91)
Paediatric dietitian 0.06 (0.35)
Family therapist 0.03 (0.18)
Community children’s nurse 0.03 (0.18)
Citizens Advice Bureau 0.09 (0.53) 0.1 (0.55)
Other 0.53a (1.67) 0.69b (1.70) 0.93c (2.28)
Observations 32 31 30
a Only 11 observations.
b Only 13 observations.
c Only 15 observations.
TABLE 100 Consumption of medications: mother and child – period between assessment 2 (post treatment) and
assessment 3 (6-month follow-up)
Resource use: medications
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Mother’s consumption of prescription medications 0.85 (1.23) 0.69 (0.75) 0.95 (1.24)
Mother’s consumption of ‘over-the-counter’ medications 0.15 (0.49) 0.11 (0.32) 0.05 (0.22)
Child’s consumption of prescription medications 0.60 (0.75) 0.53 (0.84) 0.38 (0.81)
Child’s consumption of ‘over-the-counter’ medications 0.11 (0.46) 0.21 (0.42) 0.05 (0.22)
Observations 20 19 21
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TABLE 101 Other health and social care resources: child – period between assessment 3 (6-month follow-up) and
assessment 4 (12-month follow-up)
Resource use (contacts): child
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor 0.96 (1.02) 0.35 (0.65) 0.60 (1.00)
Social worker 0.04 (0.21) 0.53 (2.92)
Practice nurse 0.22 (0.85) 0.27 (0.78)
Psychologist 0.04 (0.21) 0.09 (0.42) 0.57 (2.46)
Psychiatrist 0.03 (0.18)
Education welfare officer 0.03 (0.18)
Educational psychologist 0.04 (0.21) 0.04 (0.21)
Family liaison officer 0.13 (0.63) 0.77 (3.84)
Teacher 0.04 (0.21) 0.17 (0.58) 0.13 (0.43)
Paediatrician 0.13 (0.63) 0.35 (0.93) 0.07 (0.37)
Audiology 0.09 (0.42)
Ophthalmology 0.07 (0.37)
Hospital A&E department 0.04 (0.21) 0.04 (0.2085144) 0.03 (0.18)
Paediatric dietitian 0.23 (1.28)
Paediatric physiotherapist 0.04 (0.21)
Child and adolescent mental health worker 0.03 (0.18)
Primary mental health worker 0.03 (0.18)
Other 0.05a (0.23) 0.05b (0.23) 0.30c (0.93)
Observations 23 23 30
a Only 19 observations.
b Only 19 observations.
c Only 23 observations.
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TABLE 102 Other health and social care resources: mother – period between assessment 3 (6-month follow-up)
and assessment 4 (12-month follow-up)
Resource use (contacts): mother
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor 2.39 (3.49) 1.52 (1.98) 1.37 (1.97)
Social worker 0.22 (1.04) 0.33 (1.83)
Practice nurse 0.04 (0.21) 0.35 (1.27) 0.10 (0.31)
Psychologist 0.39 (1.88) 0.17 (0.83)
Psychiatrist 0.04 (0.21)
Education welfare officer 0.03 (0.18)
Educational psychologist 0.04 (0.21) 0.03 (0.18)
Family liaison officer 0.09 (0.29) 0.73 (3.83)
Teacher 0.13 (0.46) 0.74 (2.53) 0.13 (0.43)
Ophthalmology 0.033 (0.18)
Hospital A&E department 0.17 (0.49) 0.09 (0.42) 0.07 (0.37)
Occupational therapist 0.04 (0.21)
Housing department 0.09 (0.42) 0.03 (0.18)
Citizens Advice Bureau 0.04 (0.21) 0.03 (0.18)
Family centre 0.04 (0.21) 0.07 (0.37)
Home-Start 0.04 (0.21)
Other 0.71a (1.23) 0.37b (1.01) 0.43c (1.04)
Observations 23 23 30
a Only 21 observations.
b Only 19 observations.
c Only 23 observations.
TABLE 103 Consumption of medications: mother and child – period between assessment 3 (6-month follow-up)
and assessment 4 (12-month follow-up)
Resource use: medications
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Mother’s consumption of prescription medications 0.65a (0.93) 0.45a (0.89) 0.54b (1.07)
Mother’s consumption of ‘over-the-counter’ medications 0.14c (0.35) 0.41 (0.96) 0.26d (0.71)
Child’s consumption of prescription medications 0.52 (0.67) 0.18 (0.50) 0.17 (0.38)
Child’s consumption of ‘over-the-counter’ medications 0.22 (0.67) 0.23 (0.53) 0.21 (0.62)
Observations 23 22 29
a Only 20 observations.
b Only 28 observations.
c Only 22 observations.
d Only 27 observations.
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TABLE 104 Cost of other health and social care resources: child – period between assessment 1A (baseline) and
assessment 1B (mid-treatment)
Cost: child
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor £44.57 (63.45) £14.46 (30.56) £20.00 (32.12)
Social worker £26.30 (180.29) £51.50 (291.33)
Practice nurse £0.39 (2.31) £1.16 (3.86) £0.86 (3.37)
Psychologist £11.66 (68.96) £17.36 (100.73) £8.50 (33.45)
Education welfare officer £0.43 (2.98) £2.56 (14.45)
Educational psychologist £2.13 (12.61) £1.62 (7.69)
Family liaison officer £5.60 (33.13) £2.09 (14.29)
Teacher £12.14 (42.89) £21.85 (109.90) £23.24 (88.40)
Paediatrician £45.00 (142.30) £33.51 (104.68)
Audiology £6.29 (37.19)
Speech and language £0.97a (5.65) £0.70 (4.81) £2.06 (8.12)
Ophthalmology £6.11 (25.20) £4.55 (21.83)
Hospital A&E department £12.34 (50.87) £9.19 (30.46) £6.75 (38.18)
Occupational therapist £2.83 (16.73)
Paediatric physiotherapist £4.72 (23.93)
Community children’s nurse £13.28 (78.60)
Child and adolescent mental health worker £1.44 (9.92)
Primary mental health worker 2.13 (12.02)
Other £46.35b (83.41) £64.22c (128.77) £57.26d (110.20)
Observations 35 47 32
a Only 34 observations.
b Only 21 observations.
c Only 24 observations.
d Only 17 observations.
DOI: 10.3310/hta19380 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 38
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Creswell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
141
TABLE 105 Cost of other health and social care resources: mother – period between assessment 1A (baseline) and
assessment 1B (mid-treatment)
Cost: mother
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor £69.71 (87.50) £41.70 (60.70) £56.25 (129.66)
Social worker £26.30 (180.28) £19.31 (109.25)
Practice nurse £3.13 (6.71) £1.45 (4.27) £2.99 (10.28)
Psychologist £21.25 (78.08)
Psychiatrist £16.30 (111.73) £11.97 (67.71)
Community psychiatrist nurse £16.63 (94.05)
Education welfare officer £0.43 (2.98) £0.64 (3.61)
Family liaison officer £10.71 (60.63)
Teacher £8.09 (21.19) £5.27 (25.55) £9.96 (28.77)
Paediatrician £14.06 (55.34)
Ophthalmologist £15.20 (64.32)
Hospital A&E department £9.26 (30.68) £11.49 (40.50) £3.38 (19.09)
Family therapist £3.06 (17.32)
Community children nurse £11.87 (81.39)
Primary mental health worker £2.12 (12.02)
Housing department £0.42 (2.89) £0.619 (3.50)
Citizens Advise Bureau £0.44 (2.62)
Other £62.68a (125.00) £11.19b (47.12) £73.75c (150.02)
Observations 35 47 32
a Only 22 observations.
b Only 29 observations.
c Only 22 observations.
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TABLE 106 Cost of other health and social care resources: child – period between assessment 1B (mid-treatment)
and assessment 2 (post treatment)
Cost: child
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor £9.41 (17.49) £25.60 (41.44) £12.00 (18.81)
Social worker £157.53 (649.51) £82.40 (368.50)
Practice nurse £1.61 (6.64) £1.10 (3.79)
Psychologist £43.52 (217.6)
Education welfare officer £3.61 (14.87)
Family liaison officer £1.96 (9.8)
Teacher £8.33 (19.91) £8.50 (29.41) £7.08 (24.64)
Paediatrician £13.24 (54.57) £18 (90.00)
Speech and language £1.94 (8.00)
Ophthalmology £4.28 (21.4)
Hospital A&E department £6.35 (26.19) £4.32 (21.6)
Other £20.28a (62.84) £23.86b (62.60)
Observations 17 25 20
a Only 16 observations.
b Only 17 observations.
TABLE 107 Cost of other health and social care resources: mother – period between assessment 1B (mid-treatment)
and assessment 2 (post treatment)
Cost: mother
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor £42.35 (68.51) £32.00 (38.30) £76.00 (197.63)
Social worker £51.50 (161.99)
Practice nurse £0.81 (3.32) £1.64 (4.54) £1.37 (6.12)
Psychologist £54.4 (222.09)
Community psychiatrist nurse £3.04 (15.20) £79.80 (356.88)
Education welfare officer £6.01 (17.35)
Educational psychologist £1.49 (7.46)
Family liaison officer £1.96 (9.80) £58.8 (230.71)
Teacher £4.17 (17.17) £2.83 (14.16) £3.54 (10.90)
Audiology £25.88 (73.06)
Ophthalmology £4.28 (21.40)
Hospital A&E department £21.6 (96.60)
Occupational therapist £5.82 (24.01)
Housing department £8.16 (33.63) £1.58 (5.49)
Citizens Advice Bureau £0.78 (3.47)
Other £143.52a (269.36) £30.90b (124.29) £93.93c (191.70)
Observations 17 25 20
a Only 13 observations.
b Only 21 observations.
c Only 19 observations.
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TABLE 108 Cost of other health and social care resources: child – period between assessment 2 (post treatment)
and assessment 3 (6-month follow-up)
Cost: child
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor £26.25 (43.83) £18.06 (30.70) £37.33 (71.96)
Social worker £151.07 (597.37)
Practice nurse £1.77 (5.85) £0.91 (5.00)
Psychologist £17.00 (96.17) £22.67 (101.54)
Psychiatrist £12.76 (69.93)
Education welfare officer £3.83 (18.31)
Educational psychologist £2.49 (13.62)
Family liaison officer £1.53 (8.66) £42.47 (189.88)
Teacher £13.28 (39.97) £12.56 (40.42) £21.25 (86.04)
Paediatrician £42.19 (133.27) £29.03 (112.38) £22.50 (123.24)
Audiology £3.44 (19.45) £10.65 (43.58)
Ophthalmology £3.34 (18.92) £10.70 (43.08)
Hospital A&E department £16.88 (39.84) £6.97 (26.97) £7.20 (27.40)
Occupational therapist
Paediatric dietitian £1.06 (6.01) £9.07 (49.66)
Paediatric physiotherapist £2.31 (13.08) £2.47 (13.51)
Paediatric play specialist £2.17 (12.25)
Community children’s nurse £2.91 (16.44)
Child and adolescent mental health worker £15.87 (75.09)
Other £67.60a (123.91) £29.50b (74.99) £50.70c (132.05)
Observations 32 31 30
a Only 12 observations.
b Only 11 observations.
c Only 16 observations.
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TABLE 109 Cost of other health and social care resources: mother – period between assessment 2 (post treatment)
and assessment 3 (6-month follow-up)
Cost: mother
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor £53.75 (70.10) £32.26 (41.85) £70.67 (157.46)
Social worker £82.40 (451.32)
Practice nurse £2.14 (6.13) £3.53 (7.88) £1.83 (5.94)
Psychologist £22.67 (101.54)
Psychiatrist £23.94 (94.19) £12.77 (69.93)
Community psychiatrist nurse £23.75 (134.35) £15.2 (83.25)
Education welfare officer £5.11 (18.72) £1.36 (7.46)
Educational psychologist £1.24 (6.81)
Family liaison officer £1.53 (8.66) £35.93 (187.77)
Teacher £14.39 (53.10) £5.71 (26.02) £2.36 (2.93)
Audiology £13.75 (54.11) £10.65 (59.27) £14.67 (80.33)
Ophthalmology £6.69 (26.32)
Hospital A&E department £13.50 (45.49) £6.97 (26.97) £7.20 (27.40)
Occupational therapist £5.50 (30.12)
Paediatric dietitian £2.13 (12.02)
Family therapist £1.53 (8.66)
Community children’s nurse £2.91 (16.44)
Citizens Advice Bureau £1.45 (8.22) £1.55 (8.49)
Other £81.12a (135.73) £56.16b (138.08) £75.71c (185.15)
Observations 32 31 30
a Only 11 observations.
b Only 13 observations.
c Only 15 observations.
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TABLE 110 Cost of other health and social care resources: child – period between assessment 3 (6-month
follow-up) and assessment 4 (12-month follow-up)
Cost: child
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor £38.26 (40.86) £13.91 (25.89) £24 (40.14)
Social worker £8.96 (42.95) £109.87 (601.76)
Practice nurse £2.98 (11.64) £3.65 (10.75)
Psychologist £5.91 (28.36) £11.83 (56.72) £77.07 (334.44)
Psychiatrist £12.77 (69.93)
Education welfare officer £0.68 (3.73)
Educational psychologist £1.62 (7.78) £1.62 (7.78)
Family liaison officer £6.39 (30.65) £37.57 (188.10)
Teacher £1.54 (7.38) £6.16 (20.40) £4.72 (15.37)
Paediatrician £29.35 (140.75) £78.26 (210.29) £15.00 (82.16)
Audiology £9.57 (45.87)
Ophthalmology £7.13 (39.07)
Hospital A&E department £4.70 (22.52) £4.70 (22.52) £3.60 (19.72)
Paediatric dietitian £7.93 (43.45)
Paediatric physiotherapist £3.22 (15.43)
Child and adolescent mental health worker £2.27 (12.42)
Primary mental health worker £2.27 (12.42)
Other £4.27a (18.61) £4.27b (18.61) £24.69c (75.13)
Observations 23 23 30
a Only 19 observations.
b Only 19 observations.
c Only 23 observations.
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TABLE 111 Cost of other health and social care resources: mother – period between assessment 3 (6-month
follow-up) and assessment 4 (12-month follow-up)
Cost: mother
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Family doctor £95.65 (139.47) £60.87 (78.97) £54.67 (78.95)
Social worker £44.78 (214.77) £68.67 (376.10)
Practice nurse £0.60 (2.85) £4.76 (17.32) £1.37 (4.18)
Psychologist £53.22 (255.22) £23.65 (113.43)
Psychiatrist £16.65 (79.86)
Education welfare officer £0.68 (3.73)
Educational psychologist £1.62 (7.78) £1.24 (6.81)
Family liaison officer £4.26 (14.12) £35.93 (187.77)
Teacher £4.62 (16.21) £26.17 (89.46) £4.72 (15.37)
Ophthalmology £3.57 (19.54)
Hospital A&E department £18.78 (53.03) £9.39 (45.04) £7.20 (39.44)
Occupational therapist £1.43 (6.88)
Housing department £1.72 (8.26) £0.66 (3.62)
Citizens Advice Bureau £0.67 (3.23) £0.52 (2.83)
Family centre £2.13 (10.22) £3.27 (17.89)
Home-Start £4.16 (19.93)
Other £57.94a (103.07) £29.89b (82.06) £35.27c (84.11)
Observations 23 23 30
a Only 21 observations.
b Only 19 observations.
c Only 23 observations.
TABLE 112 Time off school (days) for the child and time off work and usual activities (days) for the mother: period
between assessment 1A (baseline) and assessment 1B (mid-treatment)
Time off (days)
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Time off school (days): child 1.46 (1.97) 0.28 (0.92) 1.88 (2.91)
Time off work (days): mother 0.50a (1.38) 0.28b (0.92) 2.00 (6.42)
Time off usual activities (days): mother 1.14 (3.04) 0.57 (2.38) 0.78 (2.76)
Observations 35 47 32
a Only 34 observations.
b Only 45 observations.
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TABLE 113 Time off school (days) for the child and time off work and usual activities (days) for the mother: period
between assessment 1B (mid-treatment) and assessment 2 (post treatment)
Time off (days)
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Time off school (days): child 2.12 (4.09) 1.84 (2.64) 3.38 (10.02)
Time off work (days): mother 0.41 (1.70) 0.72 (1.74) 2.65 (8.29)
Time off usual activities (days): mother 0.06 (0.24) 1.96 (6.09) 0.65 (2.68)
Observations 17 25 20
TABLE 114 Time off school (days) for the child and time off work and usual activities (days) for the mother: period
between assessment 2 (post treatment) and assessment 3 (6-month follow-up)
Time off (days)
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Time off school (days): child 3.38 (6.74) 1.32 (2.28) 2.55 (4.69)
Time off work (days): mother 0.59 (1.62) 0.42 (1.12) 3.03 (8.66)
Time off usual activities (days): mother 1.00 (2.75) 1.06 (3.72) 0.23 (1.28)
Observations 32 31 30
TABLE 115 Time off school (days) for the child and time off work and usual activities (days) for the mother: period
between assessment 3 (6-month follow-up) and assessment 4 (12-month follow-up)
Time off (days)
Mean (SD)
CCBT+MCBT CCBT+MCI CCBT
Time off school (days): child 3.23 (4.82) 0.61 (1.53) 3.15 (6.34)
Time off work (days): mother 1.45 (3.29) 1.00 (3.12) 1.03a (2.38)
Time off usual activities (days): mother 0.64 (2.98) 1.68 (1.99) 1.69a (6.43)
Observations 22 23 30
a Only 29 observations.
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TABLE 116 Cost–utility (health service perspective): ITT approach – CCBT+MCBT vs. CCBT
CUA results CCBT+MCBT (n= 69), mean (SE) CCBT (n= 71), mean (SE)
Cost of intervention £1888.84 (78.65) £1092.25 (61.88)
QALY gain 0.794 (0.022) 0.827 (0.024)
Incremental cost (95% CI) £796.59 (£599.48 to £993.70)
Incremental benefit, QALY gain (95% CI) –0.033 (–0.101 to 0.035)
ICER, incremental cost per QALY gain –£24,139
(95% CI) bootstrap method Lower limit, £47,106; upper limit, –£10,094
(95% CI) Fieller’s method Lower limit, –£9251; upper limit, £46,271
NMB for WTP= £20,000 –0.033 × £20,000 – £796.59= –£1456.00
NMB for WTP= £30,000 –0.033 × £30,000 – £796.59= –£1786.59
SE, standard error; WTP, willingness to pay.
TABLE 117 Cost–utility (health service perspective): ITT approach – CCBT+MCI vs. CCBT
CUA results CCBT+MCI (n= 71), mean (SE) CCBT (n= 71), mean (SE)
Cost of intervention £1899.95 (80.72) £1891.30 (87.14)
QALY gain 0.855 (0.018) 0.827 (0.024)
Incremental cost (95% CI) £807.70 (£606.55 to £1008.85)
Incremental benefit, QALY gain (95% CI) 0.028 (–0.030 to 0.086)
ICER, incremental cost per QALY gain £28,846
(95% CI) bootstrap method Lower limit, £10,129; upper limit, –£41,264
(95% CI) Fieller’s method Lower limit, £10,207; upper limit, –£41,499
NMB for WTP= £20,000 0.028 × £20,000 – £807.70= –£247.70
NMB for WTP= £30,000 0.028 × £30,000 – £807.70= £32.30
SE, standard error; WTP, willingness to pay.
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FIGURE 14 Cost-effectiveness plane showing bootstrapped replicates of the ICER: ITT analysis – CCBT+MCBT vs.
CCBT. LL, lower limit; PE, point estimate; UL, upper limit.
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FIGURE 15 Cost-effectiveness acceptability curve showing the probability that the intervention is cost-effective at
different willingness-to-pay thresholds: ITT analysis – CCBT+MCBT vs. CCBT.
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FIGURE 16 Net monetary benefit curve and limit curves: ITT analysis – CCBT+MCBT vs. CCBT. LL, lower limit;
UL, upper limit.
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FIGURE 17 Cost-effectiveness plane showing bootstrapped replicates of the ICER: ITT analysis – CCBT+MCI vs.
CCBT. LL, lower limit; PE, point estimate; UL, upper limit.
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FIGURE 18 Cost-effectiveness acceptability curve showing the probability that the intervention is cost-effective at
different willingness-to-pay thresholds: ITT analysis – CCBT+MCI vs. CCBT.
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FIGURE 19 Net monetary benefit curve and limit curves: ITT analysis – CCBT+MCI vs. CCBT. LL, lower limit;
UL, upper limit.
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Appendix 4 Teacher-reported questionnaire
Child adjustment to school: teacher report
Instructions
For each item mark the box for not true, somewhat true or certainly true. It would help us if you answered
all items as best you can, even if you are not absolutely certain or the item seems daft! Please give your
answers on the basis of the child’s behaviour over the previous 2 weeks of school.
Not true Somewhat true Certainly true
Avoids or gets worried about presenting work or showing things to
the class
Avoids or gets worried about participating in group or sports activities
Avoids or gets worried about approaching a group of children to ask to
join in
Avoids or gets worried about standing up for him/herself with peers
Avoids or gets worried about answering questions in class
Avoids or gets worried about speaking in class
Avoids or gets worried about asking questions in class
Avoids or gets worried about telling a teacher if he/she doesn’t
understand something
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Appendix 5 Summary statistics
TABLE 118 Descriptive statistics: SCAS questionnaires
Questionnaire Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
SCAS-c
Total score baseline CCBT 67 4 40.24 (21.29) 35.0 (24.0–53.0) 2 105
CCBT+MCBT 67 2 41.33 (18.26) 41.0 (29.0–56.0) 7 80
CCBT+MCI 69 2 39.16 (17.38) 39.0 (29.0–47.0) 4 92
Total score 6 months CCBT 44 27 21.05 (16.24) 18.0 (8.0–28.5) 0 73
CCBT+MCBT 43 26 24.42 (17.41) 19.0 (12.0–39.0) 0 63
CCBT+MCI 43 28 23.88 (17.37) 22.0 (9.0–35.0) 1 67
Total score 12 months CCBT 33 38 18.24 (13.31) 16.0 (9.0–27.0) 1 54
CCBT+MCBT 34 35 23.09 (14.92) 21.0 (10.0–34.0) 0 52
CCBT+MCI 39 32 21.15 (18.65) 15.0 (9.0–34.0) 0 68
SCAS-c/p
Total score baseline CCBT 64 7 43.17 (15.64) 43.0 (32.5–50.0) 16 94
CCBT+MCBT 63 6 42.19 (15.53) 39.0 (32.0–50.0) 17 82
CCBT+MCI 65 6 41.60 (16.75) 40.0 (29.0–52.0) 16 94
Total score 6 months CCBT 40 31 22.40 (16.33) 19.0 (14.0–27.5) 1 93
CCBT+MCBT 43 26 23.21 (13.53) 19.0 (14.0–31.0) 3 61
CCBT+MCI 39 32 22.26 (11.19) 22.0 (14.0–28.0) 5 51
Total score 12 months CCBT 34 37 19.44 (13.14) 15.5 (10.0–29.0) 1 51
CCBT+MCBT 32 37 24.63 (15.37) 25.0 (12.0–32.5) 1 66
CCBT+MCI 36 35 18.28 (12.80) 17.0 (9.0–24.0) 2 58
CCBT+MCBT 20 49 4.05 (3.02) 3.5 (2.0–5.5) 0 12
CCBT+MCI 26 45 5.04 (3.46) 5.0 (3.0–7.0) 0 13
SCAS-t
Total score baseline CCBT 25 46 17.60 (13.39) 15.0 (10.0–22.0) 0 49
CCBT+MCBT 37 32 14.38 (14.57) 9.0 (5.0–16.0) 1 66
CCBT+MCI 42 29 18.67 (12.98) 15.0 (10.0–26.0) 0 47
Total score 6 months CCBT 11 60 11.91 (13.16) 6.0 (1.0–15.0) 0 43
CCBT+MCBT 16 53 8.63 (7.05) 6.5 (3.5–12.0) 2 29
CCBT+MCI 22 49 11.68 (11.51) 7.0 (4.0–16.0) 0 46
Total score 12 months CCBT 9 62 9.44 (9.86) 6.0 (5.0–8.0) 1 32
CCBT+MCBT 8 61 15.75 (11.51) 14.0 (8.0–20.5) 2 39
CCBT+MCI 10 61 7.70 (5.19) 7.5 (3.0–11.0) 0 17
IQR, interquartile range.
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TABLE 119 Descriptive statistics: CAIS questionnaires
Questionnaire Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
CAIS-c
Total score baseline CCBT 66 5 18.29 (12.83) 16.5 (9.0–24.0) 1 58
CCBT+MCBT 67 2 23.15 (16.34) 20.0 (10.0–37.0) 0 70
CCBT+MCI 68 3 18.91 (14.02) 15.0 (7.5–28.0) 0 63
Total score 6 months CCBT 42 29 7.48 (7.39) 5.0 (2.0–11.0) 0 27
CCBT+MCBT 43 26 10.02 (8.56) 8.0 (3.0–14.0) 0 29
CCBT+MCI 43 28 9.74 (9.39) 7.0 (2.0–16.0) 0 39
Total score 12 months CCBT 32 39 6.75 (7.36) 4.0 (1.0–11.0) 0 29
CCBT+MCBT 33 36 11.82 (15.16) 7.0 (2.0–18.0) 0 78
CCBT+MCI 38 33 7.82 (11.23) 3.5 (1.0–10.0) 0 49
CAIS-c/p
Total score baseline CCBT 58 13 23.17 (16.04) 18.5 (11.0–32.0) 1 66
CCBT+MCBT 56 13 25.46 (15.07) 25.0 (15.0–34.5) 0 60
CCBT+MCI 58 13 20.55 (12.66) 17.0 (10.0–28.0) 1 58
Total score 6 months CCBT 40 31 13.18 (12.87) 9.0 (3.0–22.0) 0 54
CCBT+MCBT 43 26 11.65 (9.67) 9.0 (5.0–16.0) 1 44
CCBT+MCI 42 29 11.17 (9.17) 9.0 (4.0–18.0) 0 38
Total score 12 months CCBT 33 38 11.48 (12.14) 9.0 (3.0–16.0) 0 58
CCBT+MCBT 33 36 14.39 (12.15) 14.0 (6.0–19.0) 0 45
CCBT+MCI 38 33 7.92 (6.58) 7.0 (3.0–13.0) 0 24
IQR, interquartile range.
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TABLE 120 Descriptive statistics: SDQ conduct questionnaires
Questionnaire Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
SDQ-c conduct
Score baseline CCBT 68 3 2.97 (2.01) 3.0 (1.0–4.0) 0 8
CCBT+MCBT 66 3 3.05 (1.88) 3.0 (2.0–4.0) 0 8
CCBT+MCI 70 1 2.84 (1.72) 3.0 (2.0–4.0) 0 8
Score 6 months CCBT 44 27 2.07 (1.61) 2.0 (1.0–3.0) 0 6
CCBT+MCBT 44 25 2.05 (1.38) 2.0 (1.0–3.0) 0 6
CCBT+MCI 43 28 2.14 (1.93) 2.0 (1.0–3.0) 0 6
Score 12 months CCBT 33 38 1.64 (1.48) 2.0 (0.0–3.0) 0 5
CCBT+MCBT 35 34 2.06 (1.66) 2.0 (1.0–2.0) 0 8
CCBT+MCI 39 32 1.95 (2.31) 1.0 (0.0–3.0) 0 8
SDQ-c/p conduct
Score baseline CCBT 65 6 2.46 (1.96) 2.0 (1.0–3.0) 0 8
CCBT+MCBT 65 4 3.05 (1.82) 3.0 (2.0–4.0) 0 9
CCBT+MCI 70 1 2.57 (1.88) 2.0 (1.0–4.0) 0 8
Score 6 months CCBT 41 30 2.00 (1.90) 2.0 (1.0–3.0) 0 8
CCBT+MCBT 43 26 1.77 (1.62) 1.0 (1.0–3.0) 0 6
CCBT+MCI 42 29 1.45 (1.40) 1.0 (0.0–2.0) 0 6
Score 12 months CCBT 34 37 1.26 (1.64) 1.0 (0.0–2.0) 0 8
CCBT+MCBT 34 35 1.97 (1.47) 2.0 (1.0–3.0) 0 5
CCBT+MCI 38 33 1.82 (2.04) 1.0 (0.0–3.0) 0 8
IQR, interquartile range.
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TABLE 121 Descriptive statistics: SMFQ questionnaires
Questionnaire Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
SMFQ-c
Total score baseline CCBT 67 4 7.81 (6.76) 5.0 (2.0–13.0) 0 24
CCBT+MCBT 68 1 9.03 (5.52) 8.5 (5.0–12.0) 0 24
CCBT+MCI 69 2 7.42 (5.70) 6.0 (3.0–10.0) 0 23
Total score 6 months CCBT 43 28 4.51 (5.29) 3.0 (0.0–7.0) 0 19
CCBT+MCBT 44 25 5.20 (4.99) 4.5 (0.5–10.0) 0 16
CCBT+MCI 41 30 4.00 (5.17) 1.0 (0.0–7.0) 0 22
Total score 12 months CCBT 31 40 3.00 (3.91) 1.0 (0.0–5.0) 0 12
CCBT+MCBT 35 34 4.31 (5.42) 3.0 (0.0–6.0) 0 25
CCBT+MCI 38 33 4.61 (6.74) 1.0 (0.0–6.0) 0 26
SMFQ-c/p
Total score baseline CCBT 59 12 9.39 (6.61) 7.0 (4.0–14.0) 0 24
CCBT+MCBT 58 11 10.74 (7.24) 10.0 (5.0–15.0) 0 26
CCBT+MCI 62 9 8.79 (7.25) 7.0 (3.0–14.0) 0 25
Total score 6 months CCBT 41 30 5.12 (5.81) 3.0 (1.0–9.0) 0 25
CCBT+MCBT 43 26 4.65 (5.25) 3.0 (1.0–7.0) 0 20
CCBT+MCI 42 29 4.33 (4.74) 3.5 (1.0–7.0) 0 23
Total score 12 months CCBT 34 37 4.06 (5.43) 1.5 (0.0–6.0) 0 20
CCBT+MCBT 34 35 6.29 (5.84) 5.0 (1.0–10.0) 0 22
CCBT+MCI 38 33 3.71 (4.78) 1.0 (0.0–6.0) 0 18
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TABLE 122 Summary of behavioural scores at baseline and assessment 2, and the change from baseline to
assessment 2
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
Positive behaviour
Difference
baseline–assessment 2
CCBT 42 0.01 (0.40) –0.01 (–0.26 to 0.35) –1.20 0.75
CCBT+MCBT 45 0.01 (0.33) 0.02 (–0.28 to 0.24) –0.57 0.94
CCBT+MCI 49 0.08 (0.42) 0.10 (–0.19 to 0.37) –1.19 1.04
Score 2 CCBT 42 3.17 (0.36) 3.22 (2.93 to 3.43) 2.32 3.82
CCBT+MCBT 45 3.07 (0.36) 3.04 (2.86 to 3.31) 2.30 3.96
CCBT+MCI 49 3.16 (0.47) 3.17 (2.95 to 3.49) 1.81 4.34
Total score baseline CCBT 42 3.16 (0.45) 3.14 (2.88 to 3.47) 2.08 4.03
CCBT+MCBT 45 3.06 (0.39) 3.04 (2.75 to 3.38) 2.29 4.03
CCBT+MCI 49 3.08 (0.55) 3.11 (2.74 to 3.39) 1.89 4.33
Overprotection
Difference
baseline–assessment 2
CCBT 42 –0.04 (0.18) 0.00 (–0.07 to 0.00) –1.00 0.28
CCBT+MCBT 45 –0.03 (0.10) 0.00 (–0.02 to 0.00) –0.33 0.22
CCBT+MCI 49 –0.04 (0.09) 0.00 (–0.07 to 0.00) –0.33 0.07
Score 2 CCBT 42 1.04 (0.10) 1.00 (1.00 to 1.00) 1.00 1.50
CCBT+MCBT 45 1.02 (0.05) 1.00 (1.00 to 1.00) 1.00 1.22
CCBT+MCI 49 1.01 (0.03) 1.00 (1.00 to 1.00) 1.00 1.11
Total score baseline CCBT 42 1.08 (0.17) 1.00 (1.00 to 1.11) 1.00 2.00
CCBT+MCBT 45 1.05 (0.09) 1.00 (1.00 to 1.08) 1.00 1.33
CCBT+MCI 49 1.05 (0.09) 1.00 (1.00 to 1.07) 1.00 1.33
Promotion of avoidance
Difference
baseline–assessment 2
CCBT 42 –0.04 (0.13) 0.00 (–0.11 to 0.00) –0.47 0.28
CCBT+MCBT 45 –0.01 (0.13) 0.00 (–0.07 to 0.00) –0.53 0.33
CCBT+MCI 49 –0.04 (0.11) 0.00 (–0.07 to 0.00) –0.40 0.13
Score 2 CCBT 42 1.06 (0.10) 1.00 (1.00 to 1.08) 1.00 1.44
CCBT+MCBT 45 1.05 (0.09) 1.00 (1.00 to 1.07) 1.00 1.33
CCBT+MCI 49 1.03 (0.06) 1.00 (1.00 to 1.07) 1.00 1.33
Total score baseline CCBT 42 1.10 (0.12) 1.08 (1.00 to 1.13) 1.00 1.47
CCBT+MCBT 45 1.06 (0.09) 1.00 (1.00 to 1.08) 1.00 1.53
CCBT+MCI 49 1.06 (0.10) 1.00 (1.00 to 1.11) 1.00 1.40
Intrusiveness
Difference
baseline–assessment 2
CCBT 42 –0.06 (0.47) –0.04 (–0.28 to 0.13) –1.45 1.28
CCBT+MCBT 45 0.01 (0.46) 0.05 (–0.14 to 0.28) –1.08 1.00
CCBT+MCI 49 –0.10 (0.46) –0.05 (–0.27 to 0.13) –1.43 0.87
Score 2 CCBT 42 1.52 (0.44) 1.48 (1.20 to 1.84) 1.00 2.88
CCBT+MCBT 45 1.60 (0.39) 1.47 (1.31 to 1.84) 1.00 2.45
CCBT+MCI 49 1.48 (0.38) 1.41 (1.13 to 1.78) 1.00 2.43
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TABLE 122 Summary of behavioural scores at baseline and assessment 2, and the change from baseline to
assessment 2 (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
Total score baseline CCBT 42 1.58 (0.52) 1.48 (1.16 to 1.88) 1.00 2.93
CCBT+MCBT 45 1.60 (0.50) 1.40 (1.20 to 1.87) 1.00 2.86
CCBT+MCI 49 1.58 (0.49) 1.51 (1.16 to 1.80) 1.00 2.99
Expressed anxiety
Difference
baseline–assessment 2
CCBT 42 0.03 (0.34) 0.04 (–0.23 to 0.22) –0.64 0.96
CCBT+MCBT 45 0.02 (0.38) –0.01 (–0.17 to 0.24) –1.16 0.94
CCBT+MCI 49 –0.04 (0.40) –0.04 (–0.26 to 0.19) –1.03 1.43
Score 2 CCBT 42 1.61 (0.36) 1.59 (1.37 to 1.73) 1.07 2.74
CCBT+MCBT 45 1.64 (0.41) 1.56 (1.33 to 1.92) 1.00 2.66
CCBT+MCI 49 1.59 (0.36) 1.57 (1.41 to 1.79) 1.00 2.96
Total score baseline CCBT 42 1.58 (0.27) 1.49 (1.37 to 1.75) 1.18 2.23
CCBT+MCBT 45 1.62 (0.33) 1.54 (1.40 to 1.86) 1.11 2.62
CCBT+MCI 49 1.63 (0.38) 1.53 (1.36 to 1.83) 1.00 2.60
Quality of relationship
Difference
baseline–assessment 2
CCBT 42 0.00 (0.36) 0.05 (–0.20 to 0.22) –0.83 0.87
CCBT+MCBT 45 0.06 (0.37) 0.04 (–0.13 to 0.30) –0.72 0.83
CCBT+MCI 49 0.01 (0.44) –0.02 (–0.33 to 0.31) –0.95 1.42
Score 2 CCBT 42 3.37 (0.33) 3.38 (3.17 to 3.63) 2.40 3.93
CCBT+MCBT 45 3.36 (0.42) 3.38 (3.13 to 3.67) 2.36 4.32
CCBT+MCI 49 3.34 (0.39) 3.33 (3.20 to 3.60) 2.36 4.13
Total score baseline CCBT 42 3.37 (0.40) 3.44 (3.04 to 3.67) 2.53 4.07
CCBT+MCBT 45 3.30 (0.42) 3.37 (2.93 to 3.56) 2.27 4.00
CCBT+MCI 49 3.33 (0.51) 3.40 (3.08 to 3.56) 1.91 4.55
POI
Difference
baseline–assessment 2
CCBT 34 –5.94 (10.15) –6.0 (–11.0 to 2.0) –36 9
CCBT+MCBT 38 –6.53 (11.26) –6.0 (–15.0 to 0.0) –32 35
CCBT+MCI 34 –10.35 (10.22) –8.5 (–15.0 to 4.0) –41 7
Score 2 CCBT 34 21.74 (13.27) 20.0 (12.0 to 32.0) 2 56
CCBT+MCBT 38 21.82 (13.87) 20.0 (10.0 to 28.0) 3 59
CCBT+MCI 34 17.76 (9.18) 16.5 (10.0 to 25.0) 1 39
Total score baseline CCBT 34 27.68 (13.45) 27.0 (17.0 to 40.0) 5 49
CCBT+MCBT 38 28.34 (11.58) 29.5 (20.0 to 35.0) 8 54
CCBT+MCI 34 28.12 (11.99) 27.5 (19.0 to 36.0) 4 54
IQR, interquartile range; POI, Parent Over-Involvement Questionnaire.
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TABLE 123 Summary of mothers’ self-report questionnaires at baseline and assessment 1B, and change from
baseline to assessment 1B
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
PSWQ
Difference
baseline–assessment 1B
CCBT 40 –3.4 (10.2) –2.5 (–7.0 to 2.5) –37 18
CCBT+MCBT 42 –5.3 (12.5) –1.5 (–12.0 to 3.0) –41 17
CCBT+MCI 44 –3.0 (8.0) –3.0 (–8.0 to 4.5) –20 9
Self-report total score
assessment 1B
CCBT 40 35.9 (13.8) 38.0 (25.0 to 47.0) 9 64
CCBT+MCBT 42 35.6 (14.3) 36.0 (25.0 to 45.0) 12 64
CCBT+MCI 44 33.9 (13.5) 35.0 (22.0 to 46.0) 3 59
Self-report total
score baseline
CCBT 40 39.2 (13.7) 41.5 (28.5 to 49.5) 15 64
CCBT+MCBT 42 40.9 (13.4) 42.0 (34.0 to 52.0) 6 62
CCBT+MCI 44 36.8 (13.2) 36.5 (28.5 to 45.5) 8 62
SIAS
Difference
baseline–assessment 1B
CCBT 41 –0.9 (8.4) –1.0 (–4.0 to 2.0) –23 22
CCBT+MCBT 44 –1.6 (8.7) –1.5 (–6.0 to 4.5) –28 15
CCBT+MCI 47 –0.1 (8.3) 0.0 (–6.0 to 5.0) –21 16
Self-report total score
assessment 1B
CCBT 41 22.9 (14.2) 21.0 (12.0 to 30.0) 3 67
CCBT+MCBT 44 25.0 (13.5) 25.0 (14.5 to 31.5) 4 63
CCBT+MCI 47 23.5 (14.6) 18.0 (13.0 to 36.0) 0 62
Self-report total
score baseline
CCBT 41 23.8 (12.8) 23.0 (14.0 to 31.0) 1 55
CCBT+MCBT 44 26.5 (15.4) 24.0 (13.5 to 38.5) 6 66
CCBT+MCI 47 23.7 (13.7) 22.0 (15.0 to 31.0) 0 61
SPS
Difference
baseline–assessment 1B
CCBT 41 –0.9 (9.5) 0.0 (–5.0 to 2.0) –31 26
CCBT+MCBT 45 –0.6 (7.2) 0.0 (–6.0 to 3.0) –16 18
CCBT+MCI 46 0.5 (7.3) 0.5 (–3.0 to 2.0) –22 22
Self-report total score
assessment 1B
CCBT 41 13.5 (12.4) 9.0 (4.0 to 20.0) 0 53
CCBT+MCBT 45 16.6 (14.1) 14.0 (6.0 to 26.0) 0 65
CCBT+MCI 46 13.7 (12.7) 10.0 (4.0 to 18.0) 0 47
Self-report total
score baseline
CCBT 41 14.4 (11.5) 12.0 (5.0 to 21.0) 0 42
CCBT+MCBT 45 17.2 (13.0) 15.0 (7.0 to 26.0) 0 47
CCBT+MCI 46 13.2 (11.7) 9.0 (4.0 to 22.0) 0 45
DASS-21
Depression score
difference
baseline–assessment 1B
CCBT 38 –1.7 (6.9) –1.0 (–6.0 to 0.0) –20 18
CCBT+MCBT 43 –1.9 (5.2) –2.0 (–6.0 to 0.0) –10 10
CCBT+MCI 45 –1.7 (5.6) –2.0 (–6.0 to 2.0) –16 10
Self-report depression
score assessment 1B
CCBT 38 10.0 (9.6) 8.0 (4.0 to 14.0) 0 42
CCBT+MCBT 43 9.8 (9.7) 8.0 (2.0 to 14.0) 0 36
CCBT+MCI 45 10.2 (8.0) 8.0 (4.0 to 14.0) 0 32
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TABLE 123 Summary of mothers’ self-report questionnaires at baseline and assessment 1B, and change from
baseline to assessment 1B (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
Self-report depression
score baseline
CCBT 38 11.7 (8.8) 10.0 (6.0 to 14.0) 0 40
CCBT+MCBT 43 11.7 (9.2) 8.0 (6.0 to 18.0) 0 40
CCBT+MCI 45 11.9 (10.3) 10.0 (4.0 to 16.0) 0 42
Anxiety score difference
baseline–assessment 1B
CCBT 38 –0.3 (6.1) 0.0 (–2.0 to 2.0) –16 16
CCBT+MCBT 44 –2.3 (6.7) –2.0 (–6.0 to 2.0) –22 12
CCBT+MCI 45 –1.7 (6.8) –2.0 (–4.0 to 2.0) –30 12
Self-report anxiety score
assessment 1B
CCBT 38 7.3 (9.0) 6.0 (0.0 to 8.0) 0 40
CCBT+MCBT 44 8.2 (8.2) 6.0 (2.0 to 12.0) 0 36
CCBT+MCI 45 7.1 (8.1) 4.0 (2.0 to 8.0) 0 32
Self-report anxiety
score baseline
CCBT 38 7.6 (7.3) 5.0 (0.0 to 14.0) 0 24
CCBT+MCBT 44 10.5 (8.0) 9.0 (4.0 to 16.0) 0 34
CCBT+MCI 45 8.8 (8.4) 6.0 (2.0 to 14.0) 0 34
Stress score difference
baseline–assessment 1B
CCBT 41 –1.4 (6.7) –2.0 (–6.0 to 2.0) –16 14
CCBT+MCBT 45 –1.9 (9.1) –2.0 (–8.0 to 2.0) –20 28
CCBT+MCI 45 –0.7 (5.9) –2.0 (–4.0 to 2.0) –16 16
Self-report stress score
assessment 1B
CCBT 41 16.0 (9.9) 16.0 (10.0 to 22.0) 0 42
CCBT+MCBT 45 16.0 (9.3) 14.0 (8.0 to 22.0) 0 40
CCBT+MCI 45 15.4 (8.2) 16.0 (8.0 to 22.0) 0 32
Self-report stress
score baseline
CCBT 41 17.3 (10.1) 16.0 (10.0 to 22.0) 0 42
CCBT+MCBT 45 17.9 (9.9) 18.0 (10.0 to 22.0) 2 42
CCBT+MCI 45 16.1 (9.0) 14.0 (10.0 to 22.0) 0 40
IQR, interquartile range.
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TABLE 124 Summary of mothers’ self-report questionnaires at baseline and assessment 2, and change from
baseline to assessment 2
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
PSWQ
Difference
baseline–assessment 2
CCBT 35 –6.9 (12.0) –6.0 (–13.0 to –1.0) –40 21
CCBT+MCBT 41 –7.3 (12.5) –5.0 (–14.0 to 1.0) –37 13
CCBT+MCI 35 –6.0 (9.3) –8.0 (–11.0 to –2.0) –23 16
Self-report total score 2 CCBT 35 31.5 (13.7) 29.0 (19.0 to 42.0) 10 59
CCBT+MCBT 41 33.3 (15.2) 33.0 (23.0 to 43.0) 1 64
CCBT+MCI 35 30.9 (12.9) 30.0 (22.0 to 43.0) 2 54
Self-report total
score baseline
CCBT 35 38.4 (13.2) 41.0 (29.0 to 49.0) 15 60
CCBT+MCBT 41 40.6 (12.9) 42.0 (34.0 to 50.0) 6 64
CCBT+MCI 35 36.9 (13.7) 36.0 (28.0 to 47.0) 8 64
SIAS
Difference
baseline–assessment 2
CCBT 34 –2.9 (10.8) –4.0 (–8.0 to –1.0) –35 28
CCBT+MCBT 40 –5.5 (13.5) –2.0 (–11.5 to 3.0) –41 17
CCBT+MCI 36 –4.5 (8.0) –5.5 (–10.0 to 0.0) –29 16
Self-report total score 2 CCBT 34 20.5 (14.7) 17.0 (11.0 to 30.0) 0 66
CCBT+MCBT 40 22.3 (14.5) 16.5 (12.5 to 29.0) 3 65
CCBT+MCI 36 19.1 (12.8) 17.0 (10.5 to 29.0) 0 48
Self-report total
score baseline
CCBT 34 23.4 (13.4) 31.0 (22.5 to 31.0) 1 55
CCBT+MCBT 40 27.9 (15.8) 26.5 (14.0 to 39.0) 6 66
CCBT+MCI 36 23.7 (14.4) 22.5 (14.0 to 29.0) 0 61
SPS
Difference
baseline–assessment 2
CCBT 35 –3.6 (8.0) –3.0 (–8.0 to –1.0) –21 18
CCBT+MCBT 41 –4.7 (7.9) –3.0 (–9.0 to 0.0) –28 12
CCBT+MCI 36 –1.8 (7.1) –2.0 (–7.0 to 1.0) –16 28
Self-report total score 2 CCBT 35 9.7 (9.7) 7.0 (2.0 to 13.0) 0 45
CCBT+MCBT 41 11.8 (11.5) 8.0 (3.0 to 16.0) 0 52
CCBT+MCI 36 11.0 (10.9) 6.0 (3.0 to 19.5) 0 43
Self-report total
score baseline
CCBT 35 13.3 (10.9) 12.0 (5.0 to 18.0) 0 42
CCBT+MCBT 41 16.5 (12.7) 14.0 (7.0 to 23.0) 0 47
CCBT+MCI 36 12.8 (11.3) 9.5 (3.5 to 19.0) 0 45
DASS-21
Depression score
difference
baseline–assessment 2
CCBT 32 –3.2 (8.8) –4.0 (–1.00 to 1.0) –24 18
CCBT+MCBT 36 –4.0 (7.0) –4.0 (–6.0 to 0.0) –20 14
CCBT+MCI 33 –2.1 (5.2) –2.0 (–4.0 to 0.0) –14 8
Self-report depression
score assessment 2
CCBT 32 8.9 (10.6) 4.0 (2.0 to 14.0) 0 42
CCBT+MCBT 36 8.2 (8.8) 6.0 (2.0 to 12.0) 0 40
CCBT+MCI 33 7.8 (7.3) 6.0 (2.0 to 14.0) 0 26
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TABLE 124 Summary of mothers’ self-report questionnaires at baseline and assessment 2, and change from
baseline to assessment 2 (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
Self-report depression
score baseline
CCBT 32 12.1 (10.2) 10.0 (4.0 to 17.0) 0 40
CCBT+MCBT 36 12.1 (8.8) 9.0 (6.0 to 17.0) 2 40
CCBT+MCI 33 9.9 (8.2) 10.0 (4.0 to 14.0) 0 28
Anxiety score difference
baseline–assessment 2
CCBT 32 –0.6 (7.4) –2.0 (–4.0 to 2.0) –20 18
CCBT+MCBT 36 –3.1 (6.8) –4.0 (–7.0 to 0.0) –14 26
CCBT+MCI 33 –2.0 (5.0) –2.0 (–4.0 to 0.0) –14 12
Self-report anxiety score
assessment 2
CCBT 32 7.3 (10.3) 3.0 (0.0 to 9.0) 0 42
CCBT+MCBT 36 6.7 (8.0) 5.0 (0.0 to 11.0) 0 40
CCBT+MCI 33 4.5 (5.3) 2.0 (0.0 to 8.0) 0 16
Self-report anxiety
score baseline
CCBT 32 7.9 (8.0) 5.0 (2.0 to 14.0) 0 30
CCBT+MCBT 36 9.8 (6.8) 9.0 (4.0 to 15.0) 0 24
CCBT+MCI 33 6.5 (5.0) 6.0 (2.0 to 10.0) 0 18
Stress score difference
baseline–assessment 2
CCBT 34 –3.8 (8.0) –4.0 (–8.0 to 0.0) –22 14
CCBT+MCBT 41 –2.5 (6.5) –4.0 (–6.0 to 0.0) –14 12
CCBT+MCI 35 –2.5 (6.7) –2.0 (–6.0 to 0.0) –16 12
Self-report stress score
assessment 2
CCBT 34 12.9 (9.2) 11.0 (6.0 to 20.0) 0 32
CCBT+MCBT 41 14.7 (9.4) 14.0 (10.0 to 18.0) 0 42
CCBT+MCI 35 12.1 (8.8) 12.0 (4.0 to 20.0) 0 28
Self-report stress
score baseline
CCBT 34 16.7 (9.7) 16.0 (10.0 to 22.0) 0 40
CCBT+MCBT 41 17.2 (8.4) 18.0 (12.0 to 22.0) 2 36
CCBT+MCI 35 14.6 (8.2) 12.0 (8.0 to 20.0) 0 32
IQR, interquartile range.
TABLE 125 Summary of cognition scores at baseline and assessment 2, and the change from baseline to
assessment 2
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
Pre-task ‘child scared’
Difference
baseline–assessment 2
CCBT 40 –0.70 (1.78) –0.67 (–2.00 to 0.33) –3.67 4.00
CCBT+MCBT 45 –1.10 (1.62) –1.00 (–1.67 to 0.00) –6.33 1.67
CCBT+MCI 46 –1.47 (1.55) –1.33 (–2.33 to –0.33) –5.33 1.00
Score post treatment CCBT 40 3.62 (1.58) 3.33 (2.50 to 5.00) 1.00 7.67
CCBT+MCBT 45 3.10 (1.57) 3.00 (1.67 to 4.33) 0.00 7.00
CCBT+MCI 46 3.18 (1.69) 3.33 (2.00 to 4.33) 0.00 6.67
Total score baseline CCBT 40 4.31 (1.86) 4.33 (3.00 to 5.50) 0.50 8.33
CCBT+MCBT 45 4.21 (1.81) 4.00 (3.00 to 5.33) 0.33 8.33
CCBT+MCI 46 4.65 (1.82) 4.67 (3.67 to 6.00) 0.00 8.33
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TABLE 125 Summary of cognition scores at baseline and assessment 2, and the change from baseline to
assessment 2 (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
Pre-task ‘mother anxious’
Difference
baseline–assessment 2
CCBT 40 –0.85 (1.63) –1.00 (–2.33 to 0.00) –3.33 3.33
CCBT+MCBT 45 –1.46 (1.95) –1.33 (–2.67 to 0.00) –7.00 2.33
CCBT+MCI 46 –1.42 (1.73) –1.33 (–2.67 to –0.33) –5.67 2.33
Score post treatment CCBT 40 3.03 (1.41) 3.00 (2.00 to 4.00) 0.00 6.67
CCBT+MCBT 45 2.56 (1.89) 2.33 (1.33 to 3.33) 0.00 8.67
CCBT+MCI 46 2.52 (1.81) 2.50 (1.00 to 3.67) 0.00 7.00
Total score baseline CCBT 40 3.88 (1.74) 4.17 (3.00 to 5.17) 0.00 7.67
CCBT+MCBT 45 4.02 (1.91) 4.33 (2.67 to 5.33) 0.00 8.00
CCBT+MCI 46 3.95 (2.05) 3.83 (2.00 to 5.67) 0.33 8.00
Pre-task ‘child in control’
Difference
baseline–assessment 2
CCBT 40 0.16 (1.04) 0.33 (–0.42 to 0.92) –2.17 1.83
CCBT+MCBT 45 0.83 (1.55) 0.83 (0.17 to 1.50) –5.50 4.50
CCBT+MCI 46 0.78 (1.41) 1.00 (–0.17 to 1.67) –4.17 4.17
Score post treatment CCBT 40 6.93 (1.47) 7.08 (6.33 to 8.00) 3.17 10.00
CCBT+MCBT 45 7.32 (1.36) 7.50 (6.83 to 8.17) 3.00 9.50
CCBT+MCI 46 7.49 (1.22) 7.42 (7.00 to 8.50) 4.33 9.83
Total score baseline CCBT 40 6.77 (1.26) 6.83 (6.17 to 7.50) 4.00 9.33
CCBT+MCBT 45 6.49 (1.58) 6.33 (5.50 to 7.67) 2.17 9.17
CCBT+MCI 46 6.71 (1.13) 6.67 (5.83 to 7.50) 4.67 9.17
Pre-task ‘mother in control’
Difference
baseline–assessment 2
CCBT 40 –0.18 (1.52) –0.17 (–1.08 to 0.58) –3.83 3.00
CCBT+MCBT 45 –0.19 (1.73) 0.00 (–1.50 to 0.67) –3.67 3.17
CCBT+MCI 46 –0.06 (1.92) 0.17 (–1.33 to 1.17) –4.00 3.67
Score post treatment CCBT 40 4.61 (1.60) 4.83 (3.33 to 5.58) 1.00 7.50
CCBT+MCBT 45 5.15 (2.48) 5.67 (2.83 to 7.17) 0.33 8.67
CCBT+MCI 46 4.91 (1.69) 5.21 (3.67 to 6.17) 0.83 8.33
Total score baseline CCBT 40 4.79 (1.65) 5.08 (3.75 to 6.00) 0.50 7.67
CCBT+MCBT 45 5.33 (1.96) 5.17 (4.00 to 6.83) 1.17 10.00
CCBT+MCI 46 4.98 (1.73) 5.25 (3.67 to 6.33) 1.25 7.83
IQR, interquartile range.
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TABLE 126 Summary of child scores at baseline and assessment 2, and the change from baseline to assessment 2
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
SCAS-c
Difference
baseline–assessment 2
CCBT 45 –19.5 (17.2) –17.0 (–29.0 to –8.0) –68 13
CCBT+MCBT 46 –15.0 (11.6) –16.0 (–23.0 to –8.0) –37 12
CCBT+MCI 52 –14.7 (20.0) –14.5 (–24.5 to –2.5) –72 20
Total score post
treatment
CCBT 45 21.0 (15.3) 15.0 (11.0 to 30.0) 0 86
CCBT+MCBT 46 28.3 (15.2) 25.5 (16.0 to 41.0) 0 69
CCBT+MCI 52 24.9 (15.2) 23.0 (13.5 to 34.5) 0 65
Total score baseline CCBT 45 40.4 (21.7) 35.0 (24.0 to 53.0) 2 105
CCBT+MCBT 46 43.3 (17.6) 40.0 (31.0 to 58.0) 8 80
CCBT+MCI 52 39.6 (18.9) 40.0 (29.0 to 48.5) 4 92
CAIS-c
Difference
baseline–assessment 2
CCBT 44 –7.0 (17.3) –8.0 (–17.0 to –1.0) –35 52
CCBT+MCBT 45 –8.4 (15.9) –7.0 (–11.0 to –2.0) –49 53
CCBT+MCI 53 –5.6 (15.9) –6.0 (–14.0 to 0.0) –48 70
Total score post
treatment
CCBT 44 10.8 (12.2) 8.0 (3.0 to 13.0) 0 58
CCBT+MCBT 45 13.8 (13.2) 11.0 (4.0 to 21.0) 0 58
CCBT+MCI 53 12.4 (14.4) 8.0 (3.0 to 16.0) 0 78
Total score baseline CCBT 44 17.8 (12.5) 18.0 (8.5 to 24.5) 1 58
CCBT+MCBT 45 22.2 (15.9) 17.0 (10.0 to 32.0) 1 60
CCBT+MCI 53 18.1 (13.2) 15.0 (7.0 to 27.0) 0 63
SMFQ-c
Difference
baseline–assessment 2
CCBT 46 –4.9 (6.0) –3.0 (–7.0 to –1.0) –20 2
CCBT+MCBT 47 –2.8 (4.7) –3.0 (–5.0 to –1.0) –12 12
CCBT+MCI 54 –2.3 (5.7) –2.0 (–5.0 to 1.0) –15 15
Total score post
treatment
CCBT 46 2.7 (4.0) 1.5 (0.0 to 4.0) 0 23
CCBT+MCBT 47 6.0 (5.5) 4.0 (1.0 to 9.0) 0 24
CCBT+MCI 54 5.0 (5.7) 3.0 (0.0 to 8.0) 0 25
Total score baseline CCBT 46 7.6 (6.6) 5.0 (2.0 to 11.0) 0 24
CCBT+MCBT 47 8.8 (4.9) 8.0 (5.0 to 12.0) 0 22
CCBT+MCI 54 7.3 (5.6) 7.0 (3.0 to 11.0) 0 23
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TABLE 126 Summary of child scores at baseline and assessment 2, and the change from baseline to
assessment 2 (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
SDQ-c conduct problems scale
Difference
baseline–assessment 2
CCBT 47 –0.6 (1.6) –1.0 (–2.0 to 0.0) –4 1
CCBT+MCBT 47 –0.6 (2.0) 0.0 (–2.0 to 1.0) –5 3
CCBT+MCI 55 –0.5 (1.8) –1.0 (–1.0 to 0.0) –4 5
Total score post
treatment
CCBT 47 2.2 (1.6) 2.0 (1.0 to 3.0) 0 8
CCBT+MCBT 47 2.4 (2.0) 2.0 (1.0 to 4.0) 0 8
CCBT+MCI 55 2.3 (2.0) 2.0 (0.0 to 3.0) 0 7
Total score baseline CCBT 47 2.8 (1.8) 3.0 (1.0 to 4.0) 0 7
CCBT+MCBT 47 3.0 (1.9) 3.0 (2.0 to 4.0) 0 8
CCBT+MCI 55 2.8 (1.6) 3.0 (2.0 to 4.0) 0 7
IQR, interquartile range.
TABLE 127 Summary of mothers’ questionnaire scores at baseline and assessment 2, and the change from baseline
to assessment 2
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
SCAS-p
Difference
baseline–assessment 2
CCBT 36 –18.3 (10.9) –16.5 (–27.0 to –11.5) –36 12
CCBT+MCBT 39 –17.5 (12.2) –21.0 (–25.0 to –7.0) –38 10
CCBT+MCI 38 –17.3 (11.5) –16.0 (–24.0 to –9.0) –46 5
Total score post
treatment
CCBT 36 23.8 (14.5) 20.0 (14.0 to 29.0) 3 80
CCBT+MCBT 39 26.0 (15.0) 24.0 (14.0 to 33.0) 2 62
CCBT+MCI 38 23.8 (8.7) 23.5 (19.0 to 28.0) 6 41
Total score baseline CCBT 36 42.0 (15.3) 41.5 (32.0 to 47.0) 16 94
CCBT+MCBT 39 43.5 (17.2) 38.0 (32.0 to 57.0) 17 82
CCBT+MCI 38 41.1 (13.3) 41.0 (30.0 to 50.0) 17 81
CAIS-p
Difference
baseline–assessment 2
CCBT 33 –10.5 (8.9) –9.0 (–15.0 to –5.0) –34 5
CCBT+MCBT 35 –14.5 (10.5) –16.0 (–19.0 to –6.0) –45 2
CCBT+MCI 31 –8.1 (8.5) –8.0 (–14.0 to 0.0) –26 8
Total score post
treatment
CCBT 33 12.6 (12.0) 8.0 (3.0 to 18.0) 0 48
CCBT+MCBT 35 11.2 (10.7) 9.0 (4.0 to 14.0) 0 38
CCBT+MCI 31 11.4 (8.2) 11.0 (4.0 to 15.0) 1 33
Total score baseline CCBT 33 23.1 (16.7) 18.0 (10.0 to 32.0) 1 66
CCBT+MCBT 35 25.7 (16.2) 25.0 (12.0 to 35.0) 0 60
CCBT+MCI 31 19.5 (11.9) 17.0 (10.0 to 28.0) 2 52
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TABLE 127 Summary of mothers’ questionnaire scores at baseline and assessment 2, and the change from baseline
to assessment 2 (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
SMFQ-p
Difference
baseline–assessment 2
CCBT 34 –4.1 (7.4) –4.0 (–6.0 to 0.0) –23 8
CCBT+MCBT 38 –6.8 (5.6) –6.0 (–10.0 to –3.0) –23 5
CCBT+MCI 35 –4.9 (6.6) –3.0 (–9.0 to 0.0) –23 5
Total score post
treatment
CCBT 34 4.7 (5.1) 2.5 (1.0 to 8.0) 0 19
CCBT+MCBT 38 4.6 (5.7) 2.5 (0.0 to 6.0) 0 22
CCBT+MCI 35 3.9 (4.1) 2.0 (0.0 to 8.0) 0 14
Total score baseline CCBT 34 8.8 (7.3) 6.0 (4.0 to 14.0) 0 24
CCBT+MCBT 38 11.3 (7.7) 10.0 (5.0 to 16.0) 0 26
CCBT+MCI 35 8.9 (7.3) 7.0 (2.0 to 14.0) 0 23
SDQ-p conduct problems scale
Difference
baseline–assessment 2
CCBT 37 –0.5 (1.6) –1.0 (–1.0 to 0.0) –6 3
CCBT+MCBT 41 –0.9 (1.3) –1.0 (–2.0 to 0.0) –4 3
CCBT+MCI 40 –0.9 (1.4) –1.0 (–1.0 to 0.0) –6 1
Total score post
treatment
CCBT 37 1.7 (1.6) 1.0 (1.0 to 2.0) 0 8
CCBT+MCBT 41 1.9 (1.7) 2.0 (0.0 to 3.0) 0 6
CCBT+MCI 40 1.7 (1.8) 1.0 (0.0 to 2.5) 0 7
Total score baseline CCBT 37 2.2 (1.7) 2.0 (1.0 to 3.0) 0 8
CCBT+MCBT 41 2.8 (1.9) 3.0 (2.0 to 4.0) 0 9
CCBT+MCI 40 2.6 (2.0) 2.0 (1.0 to 4.0) 0 8
IQR, interquartile range.
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TABLE 128 Summary of teachers’ questionnaire scores at baseline and assessment 2, and the change from baseline
to assessment 2
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
SCAS-t
Difference baseline–assessment 2 CCBT 7 –6.1 (9.4) –8.0 (–16.0 to 0.0) –18 8
CCBT+MCBT 14 –3.3 (12.1) –2.5 (–9.0 to 4.0) –34 21
CCBT+MCI 12 –6.0 (11.7) –5.0 (–7.0 to –0.5) –30 14
Total score post treatment CCBT 7 13.4 (11.5) 10.0 (7.0 to 25.0) 0 33
CCBT+MCBT 14 10.7 (9.4) 8.0 (7.0 to 10.0) 0 37
CCBT+MCI 12 12.4 (11.9) 9.0 (5.5 to 16.0) 1 46
Total score baseline CCBT 7 19.6 (19.5) 15.0 (2.0 to 43.0) 0 49
CCBT+MCBT 14 14.0 (12.2) 9.5 (5.0 to 16.0) 3 42
CCBT+MCI 12 18.4 (13.2) 11.5 (8.0 to 29.0) 4 40
CAS-t
Difference baseline–assessment 2 CCBT 18 –1.6 (3.8) –1.0 (–3.0 to 0.0) –11 5
CCBT+MCBT 24 –1.3 (4.6) –2.0 (–3.0 to 1.0) –16 8
CCBT+MCI 25 –1.4 (4.2) –2.0 (–4.0 to 2.0) –9 7
Total score post treatment CCBT 18 5.3 (4.3) 5.0 (2.0 to 8.0) 0 15
CCBT+MCBT 24 3.4 (2.9) 3.0 (0.5 to 6.0) 0 9
CCBT+MCI 25 3.8 (3.8) 3.0 (1.0 to 5.0) 0 16
Total score baseline CCBT 18 6.9 (5.2) 5.5 (3.0 to 10.0) 0 16
CCBT+MCBT 24 4.7 (4.2) 4.5 (1.0 to 6.0) 0 16
CCBT+MCI 25 5.1 (4.3) 5.0 (2.0 to 8.0) 0 14
SDQ-t conduct problems scale
Difference baseline–assessment 2 CCBT 18 0.4 (0.7) 0.0 (0.0 to 1.0) 0 2
CCBT+MCBT 22 –0.3 (1.5) 0.0 (–1.0 to 1.0) –4 3
CCBT+MCI 23 –0.1 (1.2) 0.0 (0.0 to 0.0) –3 3
Total score post treatment CCBT 18 1.2 (1.8) 0.5 (0.0 to 2.0) 0 7
CCBT+MCBT 22 1.1 (2.1) 0.0 (0.0 to 1.0) 0 8
CCBT+MCI 23 0.8 (1.7) 0.0 (0.0 to 1.0) 0 7
Total score baseline CCBT 18 0.7 (1.2) 0.0 (0.0 to 1.0) 0 5
CCBT+MCBT 22 1.4 (2.3) 0.5 (0.0 to 2.0) 0 10
CCBT+MCI 23 0.9 (1.7) 0.0 (0.0 to 1.0) 0 6
IQR, interquartile range.
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Questionnaires: assessment 2 – data summaries by treatment
arm (all available participants)
TABLE 129 Descriptive statistics: SCAS questionnaires post treatment
Questionnaire
subscale Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
SCAS-c total score
post treatment
CCBT 49 22 21.0 (15.6) 15.0 (10.0–30.0) 0 86
CCBT+MCBT 47 22 29.1 (16.0) 26.0 (16.0–42.0) 0 69
CCBT+MCI 54 17 25.3 (15.5) 23.0 (14.0–35.0) 0 65
SCAS-p total score
post treatment
CCBT 40 31 23.3 (13.8) 20.0 (14.5–28.5) 3 80
CCBT+MCBT 41 28 25.5 (14.8) 22.0 (14.0–32.0) 2 62
CCBT+MCI 40 31 23.9 (8.7) 23.5 (19.0–28.0) 6 41
SCAS-t total score
post treatment
CCBT 18 53 11.9 (10.3) 8.5 (5.0–16.0) 0 36
CCBT+MCBT 22 47 12.2 (9.1) 9.0 (7.0–17.0) 0 37
CCBT+MCI 19 52 15.7 (12.8) 9.0 (7.0–20.0) 1 46
IQR, interquartile range.
TABLE 130 Descriptive statistics: CAIS questionnaires post treatment
Questionnaire
subscale Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
CAIS-c total score
post treatment
CCBT 49 22 10.9 (12.5) 8.0 (2.0–13.0) 0 58
CCBT+MCBT 45 24 13.8 (13.2) 11.0 (4.0–21.0) 0 58
CCBT+MCI 56 15 12.5 (14.1) 9.5 (3.0–16.0) 0 78
CAIS-p total score
post treatment
CCBT 39 32 12.3 (11.3) 8.0 (4.0–19.0) 0 48
CCBT+MCBT 42 27 12.5 (10.9) 10.0 (5.0–16.0) 0 38
CCBT+MCI 41 30 10.9 (8.2) 11.0 (4.0–15.0) 1 33
IQR, interquartile range.
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TABLE 131 Descriptive statistics: SDQ and SMFQ questionnaires post treatment
Questionnaire
subscale Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
SDQ-c conduct
problems scale
post treatment
CCBT 50 21 2.2 (1.6) 2.0 (1.0–3.0) 0 8
CCBT+MCBT 48 21 2.4 (2.0) 2.0 (1.0–4.0) 0 8
CCBT+MCI 56 15 2.3 (2.0) 2.0 (0.5–3.0) 0 7
SDQ-p conduct
problems scale
post treatment
CCBT 40 31 1.7 (1.6) 1.5 (0.5–2.0) 0 8
CCBT+MCBT 44 25 2.0 (1.7) 2.0 (0.5–3.0) 0 6
CCBT+MCI 41 30 1.7 (1.8) 1.0 (0.0–2.0) 0 7
SDQ-t conduct
problems scale
post treatment
CCBT 23 48 1.1 (1.7) 0.0 (0.0–2.0) 0 7
CCBT+MCBT 27 42 1.0 (2.0) 0.0 (0.0–1.0) 0 8
CCBT+MCI 31 40 0.9 (1.6) 0.0 (0.0–2.0) 0 7
SMFQ-c total score
post treatment
CCBT 50 21 3.1 (4.4) 1.5 (0.0–5.0) 0 23
CCBT+MCBT 48 21 6.3 (5.8) 4.0 (1.5–9.5) 0 24
CCBT+MCI 56 15 4.9 (5.6) 3.0 (0.0–8.0) 0 25
SMFQ-p total score
post treatment
CCBT 40 31 4.2 (4.9) 2.0 (0.0–6.5) 0 19
CCBT+MCBT 43 26 5.3 (5.9) 3.0 (1.0–8.0) 0 22
CCBT+MCI 42 29 4.0 (4.5) 2.0 (0.0–7.0) 0 18
IQR, interquartile range.
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Questionnaire baseline results by treatment arm (all available
participants)
TABLE 133 Descriptive statistics: SCAS questionnaires baseline
Questionnaire
subscale Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
SCAS-c total score
post baseline
CCBT 67 4 40.2 (21.3) 35.0 (24.0–53.0) 2 105
CCBT+MCBT 67 2 41.3 (18.3) 41.0 (29.0–56.0) 7 80
CCBT+MCI 69 2 39.2 (17.4) 39.0 (29.0–47.0) 4 92
SCAS-p total
score baseline
CCBT 64 7 43.2 (15.6) 43.0 (32.5–50.0) 16 94
CCBT+MCBT 63 6 42.2 (15.5) 39.0 (32.0–50.0) 17 82
CCBT+MCI 65 6 41.6 (16.7) 40.0 (29.0–52.0) 16 94
SCAS-t total
score baseline
CCBT 25 46 17.6 (13.4) 15.0 (10.0–22.0) 0 49
CCBT+MCBT 37 32 14.4 (14.6) 9.0 (5.0–16.0) 1 66
CCBT+MCI 42 29 18.7 (13.0) 15.0 (10.0–26.0) 0 47
IQR, interquartile range.
TABLE 134 Descriptive statistics: CAIS questionnaires baseline
Questionnaire
subscale Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
CAIS-c total
score baseline
CCBT 66 5 18.3 (12.8) 16.5 (9.0–24.0) 1 58
CCBT+MCBT 67 2 23.1 (16.3) 20.0 (10.0–37.0) 0 70
CCBT+MCI 68 3 18.9 (14.0) 15.0 (7.5–28.0) 0 63
CAIS-p total
score baseline
CCBT 58 13 23.2 (16.0) 18.5 (11.0–32.0) 1 66
CCBT+MCBT 56 13 25.5 (15.1) 25.0 (15.0–34.5) 0 60
CCBT+MCI 58 13 20.6 (12.7) 17.0 (10.0–28.0) 1 58
IQR, interquartile range.
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TABLE 135 Descriptive statistics: SDQ and SMFQ baseline
Questionnaire
subscale Treatment n n missing Mean (SD) Median (IQR) Minimum Maximum
SDQ-c conduct
problems
scale baseline
CCBT 68 3 3.0 (2.0) 3.0 (1.0–4.0) 0 8
CCBT+MCBT 66 3 3.0 (1.9) 3.0 (2.0–4.0) 0 8
CCBT+MCI 70 1 2.8 (1.7) 3.0 (2.0–4.0) 0 8
SDQ-p conduct
problems
scale baseline
CCBT 65 6 2.5 (2.0) 2.0 (1.0–3.0) 0 8
CCBT+MCBT 65 4 3.0 (1.8) 3.0 (2.0–4.0) 0 9
CCBT+MCI 70 1 2.6 (1.9) 2.0 (1.0–4.0) 0 8
SDQ-t conduct
problems
scale baseline
CCBT 44 27 0.9 (1.5) 0.0 (0.0–1.0) 0 6
CCBT+MCBT 54 15 1.2 (1.9) 0.0 (0.0–2.0) 0 10
CCBT+MCI 56 15 1.8 (1.5) 0.0 (0.0–1.0) 0 6
SMFQ-c total
score baseline
CCBT 67 4 7.8 (6.8) 5.0 (2.0–13.0) 0 24
CCBT+MCBT 68 1 9.0 (5.5) 8.5 (5.0–12.0) 0 24
CCBT+MCI 69 2 7.4 (5.7) 6.0 (3.0–10.0) 0 23
SMFQ-p report total
score baseline
CCBT 59 12 9.4 (6.6) 7.0 (4.0–14.0) 0 24
CCBT+MCBT 58 11 10.7 (7.2) 10.0 (5.0–15.0) 0 26
CCBT+MCI 62 9 8.8 (7.2) 7.0 (3.0–14.0) 0 25
IQR, interquartile range.
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Summary of questionnaire scores at different time points by
treatment arm
TABLE 136 Summary of child-reported questionnaire scores at baseline, 6 months, and change from baseline to
6 months
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
CAIS-c
Total score difference
baseline–6 months
CCBT 38 –10.87 (13.07) –11.0 (–20.0 to 1.0) –37 15
CCBT+MCBT 43 –13.86 (15.74) –11.0 (–21.0 to –5.0) –62 13
CCBT+MCI 41 –9.56 (13.48) –9.0 (–17.0 to 0.0) –47 13
Total score 6 months CCBT 38 7.37 (7.01) 5.5 (2.0 to 11.0) 0 27
CCBT+MCBT 43 10.02 (8.56) 8.0 (3.0 to 14.0) 0 29
CCBT+MCI 41 9.63 (9.35) 7.0 (2.0 to 15.0) 0 39
Total score baseline CCBT 38 18.24 (13.10) 18.0 (9.0 to 25.0) 1 58
CCBT+MCBT 43 23.88 (16.41) 21.0 (11.0 to 37.0) 1 70
CCBT+MCI 41 19.20 (13.44) 18.0 (8.0 to 27.0) 0 63
SCAS-c
Total score difference
baseline–6 months
CCBT 41 –17.80 (17.91) –15.0 (–28.0 to –6.0) –61 13
CCBT+MCBT 43 –17.47 (16.35) –18.0 (–26.0 to –6.0) –51 29
CCBT+MCI 41 –16.83 (21.80) –13.0 (–28.0 to –5.0) –70 22
Total score 6 months CCBT 41 22.20 (16.22) 19.0 (10.0 to 30.0) 0 73
CCBT+MCBT 43 24.42 (17.41) 19.0 (12.0 to 39.0) 0 63
CCBT+MCI 41 23.73 (17.51) 22.0 (9.0 to 30.0) 1 67
Total score baseline CCBT 41 40.00 (21.60) 35.0 (24.0 to 53.0) 2 105
CCBT+MCBT 43 41.88 (16.63) 39.0 (31.0 to 54.0) 10 80
CCBT+MCI 41 40.56 (18.60) 42.0 (30.0 to 48.0) 11 92
SDQ-c conduct subscale
Total score difference
baseline–6 months
CCBT 42 –0.86 (1.76) –1.0 (–2.0 to 0.0) –4 3
CCBT+MCBT 44 –0.89 (2.08) –1.0 (–2.0 to 1.0) –6 3
CCBT+MCI 42 –0.86 (1.47) –1.0 (–2.0 to 0.0) –4 2
Total score 6 months CCBT 42 2.10 (1.64) 2.0 (1.0 to 3.0) 0 6
CCBT+MCBT 44 2.05 (1.38) 2.0 (1.0 to 3.0) 0 6
CCBT+MCI 42 2.17 (1.95) 2.0 (1.0 to 3.0) 0 6
Total score baseline CCBT 42 2.95 (1.82) 3.0 (1.0 to 4.0) 0 8
CCBT+MCBT 44 2.93 (1.90) 3.0 (1.5 to 4.5) 0 8
CCBT+MCI 42 3.02 (1.79) 3.0 (2.0 to 4.0) 0 8
continued
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TABLE 136 Summary of child-reported questionnaire scores at baseline, 6 months, and change from baseline to
6 months (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
SMFQ-c
Total score difference
baseline–6 months
CCBT 40 –3.45 (6.49) –2.0 (–5.5 to 1.0) –23 7
CCBT+MCBT 44 –4.25 (6.03) –3.0 (–6.0 to –0.5) –24 7
CCBT+MCI 39 –3.51 (6.12) –4.0 (–7.0 to 0.0) –20 15
Total score 6 months CCBT 40 4.18 (5.01) 3.0 (0.0 to 6.0) 0 19
CCBT+MCBT 44 5.20 (4.99) 4.5 (0.5 to 10.0) 0 16
CCBT+MCI 39 4.03 (5.24) 1.0 (0.0 to 8.0) 0 22
Total score baseline CCBT 40 7.63 (6.93) 5.0 (2.5 to 11.5) 0 24
CCBT+MCBT 44 9.45 (5.94) 8.5 (5.0 to 13.0) 0 24
CCBT+MCI 39 7.54 (5.88) 5.0 (3.0 to 11.0) 0 23
IQR, interquartile range.
TABLE 137 Summary of mother- and child-reported questionnaire scores at baseline, 6 months, and change from
baseline to 6 months
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
CAIS-c/p
Total score difference
baseline–6 months
CCBT 35 –9.40 (10.26) –7.0 (–17.0 to –1.0) –33 8
CCBT+MCBT 37 –13.78 (13.07) –12.0 (–21.0 to –4.0) –47 4
CCBT+MCI 34 –8.47 (10.71) –9.0 (–14.0 to 0.0) –29 11
Total score 6 months CCBT 35 13.51 (13.24) 9.0 (3.0 to 22.0) 0 54
CCBT+MCBT 37 11.46 (10.00) 9.0 (5.0 to 16.0) 1 44
CCBT+MCI 34 11.24 (9.24) 9.0 (5.0 to 17.0) 0 38
Total score baseline CCBT 35 22.91 (15.48) 20.0 (11.0 to 30.0) 1 66
CCBT+MCBT 37 25.24 (16.00) 25.0 (12.0 to 35.0) 0 60
CCBT+MCI 34 19.71 (11.13) 17.0 (11.0 to 26.0) 2 52
SCAS-c/p
Total score difference
baseline–6 months
CCBT 36 –17.81 (11.43) –19.0 (–25.5 to –11.5) –44 3
CCBT+MCBT 41 –17.32 (12.64) –18.0 (–24.0 to –10.0) –45 13
CCBT+MCI 38 –18.29 (13.59) –16.0 (–27.0 to –9.0) –44 15
Total score 6 months CCBT 36 23.11 (16.89) 20.0 (14.0 to 28.5) 1 93
CCBT+MCBT 41 23.66 (13.68) 20.0 (14.0 to 31.0) 3 61
CCBT+MCI 38 22.68 (11.01) 22.0 (15.0 to 28.0) 5 51
Total score baseline CCBT 36 40.92 (14.95) 39.0 (31.0 to 46.0) 20 94
CCBT+MCBT 41 40.98 (15.15) 38.0 (32.0 to 49.0) 17 82
CCBT+MCI 38 40.97 (14.64) 41.0 (29.0 to 52.0) 16 81
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TABLE 137 Summary of mother- and child-reported questionnaire scores at baseline, 6 months, and change from
baseline to 6 months (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
SDQ-c/p conduct subscale
Total score difference
baseline–6 months
CCBT 39 –0.36 (1.50) 0.0 (–1.0 to 0.0) –5 3
CCBT+MCBT 42 –1.12 (1.21) –1.0 (–2.0 to 0.0) –4 2
CCBT+MCI 41 –1.12 (1.50) –1.0 (–2.0 to 0.0) –4 1
Total score 6 months CCBT 39 2.05 (1.92) 2.0 (1.0 to 3.0) 0 8
CCBT+MCBT 42 1.79 (1.63) 1.0 (1.0 to 3.0) 0 6
CCBT+MCI 41 1.44 (1.42) 1.0 (0.0 to 2.0) 0 6
Total score baseline CCBT 39 2.41 (1.98) 2.0 (1.0 to 3.0) 0 8
CCBT+MCBT 42 2.90 (1.69) 3.0 (2.0 to 4.0) 0 9
CCBT+MCI 41 2.56 (1.90) 2.0 (1.0 to 4.0) 0 8
SMFQ-c/p
Total score difference
baseline–6 months
CCBT 36 –3.56 (6.53) –2.5 (–5.5 to 1.0) –21 10
CCBT+MCBT 38 –6.76 (6.66) –6.0 (–9.0 to –2.0) –25 3
CCBT+MCI 36 –4.64 (6.33) –3.0 (–9.0 to –0.5) –19 8
Total score 6 months CCBT 36 5.31 (5.95) 3.0 (0.5 to 9.0) 0 25
CCBT+MCBT 38 4.61 (5.53) 2.0 (0.0 to 6.0) 0 20
CCBT+MCI 36 4.56 (4.87) 4.0 (1.0 to 7.5) 0 23
Total score baseline CCBT 36 8.86 (6.86) 6.0 (4.0 to 13.0) 0 24
CCBT+MCBT 38 11.37 (7.72) 10.0 (6.0 to 17.0) 0 26
CCBT+MCI 36 9.19 (6.86) 8.5 (2.5 to 14.0) 0 23
IQR, interquartile range.
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TABLE 138 Summary of teacher-reported questionnaire scores at baseline, 6 months, and change from baseline
to 6 months
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
CAS-t
Total score difference
baseline–6 months
CCBT 11 –2.55 (5.82) –1.0 (–9.0 to 1.0) –13 5
CCBT+MCBT 17 –2.35 (5.15) –2.0 (–5.0 to 2.0) –16 5
CCBT+MCI 23 –1.30 (3.94) 0.0 (–5.0 to 1.0) –9 5
Total score 6 months CCBT 11 4.82 (5.08) 2.0 (0.0 to 8.0) 0 14
CCBT+MCBT 17 3.35 (3.32) 2.0 (1.0 to 5.0) 0 10
CCBT+MCI 23 4.74 (4.54) 4.0 (1.0 to 8.0) 0 16
Total score baseline CCBT 11 7.36 (5.26) 6.0 (3.0 to 13.0) 0 16
CCBT+MCBT 17 5.71 (5.58) 6.0 (0.0 to 10.0) 0 16
CCBT+MCI 23 6.04 (4.72) 7.0 (1.0 to 9.0) 0 16
SCAS-t
Total score difference
baseline–6 months
CCBT 4 –1.25 (4.99) –0.5 (–4.5 to 2.0) –8 4
CCBT+MCBT 9 –12.22 (12.28) –9.0 (–13.0 to –8.0) –37 4
CCBT+MCI 15 –11.73 (11.63) –9.0 (–24.0 to –3.0) –36 1
Total score 6 months CCBT 4 15.75 (19.05) 10.0 (3.0 to 28.5) 0 43
CCBT+MCBT 9 5.56 (4.07) 4.0 (3.0 to 7.0) 2 15
CCBT+MCI 15 10.73 (9.04) 7.0 (4.0 to 16.0) 0 31
Total score baseline CCBT 4 17.00 (16.19) 14.5 (7.0 to 27.0) 0 39
CCBT+MCBT 9 17.78 (13.23) 16.0 (12.0 to 17.0) 3 40
CCBT+MCI 15 22.47 (13.08) 20.0 (10.0 to 36.0) 6 44
SDQ-t conduct subscale
Total score difference
baseline–6 months
CCBT 12 0.58 (2.11) 0.0 (0.0 to 0.5) –1 7
CCBT+MCBT 18 –0.06 (1.70) 0.0 (0.0 to 0.0) –2 6
CCBT+MCI 22 0.41 (1.37) 0.0 (0.0 to 0.0) –1 5
Total score 6 months CCBT 12 1.25 (2.18) 0.0 (0.0 to 1.5) 0 7
CCBT+MCBT 18 0.61 (1.54) 0.0 (0.0 to 0.0) 0 6
CCBT+MCI 22 0.86 (1.70) 0.0 (0.0 to 1.0) 0 5
Total score baseline CCBT 12 0.67 (1.44) 0.0 (0.0 to 1.0) 0 5
CCBT+MCBT 18 0.67 (1.08) 0.0 (0.0 to 1.0) 0 3
CCBT+MCI 22 0.45 (1.14) 0.0 (0.0 to 0.0) 0 5
IQR, interquartile range.
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TABLE 139 Summary of child-reported questionnaire scores at baseline, 12 months, and change from baseline to
12 months
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
CAIS-c
Total score difference
baseline–12 months
CCBT 29 –8.41 (12.18) –6.0 (–15.0 to 0.0) –34 16
CCBT+MCBT 33 –15.24 (23.01) –14.0 (–29.0 to –6.0) –51 77
CCBT+MCI 37 –9.86 (10.88) –8.0 (–19.0 to –1.0) –36 13
Total score 12 months CCBT 29 6.38 (6.30) 4.0 (1.0 to 10.0) 0 25
CCBT+MCBT 33 11.82 (15.16) 7.0 (2.0 to 18.0) 0 78
CCBT+MCI 37 8.00 (11.33) 4.0 (1.0 to 10.0) 0 49
Total score baseline CCBT 29 14.79 (11.48) 14.0 (3.0 to 22.0) 1 40
CCBT+MCBT 33 27.06 (17.26) 22.0 (14.0 to 41.0) 1 60
CCBT+MCI 37 17.86 (14.00) 15.0 (6.0 to 26.0) 0 63
SCAS-c
Total score difference
baseline–12 months
CCBT 31 –14.68 (17.11) –12.0 (–25.0 to 0.0) –52 21
CCBT+MCBT 34 –21.44 (15.86) –22.5 (–27.0 to –13.0) –59 12
CCBT+MCI 37 –17.78 (19.53) –20.0 (–28.0 to –4.0) –58 22
Total score 12 months CCBT 31 18.94 (13.34) 18.0 (9.0 to 29.0) 1 54
CCBT+MCBT 34 23.09 (14.92) 21.0 (10.0 to 34.0) 0 52
CCBT+MCI 37 20.78 (19.04) 13.0 (9.0 to 33.0) 0 68
Total score baseline CCBT 31 33.61 (18.20) 30.0 (22.0 to 45.0) 2 88
CCBT+MCBT 34 44.53 (17.52) 42.5 (31.0 to 59.0) 10 80
CCBT+MCI 37 38.57 (19.17) 41.0 (29.0 to 47.0) 4 92
SDQ-c conduct subscale
Total score difference
baseline–12 months
CCBT 31 –1.06 (1.73) –1.0 (–2.0 to 0.0) –5 3
CCBT+MCBT 34 –0.97 (2.12) –1.0 (–2.0 to 0.0) –7 3
CCBT+MCI 38 –1.08 (2.50) –1.0 (–2.0 to 0.0) –8 8
Total score 12 months CCBT 31 1.65 (1.52) 2.0 (0.0 to 3.0) 0 5
CCBT+MCBT 34 2.03 (1.68) 2.0 (1.0 to 2.0) 0 8
CCBT+MCI 38 1.97 (2.33) 1.0 (0.0 to 3.0) 0 8
Total score baseline CCBT 31 2.71 (1.81) 3.0 (1.0 to 4.0) 0 7
CCBT+MCBT 34 3.00 (2.09) 3.0 (1.0 to 4.0) 0 8
CCBT+MCI 38 3.05 (1.84) 3.0 (2.0 to 4.0) 0 8
SMFQ-c
Total score difference
baseline–12 months
CCBT 28 –2.89 (6.11) –2.0 (–5.0 to 1.0) –24 5
CCBT+MCBT 35 –5.51 (5.73) –6.0 (–11.0 to –2.0) –13 9
CCBT+MCI 37 –1.95 (5.68) –2.0 (–5.0 to 1.0) –20 12
Total score 12 months CCBT 28 2.86 (3.67) 1.0 (0.0 to 5.0) 0 12
CCBT+MCBT 35 4.31 (5.42) 3.0 (0.0 to 6.0) 0 25
CCBT+MCI 37 4.73 (6.78) 1.0 (0.0 to 6.0) 0 26
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TABLE 139 Summary of child-reported questionnaire scores at baseline, 12 months, and change from baseline to
12 months (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
Total score baseline CCBT 28 5.75 (5.69) 4.5 (1.5 to 8.0) 0 24
CCBT+MCBT 35 9.83 (5.39) 11.0 (5.0 to 14.0) 0 22
CCBT+MCI 37 6.68 (5.47) 5.0 (3.0 to 9.0) 0 23
IQR, interquartile range.
TABLE 140 Summary of mother- and child-reported questionnaire scores at baseline, 12 months, and change from
baseline to 12 months
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
CAIS-c/p
Total score difference
baseline–12 months
CCBT 28 –9.32 (10.99) –7.5 (–15.5 to –1.0) –37 6
CCBT+MCBT 27 –15.07 (11.07) –16.0 (–22.0 to –5.0) –37 2
CCBT+MCI 31 –9.90 (10.31) –8.0 (–16.0 to –1.0) –39 5
Total score 12 months CCBT 28 11.57 (12.64) 8.0 (3.5 to 15.5) 0 58
CCBT+MCBT 27 12.74 (11.72) 8.0 (4.0 to 17.0) 0 42
CCBT+MCI 31 8.03 (6.79) 7.0 (1.0 to 13.0) 0 24
Total score baseline CCBT 28 20.89 (15.12) 17.0 (10.5 to 26.5) 1 66
CCBT+MCBT 27 27.81 (16.82) 25.0 (16.0 to 44.0) 0 60
CCBT+MCI 31 17.94 (11.52) 15.0 (10.0 to 24.0) 1 52
SCAS-c/p
Total score difference
baseline–12 months
CCBT 30 –21.97 (13.18) –23.5 (–31.0 to –11.0) –48 3
CCBT+MCBT 31 –16.26 (14.23) –15.0 (–26.0 to –6.0) –43 12
CCBT+MCI 33 –20.85 (15.57) –19.0 (–29.0 to –12.0) –59 6
Total score 12 months CCBT 30 18.67 (13.68) 14.0 (9.0 to 29.0) 1 51
CCBT+MCBT 31 24.90 (15.55) 25.0 (12.0 to 33.0) 1 66
CCBT+MCI 33 19.12 (12.99) 17.0 (13.0 to 24.0) 2 58
Total score baseline CCBT 30 40.63 (14.09) 39.5 (32.0 to 46.0) 16 74
CCBT+MCBT 31 41.16 (17.02) 37.0 (29.0 to 55.0) 17 75
CCBT+MCI 33 39.97 (14.44) 42.0 (29.0 to 50.0) 16 81
SDQ-c/p conduct subscale
Total score difference
baseline–12 months
CCBT 32 –0.75 (1.74) 0.0 (–2.0 to 0.0) –6 2
CCBT+MCBT 32 –1.13 (1.50) –1.0 (–2.0 to 0.0) –4 1
CCBT+MCI 38 –0.95 (1.66) –1.0 (–2.0 to 0.0) –4 3
Total score 12 months CCBT 32 1.25 (1.65) 1.0 (0.0 to 2.0) 0 8
CCBT+MCBT 32 1.91 (1.47) 2.0 (0.5 to 3.0) 0 5
CCBT+MCI 38 1.82 (2.04) 1.0 (0.0 to 3.0) 0 8
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TABLE 140 Summary of mother- and child-reported questionnaire scores at baseline, 12 months, and change from
baseline to 12 months (continued )
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
Total score baseline CCBT 32 2.00 (1.95) 2.0 (1.0 to 3.0) 0 8
CCBT+MCBT 32 3.03 (1.82) 3.0 (2.0 to 4.0) 0 7
CCBT+MCI 38 2.76 (2.03) 2.0 (1.0 to 4.0) 0 8
SMFQ-c/p
Total score difference
baseline–12 months
CCBT 30 –4.00 (6.37) –3.0 (–5.0 to –1.0) –24 8
CCBT+MCBT 29 –6.31 (6.20) –5.0 (–9.0 to –1.0) –24 4
CCBT+MCI 33 –5.64 (6.95) –3.0 (–10.0 to –1.0) –22 4
Total score 12 months CCBT 30 4.10 (5.36) 2.0 (0.0 to 6.0) 0 20
CCBT+MCBT 29 6.21 (6.04) 5.0 (1.0 to 9.0) 0 22
CCBT+MCI 33 3.45 (4.83) 1.0 (0.0 to 5.0) 0 18
Total score baseline CCBT 30 8.10 (6.72) 5.5 (4.0 to 9.0) 1 24
CCBT+MCBT 29 12.52 (8.17) 12.0 (7.0 to 19.0) 0 26
CCBT+MCI 33 9.09 (7.15) 8.0 (2.0 to 14.0) 0 23
IQR, interquartile range.
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TABLE 141 Summary of teacher-reported questionnaire scores at baseline, 12 months, and change from baseline to
12 months
Questionnaire Treatment n Mean (SD) Median (IQR) Minimum Maximum
CAS-t
Total score difference
baseline–12 months
CCBT 9 –2.22 (4.99) –1.0 (–3.0 to 2.0) –11 3
CCBT+MCBT 10 0.40 (4.14) –0.5 (–3.0 to 2.0) –4 8
CCBT+MCI 12 –1.75 (4.05) –2.0 (–5.0 to 1.5) –7 5
Total score 12 months CCBT 9 5.00 (4.92) 2.0 (2.0 to 8.0) 0 14
CCBT+MCBT 10 4.60 (3.41) 4.5 (2.0 to 7.0) 0 10
CCBT+MCI 12 5.25 (2.93) 6.0 (3.5 to 7.5) 0 9
Total score baseline CCBT 9 7.22 (3.63) 6.0 (5.0 to 10.0) 3 13
CCBT+MCBT 10 4.20 (2.90) 3.5 (3.0 to 6.0) 0 10
CCBT+MCI 12 7.00 (4.29) 6.5 (4.5 to 10.0) 1 16
SCAS-t
Total score difference
baseline–12 months
CCBT 4 –8.25 (3.77) –8.0 (–11.0 to –5.5) –13 –4
CCBT+MCBT 4 4.25 (23.13) 2.0 (–12.5 to 21.0) –21 34
CCBT+MCI 5 –13.20 (16.30) –15.0 (–20.0 to 2.0) –36 3
Total score 12 months CCBT 4 13.00 (12.70) 7.0 (6.0 to 20.0) 6 32
CCBT+MCBT 4 22.00 (11.92) 18.5 (14.0 to 30.0) 12 39
CCBT+MCI 5 8.80 (3.90) 10.0 (7.0 to 11.0) 3 13
Total score baseline CCBT 4 21.25 (12.66) 18.0 (12.5 to 30.0) 10 39
CCBT+MCBT 4 17.75 (16.82) 12.0 (6.5 to 29.0) 5 42
CCBT+MCI 5 22.00 (14.25) 25.0 (10.0 to 31.0) 5 39
SDQ-t conduct subscale
Total score difference
baseline–12 months
CCBT 9 –0.11 (1.17) 0.0 (–1.0 to 0.0) –2 2
CCBT+MCBT 11 –0.27 (1.49) 0.0 (–1.0 to 0.0) –4 2
CCBT+MCI 12 0.58 (1.62) 0.0 (–0.5 to 1.5) –1 4
Total score 12 months CCBT 9 1.22 (1.92) 0.0 (0.0 to 1.0) 0 5
CCBT+MCBT 11 0.36 (0.67) 0.0 (0.0 to 1.0) 0 2
CCBT+MCI 12 1.33 (1.78) 0.5 (0.0 to 2.5) 0 5
Total score baseline CCBT 9 1.33 (1.58) 1.0 (0.0 to 2.0) 0 5
CCBT+MCBT 11 0.64 (1.29) 0.0 (0.0 to 1.0) 0 4
CCBT+MCI 12 0.75 (1.48) 0.0 (0.0 to 1.0) 0 5
IQR, interquartile range.
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